0001811764-23-000046.txt : 20231113 0001811764-23-000046.hdr.sgml : 20231113 20231113071536 ACCESSION NUMBER: 0001811764-23-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: POINT Biopharma Global Inc. CENTRAL INDEX KEY: 0001811764 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850800493 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39373 FILM NUMBER: 231395070 BUSINESS ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 BUSINESS PHONE: (317) 543-9957 MAIL ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 FORMER COMPANY: FORMER CONFORMED NAME: Therapeutics Acquisition Corp. DATE OF NAME CHANGE: 20200511 10-Q 1 pnt-20230930.htm 10-Q pnt-20230930
0001811764--12-312023Q3FALSEP3YP3YP3YP3YP2YP1Y00018117642023-01-012023-09-3000018117642023-11-08xbrli:shares00018117642023-09-30iso4217:USD00018117642022-12-31iso4217:USDxbrli:shares00018117642023-07-012023-09-3000018117642022-07-012022-09-3000018117642022-01-012022-09-300001811764us-gaap:CommonStockMember2022-12-310001811764us-gaap:AdditionalPaidInCapitalMember2022-12-310001811764us-gaap:RetainedEarningsMember2022-12-310001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001811764us-gaap:CommonStockMember2023-01-012023-03-310001811764us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100018117642023-01-012023-03-310001811764us-gaap:RetainedEarningsMember2023-01-012023-03-310001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001811764us-gaap:CommonStockMember2023-03-310001811764us-gaap:AdditionalPaidInCapitalMember2023-03-310001811764us-gaap:RetainedEarningsMember2023-03-310001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100018117642023-03-310001811764us-gaap:CommonStockMember2023-04-012023-06-300001811764us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000018117642023-04-012023-06-300001811764us-gaap:RetainedEarningsMember2023-04-012023-06-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001811764us-gaap:CommonStockMember2023-06-300001811764us-gaap:AdditionalPaidInCapitalMember2023-06-300001811764us-gaap:RetainedEarningsMember2023-06-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000018117642023-06-300001811764us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001811764us-gaap:RetainedEarningsMember2023-07-012023-09-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001811764us-gaap:CommonStockMember2023-09-300001811764us-gaap:AdditionalPaidInCapitalMember2023-09-300001811764us-gaap:RetainedEarningsMember2023-09-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001811764us-gaap:CommonStockMember2021-12-310001811764us-gaap:AdditionalPaidInCapitalMember2021-12-310001811764us-gaap:RetainedEarningsMember2021-12-310001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100018117642021-12-310001811764us-gaap:CommonStockMember2022-01-012022-03-310001811764us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100018117642022-01-012022-03-310001811764us-gaap:RetainedEarningsMember2022-01-012022-03-310001811764us-gaap:CommonStockMember2022-03-310001811764us-gaap:AdditionalPaidInCapitalMember2022-03-310001811764us-gaap:RetainedEarningsMember2022-03-310001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100018117642022-03-310001811764us-gaap:CommonStockMember2022-04-012022-06-300001811764us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000018117642022-04-012022-06-300001811764us-gaap:RetainedEarningsMember2022-04-012022-06-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001811764us-gaap:CommonStockMember2022-06-300001811764us-gaap:AdditionalPaidInCapitalMember2022-06-300001811764us-gaap:RetainedEarningsMember2022-06-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000018117642022-06-300001811764us-gaap:CommonStockMember2022-07-012022-09-300001811764us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001811764us-gaap:RetainedEarningsMember2022-07-012022-09-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001811764us-gaap:CommonStockMember2022-09-300001811764us-gaap:AdditionalPaidInCapitalMember2022-09-300001811764us-gaap:RetainedEarningsMember2022-09-300001811764us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000018117642022-09-30pnt:subsidiary0001811764pnt:LantheusHoldingsIncMemberpnt:LicenseAgreementsPNT2002AgreementMember2022-12-012022-12-310001811764pnt:LantheusHoldingsIncMemberpnt:LicenseAgreementsPNT2002AgreementMember2022-12-31xbrli:pure0001811764pnt:LicenseAgreementsPNT2003AgreementMemberpnt:LantheusHoldingsIncMember2022-12-012022-12-310001811764pnt:LicenseAgreementsPNT2003AgreementMemberpnt:LantheusHoldingsIncMember2022-12-3100018117642022-12-012022-12-310001811764us-gaap:CommercialPaperMember2023-09-300001811764us-gaap:CommercialPaperMember2022-12-310001811764us-gaap:CorporateBondSecuritiesMember2023-09-300001811764us-gaap:CorporateBondSecuritiesMember2022-12-310001811764us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001811764us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001811764us-gaap:AssetBackedSecuritiesMember2023-09-300001811764us-gaap:AssetBackedSecuritiesMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300001811764us-gaap:FairValueMeasurementsRecurringMember2023-09-300001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001811764us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001811764us-gaap:FairValueMeasurementsRecurringMember2022-12-3100018117642023-06-012023-06-010001811764us-gaap:SubsequentEventMember2023-10-022023-10-020001811764us-gaap:LandAndBuildingMember2023-09-300001811764us-gaap:LandAndBuildingMember2022-12-310001811764us-gaap:MachineryAndEquipmentMember2023-09-300001811764us-gaap:MachineryAndEquipmentMember2022-12-310001811764us-gaap:ConstructionInProgressMember2023-09-300001811764us-gaap:ConstructionInProgressMember2022-12-310001811764us-gaap:FurnitureAndFixturesMember2023-09-300001811764us-gaap:FurnitureAndFixturesMember2022-12-310001811764us-gaap:ComputerEquipmentMember2023-09-300001811764us-gaap:ComputerEquipmentMember2022-12-310001811764pnt:GoodManufacturingPracticesMember2020-07-31utr:sqft0001811764pnt:FacilityLeaseMember2023-09-300001811764us-gaap:BuildingMember2023-09-300001811764pnt:UHNMember2023-02-020001811764pnt:UHNMembersrt:MinimumMember2023-02-02pnt:people0001811764pnt:IndianapolisLeaseMember2023-03-10pnt:renewal00018117642023-03-100001811764pnt:LabratorySpaceMember2023-04-120001811764us-gaap:PreferredStockMember2023-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:CommonStockMember2023-01-012023-09-300001811764pnt:ShareBasedCompensationToBoardMemberMemberus-gaap:CommonStockMember2023-01-012023-09-300001811764pnt:PublicShareOfferingMember2022-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:CommonStockMember2022-07-012022-09-300001811764us-gaap:CommonStockMember2022-01-012022-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:CommonStockMember2022-01-012022-09-30pnt:vote0001811764us-gaap:PreferredStockMember2023-01-012023-09-3000018117642023-01-012023-01-010001811764us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001811764us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001811764us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001811764us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001811764us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001811764us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001811764us-gaap:EmployeeStockOptionMember2022-12-310001811764us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764us-gaap:EmployeeStockOptionMember2023-09-300001811764pnt:EmployeeMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001811764pnt:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764us-gaap:ShareBasedCompensationAwardTrancheTwoMemberpnt:EmployeeMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001811764us-gaap:ShareBasedCompensationAwardTrancheTwoMemberpnt:EmployeeMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764pnt:ShareBasedPaymentArrangementTrancheFourMemberpnt:EmployeeMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001811764pnt:ShareBasedPaymentArrangementTrancheFourMemberpnt:EmployeeMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:DirectorMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001811764pnt:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001811764us-gaap:ShareBasedCompensationAwardTrancheTwoMemberpnt:EmployeesAndDirectorsMember2022-01-012022-09-300001811764us-gaap:ShareBasedCompensationAwardTrancheTwoMemberpnt:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001811764pnt:ShareBasedPaymentArrangementTrancheFourMemberpnt:EmployeesAndDirectorsMember2022-01-012022-09-300001811764pnt:ShareBasedPaymentArrangementTrancheFourMemberpnt:EmployeesAndDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001811764srt:DirectorMemberus-gaap:EmployeeStockOptionMember2022-06-062022-06-060001811764srt:MinimumMember2023-01-012023-09-300001811764srt:MaximumMember2023-01-012023-09-300001811764srt:MinimumMember2022-01-012022-09-300001811764srt:MaximumMember2022-01-012022-09-300001811764us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMember2023-01-012023-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMember2022-07-012022-09-300001811764pnt:ShareBasedCompensationToNonEmployeeConsultantMember2022-01-012022-09-300001811764us-gaap:PerformanceSharesMember2022-01-012022-12-310001811764pnt:PropertyInDevelopmentCommitmentMember2023-09-300001811764pnt:PropertyInDevelopmentCommitmentMember2023-07-012023-09-300001811764pnt:PropertyInDevelopmentCommitmentMember2023-01-012023-09-300001811764pnt:PropertyInDevelopmentCommitmentMember2022-07-012022-09-300001811764pnt:PropertyInDevelopmentCommitmentMember2022-01-012022-09-300001811764pnt:SupplyAgreementsInConnectionWithClinicalTrialsMember2023-01-012023-09-300001811764pnt:SupplyAgreementsInConnectionWithClinicalTrialsMembersrt:MinimumMember2023-01-012023-09-300001811764pnt:SupplyAgreementsInConnectionWithClinicalTrialsMembersrt:MaximumMember2023-01-012023-09-300001811764pnt:SupplyAgreementsInConnectionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:SupplyAgreementsInConnectionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:SupplyAgreementsInConnectionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001811764pnt:SupplyAgreementsInConnectionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMember2023-01-012023-09-30iso4217:CAD0001811764pnt:SupplyAgreementToPurchaseCertainProductsMembersrt:MinimumMember2023-01-012023-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMembersrt:MaximumMember2023-01-012023-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:SupplyAgreementToPurchaseCertainProductsMember2023-05-102023-05-100001811764pnt:SupplyAgreementToPurchaseNcaLuMember2023-09-252023-09-25iso4217:EUR0001811764pnt:SupplyAgreementToPurchaseNcaLuMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:SupplyAgreementToPurchaseNcaLuMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember2023-01-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMembersrt:MinimumMember2023-01-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMembersrt:MaximumMember2023-01-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001811764pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001811764pnt:AthebioMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:AthebioMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:StockPurchaseAgreementMemberpnt:AthebioMember2023-09-110001811764pnt:LicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001811764pnt:LicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001811764pnt:LicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001811764pnt:LicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001811764pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember2023-07-012023-09-300001811764pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember2022-07-012022-09-300001811764pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember2023-01-012023-09-300001811764pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember2022-01-012022-09-300001811764pnt:ReimbursementToBoardMemberForOccupancyCostsMember2023-07-012023-09-300001811764pnt:ReimbursementToBoardMemberForOccupancyCostsMember2022-07-012022-09-300001811764pnt:ReimbursementToBoardMemberForOccupancyCostsMember2023-01-012023-09-300001811764pnt:ReimbursementToBoardMemberForOccupancyCostsMember2022-01-012022-09-300001811764srt:DirectorMember2023-09-300001811764us-gaap:RelatedPartyMember2023-01-012023-09-300001811764pnt:EliLillyMemberus-gaap:SubsequentEventMember2023-10-020001811764us-gaap:SubsequentEventMember2023-10-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2023
or
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from ______to ______.

Commission file number: 001-39311

POINT BIOPHARMA GLOBAL INC.
(Exact name of registrant as specified in its charter)
Delaware85-0800493
(State or other jurisdiction of(IRS Employer Identification No.)
incorporation or organization) 
  
4850 West 78th Street 
Indianapolis,IN46268
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (317) 543-9957
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockPNTTheNasdaqCapital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
  Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.0001 per share – 106,569,231 shares outstanding as of November 8, 2023.


INDEX























Introductory Note

On October 2, 2023, Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and POINT Biopharma Global Inc., a Delaware corporation (the “Company” or “POINT”) entered into an Agreement and Plan of Merger (the “Merger Agreement”). Merger Sub commenced a cash tender offer (the “Offer”) to purchase all of the outstanding shares of the Company’s common stock, par value of $0.0001 per share (the “Shares”), at a price of $12.50 per share (the “Offer Price”), net to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement.

Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”)) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended, the “HSR Act”), (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. The consummation of the Offer and the Merger is not subject to a financing condition. For more information on the Offer and the Merger, refer to the Company's Current Report on Form 8-K filed October 3, 2023.

The Offer commenced on October 13, 2023. The Offer was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice, initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 p.m., Eastern time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.

Following consummation of the Offer, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (the “Effective Time”) that is not tendered and accepted pursuant to the Offer (other than the Shares owned by the Company or any subsidiary of the Company, Shares held by Parent, Merger Sub or any other subsidiary of Parent, and Shares as to which appraisal rights have been perfected in accordance with applicable law) will be canceled and converted into the right to receive the Offer Price in cash and without interest, less any applicable tax withholding. Prior to the Effective Time, each Company stock option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the Effective Time, each Company stock option that has an exercise price less than the Offer Price will be canceled and converted into the right to receive, for each Share underlying such Company stock option, an amount in cash without interest equal to the difference between the Offer Price and the applicable per share exercise price, less any applicable tax withholding. At the Effective Time, each Company stock option that has an exercise price equal to or greater than the Offer Price will be canceled for no consideration. At the Effective Time, each Company performance stock unit will be canceled and converted into the right to receive, for each Share underlying such Company performance stock unit, an amount in cash without interest equal to the Offer Price, less any applicable tax withholding, which replacement cash award will vest and be payable at the same time as the Company performance stock unit would have vested pursuant to its terms.

In connection with the Merger Agreement, each of Joe A. McCann, Allan Charles Silber and Neil E. Fleshner (collectively, the “Supporting Stockholders”), in each case, in his capacity as a stockholder of the Company and who, collectively, beneficially own approximately 15% of the outstanding Shares, entered into a Tender and Support Agreement (together, the “Tender and Support Agreements”) with Parent and Merger Sub. The Tender and Support Agreements provide, among other things, that each of the Supporting Stockholders will tender all of the Shares held by such Supporting Stockholder, as applicable, in the Offer. The foregoing description of the Tender and Support Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Tender and Support Agreements, which were filed as Exhibits 99.1, 99.2 and 99.3 to our Current Report on Form 8-K filed on October 3, 2023.



The Offer and the Merger are subject to customary closing conditions and are expected to be completed near the end of 2023. The description of the Merger Agreement herein does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to our Current Report on Form 8-K filed on October 3, 2023.

Unless stated otherwise, any forward-looking information contained in this report does not take into account or give any effect to the consummation of the proposed Offer and Merger.


PART I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
POINT Biopharma Global Inc.
Interim Condensed Consolidated Balance Sheets
(In U.S. dollars)
September 30, 2023
(Unaudited)December 31, 2022
$$
ASSETS  
Current assets  
Cash and cash equivalents21,607,412 286,428,371 
Short-term investments317,555,936 238,783,470 
Prepaid expenses and other current assets9,901,729 5,610,889 
Income taxes receivable4,181,469  
Total current assets353,246,546 530,822,730 
Non-current assets
Long-term investments59,793,161 16,119,430 
Note receivable5,116,667  
Property, plant and equipment, net54,042,353 31,380,576 
Operating lease right-of-use asset5,505,693  
Total non-current assets124,457,874 47,500,006 
Total assets 477,704,420 578,322,736 
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable 8,886,750 7,703,150 
Accrued liabilities14,529,354 19,094,454 
Deferred revenue12,586,443 23,242,290 
Income taxes payable736,729 29,698,546 
Finance lease current liability987,018  
Operating lease current liability939,983  
Total current liabilities 38,666,277 79,738,440 
Deferred revenue, net of current portion3,720,881 10,178,147 
Long-term income taxes payable2,389,109 1,452,356 
Finance lease liability, net of current portion4,093,202  
Operating lease liability, net of current portion4,642,565  
Total liabilities 53,512,034 91,368,943 
Commitments and contingencies (Note 12)
Stockholders’ equity
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 105,765,954 and 105,649,741 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
10,576 10,565 
Additional paid-in capital 453,319,762 448,391,574 
(Accumulated deficit) Retained earnings(27,707,358)39,008,505 
Accumulated other comprehensive loss(1,430,594)(456,851)
Total stockholders’ equity424,192,386 486,953,793 
Total liabilities and stockholders’ equity477,704,420 578,322,736 
See accompanying notes to the unaudited interim condensed consolidated financial statements
1

POINT Biopharma Global Inc.
Unaudited Interim Condensed Consolidated Statements of Operations
(In U.S. dollars, except share amounts)
For the three months endedFor the nine months ended
September 30,
2023
September 30,
2022
September 30,
2023
September 30,
2022
$ $$$
Revenue
Service revenue2,789,993  17,113,113  
Total revenue2,789,993  17,113,113  
Operating expenses 
Research and development26,910,286 20,797,406 85,097,331 54,112,136 
General and administrative5,505,869 3,839,626 15,604,401 11,727,969 
Total operating expenses 32,416,155 24,637,032 100,701,732 65,840,105 
Loss from operations(29,626,162)(24,637,032)(83,588,619)(65,840,105)
Other income (expenses)
Investment income5,617,736 1,048,254 16,717,703 1,605,927 
Foreign currency gain (loss)105,522 (243,791)(133,438)(287,691)
Total other income (expenses)5,723,258 804,463 16,584,265 1,318,236 
Loss before income taxes (23,902,904)(23,832,569)(67,004,354)(64,521,869)
Income tax (provision) benefit(871,449)(180,500)288,491 (452,021)
Net loss (24,774,353)(24,013,069)(66,715,863)(64,973,890)
Net loss per basic and diluted common share:
Basic and diluted net loss per common share$(0.23)$(0.26)$(0.63)$(0.71)
Basic and diluted weighted average common shares outstanding105,765,954 92,401,484 105,717,330 90,891,031 
See accompanying notes to the unaudited interim condensed consolidated financial statements
2

POINT Biopharma Global Inc.
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss
(In U.S. dollars)
For the three months endedFor the nine months ended
September 30,
2023
September 30,
2022
September 30,
2023
September 30,
2022
$ $$$
Net loss(24,774,353)(24,013,069)(66,715,863)(64,973,890)
Other comprehensive loss, net of tax
Net unrealized loss on available-for-sale debt securities(361,611)(266,320)(973,743)(608,698)
Total comprehensive loss(25,135,964)(24,279,389)(67,689,606)(65,582,588)

See accompanying notes to the unaudited interim condensed consolidated financial statements
3

POINT Biopharma Global Inc.
Unaudited Interim Condensed Consolidated Statements of Stockholders’ Equity
(In U.S. dollars, except share amounts)
Common StockAdditional
Paid-in Capital
Retained Earnings (Accumulated Deficit)Accumulated Other Comprehensive LossTotal Equity
Number Amount   
 # $ $ $$ $
Balance at December 31, 2022
105,649,741 10,565 448,391,574 39,008,505 (456,851)486,953,793 
Issuance of shares of Common Stock in connection with stock option exercises32,936 3 145,861 — — 145,864 
Stock-based compensation— — 1,009,496 — — 1,009,496 
Net loss— — — (16,530,671)— (16,530,671)
Other comprehensive income, net of tax— — — — 201,294 201,294 
Balance at March 31, 2023105,682,677 10,568 449,546,931 22,477,834 (255,557)471,779,776 
Issuance of shares of Common Stock in connection with stock option exercises83,277 8 186,050 — — 186,058 
Stock-based compensation— — 1,710,349 — — 1,710,349 
Net loss— — — (25,410,839)— (25,410,839)
Other comprehensive loss, net of tax— — — — (813,426)(813,426)
Balance at June 30, 2023105,765,954 10,576 451,443,330 (2,933,005)(1,068,983)447,451,918 
Stock-based compensation— — 1,876,432 — — 1,876,432 
Net loss— — — (24,774,353)— (24,774,353)
Other comprehensive loss, net of tax— — — — (361,611)(361,611)
Balance at September 30, 2023
105,765,954 10,576 453,319,762 (27,707,358)(1,430,594)424,192,386 
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated Other Comprehensive LossTotal Equity
Number Amount   
 # $ $ $$ $
Balance at December 31, 202190,121,794 9,012 314,488,782 (59,284,708) 255,213,086 
Issuance of shares of Common Stock in connection with stock option exercises678 — 942 — — 942 
Stock-based compensation— — 440,450 — — 440,450 
Net loss— — — (16,380,574)— (16,380,574)
Balance at March 31, 202290,122,472 9,012 314,930,174 (75,665,282) 239,273,904 
Issuance of shares of Common Stock in connection with stock option exercises2,490 — 3,461 — — 3,461 
Stock-based compensation— — 1,027,563 — — 1,027,563 
Net loss— — — (24,580,247)— (24,580,247)
Other comprehensive loss, net of tax— — — — (342,378)(342,378)
Balance at June 30, 202290,124,962 9,012 315,961,198 (100,245,529)(342,378)215,382,303 
Issuance of shares of Common Stock, net of direct and incremental costs13,900,000 1,390 116,854,772 — — 116,856,162 
Issuance of shares of Common Stock in connection with stock option exercises30,000 3 41,697 — — 41,700 
Stock-based compensation— — 1,079,056 — — 1,079,056 
Net loss— — — (24,013,069)— (24,013,069)
Other comprehensive loss, net of tax— — — — (266,320)(266,320)
Balance at September 30, 2022104,054,962 10,405 433,936,723 (124,258,598)(608,698)309,079,832 
See accompanying notes to the unaudited interim condensed consolidated financial statements
4

POINT Biopharma Global Inc.
Unaudited Interim Condensed Consolidated Statements of Cash Flows
(In U.S. dollars)
For the nine months ended
September 30, 2023September 30, 2022
$$
Cash flows from operating activities  
Net loss:(66,715,863)(64,973,890)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation on property, plant and equipment2,186,253 980,995 
Deferred and non-current income taxes936,753 (65,592)
Stock-based compensation expense4,596,277 2,547,069 
Non-cash lease expense196,772  
Amortization of premiums (accretion of discounts) on investments, net(9,457,635)(435,238)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets709,160 318,586 
Accounts payable(1,060,594)1,261,082 
Accrued liabilities(4,534,719)6,926,449 
Deferred revenue(17,113,113) 
Income taxes receivable and payable(33,143,286)110,745 
Operating lease liabilities(62,014) 
Change in accrued interest and dividends within investments(1,397,490)(67,483)
Net cash used in operating activities(124,859,499)(53,397,277)
Cash flows from investing activities
Purchase of investments, net of sales and maturities(117,757,923)(165,841,488)
Purchase of property, plant and equipment(17,249,510)(10,696,365)
Purchase of note receivable(5,000,000) 
Net cash used in investing activities(140,007,433)(176,537,853)
Cash flows from financing activities
Issuance of shares of Common Stock in connection with stock option exercises331,922 46,103 
Payments on finance lease(285,949) 
Issuance of shares of Common Stock, net of direct and incremental costs paid 116,856,162 
Net cash provided by financing activities45,973 116,902,265 
Net decrease in cash and cash equivalents(264,820,959)(113,032,865)
Cash and cash equivalents, beginning of period286,428,371 238,815,991 
Cash and cash equivalents, end of period 21,607,412 125,783,126 
Supplemental disclosure of cash flow information:
Cash paid for income taxes31,924,135 411,424 
Non-cash investment activities:
Receivable for investment maturities5,000,000  
Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities3,623,314 1,142,278 

See accompanying notes to the unaudited interim condensed consolidated financial statements
5

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

1. Nature of business
POINT Biopharma Global Inc., together with its consolidated subsidiaries ("POINT" or the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere.
The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78th Street, LLC, each located in the U.S., and POINT Biopharma Corp., located in Canada (collectively the "Subsidiaries"). The Company’s headquarters is located at 4850 West 78th Street, Indianapolis, Indiana, 46268.
2. Summary of significant accounting policies
Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and the Subsidiaries, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023 (the “2022 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2022 Financial Statements.
These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
COVID-19 Pandemic, macroeconomics and other geopolitical events
The Company is currently operating in a period of significant economic uncertainty, resulting from, among other things, the impact of the COVID-19 pandemic, geopolitical tensions, such as the ongoing military conflict between Russia and Ukraine, the Israel-Palestine conflict and heightened tensions between China and Taiwan, trade uncertainty, including changes in tariffs, sanctions, international treaties, and other trade restrictions, rising inflation and interest rates, and uncertainty and liquidity concerns in the broader financial services industry, including those caused by certain recent banking failures.

The Company is continuing to monitor the development and potential impact of these global economic and geopolitical events on its business and unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of these events and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. However, estimates and assumptions about future events and their effects cannot be determined with certainty, and therefore, require the exercise of judgment; as a result, the Company’s estimates may change as new events occur and additional information is obtained.
Risks and uncertainties
Except for the upfront payment received pursuant to the Lantheus License Agreements (as defined in Note 3 below), the Company has incurred significant net losses and has funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to continue to be incurred in future periods. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence
6

on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from public health crisis or military conflicts and adverse developments affecting the financial services industry, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
The Company also has a number of risks and uncertainties related to the Offer and Merger described in Note 16. These risks and uncertainties are described in more detail in Part II. Item 1A. “Risk Factors” starting on page 34.
Use of estimates
The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the allocation of consideration and the recognition of revenues in respect of the performance obligations under the Lantheus License Agreements, the accrual of research and development expenses, incremental borrowing rates determined in connection with finance and operating lease obligations, the valuations of stock options, the expected recoverability of and the estimated useful lives of our long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experiences. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Leases
The Company accounts for leases in accordance with ASC Topic 842, Leases ("ASC 842"). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less in the consolidated balance sheets. The Company has also elected to account for the lease and non-lease components as a combined lease component for its current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.

Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

Recent accounting pronouncements
The Company has evaluated accounting pronouncements recently issued but not yet adopted and believes that the accounting pronouncements currently do not apply to the Company’s operations and are not expected to have a material impact on the Company’s unaudited interim condensed consolidated financial statements or disclosures.
3. Revenue
In November 2022, POINT announced strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. ("Lantheus") for exclusive worldwide rights for POINT's programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003), excluding certain territories (Japan, South Korea, Singapore, Indonesia, and China including Hong Kong, Macau and Taiwan) (the "PNT2002 Agreement" and the "PNT2003 Agreement", respectively, and collectively the "Lantheus License Agreements"). The collaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in Prostate-Specific Membrane Antigen ("PSMA") PET and radiopharmaceuticals.

7

In December 2022, closing conditions for the Lantheus transaction, including antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended, the "HSR Act"), were satisfied. POINT received a $250.0 million upfront payment under the PNT2002 Agreement and will receive an additional payment of up to $250.0 million upon U.S. regulatory approval. In addition, once certain return on investment financial thresholds have been achieved and other conditions satisfied, POINT will be eligible to receive royalties of 20% on all net sales (prior to which there is a period of sales in which the royalty may be based on only a portion of the gross profit), and contingent upon the satisfaction of certain net sales milestones, additional payments of up to $1.3 billion. POINT received a $10.0 million upfront payment under the PNT2003 Agreement, and will receive up to an additional $30.0 million upon U.S. regulatory approval. The PNT2003 Agreement also provides that POINT will receive royalties of 15% on net sales and, contingent upon the satisfaction of certain net sales milestones, an additional payment of up to $275.0 million.

In connection with the PNT2002 Agreement, the Company is responsible for completing the Company's multi-center, randomized, open label phase 3 Study evaluating metastatic castration-resistant Prostate cancer using 177Lu-PNT2002 PSMA therapy After Second-line Hormonal treatment (“SPLASH") trial and the parties will work together to file the New Drug Application (“NDA”), with the costs incurred in connection with the U.S. Food and Drug Administration ("FDA") submission being borne by Lantheus. Thereafter, Lantheus will be responsible for all additional clinical and regulatory costs in the U.S., as well as all costs for development, clinical trials and regulatory approval in the rest of its territories outside the U.S., except Asia.
To determine the appropriate amount of revenue to be recognized under ASC Topic 606, Revenue from Contracts with Customers, the Company performs the following steps: (i) identify the promised goods or services in the contract, (ii) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract, (iii) measure the transaction price, including the constraint on variable consideration, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when (or as) the Company satisfies each performance obligation.
In connection with the PNT2002 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the SPLASH trial, support the NDA submission and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2002 Agreement to be the $250.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.
In connection with the PNT2003 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the necessary submissions for regulatory approval and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2003 Agreement to be the $10.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.
The Company does not include variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will occur. Variable consideration in the PNT2002 Agreement and PNT2003 Agreement consists of:
Potential future regulatory milestone payments. The Company concluded that this variable consideration is constrained considering that achievement of the milestones is outside its control and contingent upon the future success of clinical trials and regulatory approval by the FDA and in respect of other territories outside the U.S.
Potential future milestone payments in connection with certain sales targets as well as any future royalties. The Company concluded that these payments qualify for the royalty exception. Under the royalty exception, sales-based royalties are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). That is, an entity does not estimate the amount of a sales-based royalty at contract inception; rather, revenue
8

would be recognized when the subsequent sales occur (under the assumption that the associated performance obligation has been satisfied or partially satisfied).
Potential payments for the manufacturing and supply of commercial product. The Company concluded that this variable consideration is constrained as it is contingent upon future regulatory approvals and the execution of a manufacturing and supply agreement.
The estimate of the Company’s variable consideration to be included in the transaction price is updated at each reporting date as a change in estimate. For the potential future regulatory milestone payments, the Company utilizes the most likely amount approach to determine the amounts recognized and timing of recognition. For the potential payments for manufacturing and supply of commercial product, the Company utilizes the expected value approach to determine the amounts recognized and timing of recognition. Once the constraint is removed, the milestone payments will be accounted for and allocated to the performance obligations.
For the licenses conveyed to Lantheus, the Company recognized revenue upon execution and regulatory approval of the Lantheus License Agreements. The Company concluded that the licenses represent that of functional intellectual property as each has significant standalone functionality and derives a substantial portion of its utility from that standalone functionality.
For the obligations to complete the SPLASH trial, support the NDA submission and participate in joint steering activities in connection with the PNT2002 Agreement as well as the obligations to complete the necessary submissions for regulatory approval and participate in joint steering activities for the PNT2003 Agreement, the Company recognizes revenue using the cost-to-cost method, which it concluded best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion.
The following table presents the Company’s contract liabilities as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Deferred revenue
Deferred revenue, current$12,586,443 $23,242,290 
Deferred revenue, net of current portion3,720,881 10,178,147 
Total$16,307,324 $33,420,437 
At inception of the Lantheus License Agreements, deferred revenue of $34.8 million was recognized in connection with future performance. During the three and nine months ended September 30, 2023, the Company recognized $2.8 million and $17.1 million in revenue for services performed (three and nine months ended September 30, 2022 — $nil and $nil, respectively). The current portion of deferred revenue reflects the Company’s estimate of the revenue it expects to recognize within the next 12 months. The Company expects to recognize the remainder of the deferred revenue balance in subsequent periods through the year ending December 31, 2028. No contract assets were recognized in connection with the Lantheus License Agreements, including costs incurred in obtaining the agreements.
9

4. Cash, cash equivalents and investments
Cash, cash equivalents and investments consisted of the following:
As of September 30, 2023As of December 31, 2022
Cash$11,446,728 $12,429,627 
Cash equivalents:
Money market funds6,852,616 273,998,744 
Commercial paper3,308,068  
Total cash and cash equivalents21,607,412 286,428,371 
Short-term investments
Commercial paper107,567,350 115,156,455 
Corporate bonds93,787,733 45,219,042 
U.S. Government agency debt securities35,942,645 42,577,762 
Asset backed securities80,258,208 35,830,211 
Total short-term investments317,555,936 238,783,470 
Long-term investments
U.S. Government agency debt securities16,098,662  
Asset backed securities8,634,828 16,119,430 
Corporate bonds35,059,671  
Total long-term investments59,793,161 16,119,430 
Total cash, cash equivalents and investments$398,956,509 $541,331,271 
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of September 30, 2023 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$107,597,155 $981 $(30,786)$107,567,350 $107,567,350 $ 
Corporate bonds129,438,4505,918(596,964)128,847,40493,787,73335,059,671 
Asset backed securities89,554,665204 (661,833)88,893,03680,258,2088,634,828 
U.S. Government agency debt securities52,186,023 (144,716)52,041,30735,942,64516,098,662 
Total available-for-sale securities$378,776,293 $7,103 $(1,434,299)$377,349,097 $317,555,936 $59,793,161 

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of December 31, 2022 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$115,156,455 $ $ $115,156,455 $115,156,455 $ 
Asset backed securities52,019,619 26,527 (96,505)51,949,641 35,830,211 16,119,430 
Corporate bonds45,468,482  (249,440)45,219,042 45,219,042  
U.S. Government agency debt securities42,715,195  (137,433)42,577,762 42,577,762  
Total available-for-sale securities$255,359,751 $26,527 $(483,378)$254,902,900 $238,783,470 $16,119,430 
10


The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of September 30, 2023:
Amortized CostFair Value
Due within one year$318,607,866 $317,555,936 
Due between one and five years60,168,427 59,793,161 
Total$378,776,293 $377,349,097 

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2022:

Amortized CostFair Value
Maturing within one year$239,236,498 $238,783,470 
Maturing between one and five years16,123,253 16,119,430 
Total$255,359,751 $254,902,900 

The primary objective of our investment portfolio is to maintain safety of principal balances, provide sufficient levels of liquidity and enhance overall returns in an efficient manner with acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

During the three and nine months ended September 30, 2023, we had $611 of realized gains on available-for-sale investments.
5. Fair value measurements
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The following tables present information about the Company’s financial assets and liabilities as of September 30, 2023 and December 31, 2022, that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
11

Level 1Level 2Level 3Total
September 30, 2023
Cash equivalents:
Money market mutual fund$6,852,616 $ $ $6,852,616 
Commercial paper 3,308,068  3,308,068 
Available-for-sale debt securities:
Commercial paper 107,567,350  107,567,350 
Corporate bonds 128,847,404  128,847,404 
Asset backed securities 88,893,036  88,893,036 
U.S. Government agency debt securities52,041,307   52,041,307 
Total$58,893,923 $328,615,858 $ $387,509,781 

Level 1Level 2Level 3Total
December 31, 2022
Cash equivalents:
Money market mutual fund$273,998,744 $ $ $273,998,744 
Commercial paper    
Available-for-sale debt securities:
Commercial paper 115,156,455  115,156,455 
Asset backed securities 51,949,641  51,949,641 
Corporate bonds 45,219,042  45,219,042 
U.S. Government agency debt securities42,577,762   42,577,762 
Total$316,576,506 $212,325,138 $ $528,901,644 

Certain of our available-for-sale debt securities, including U.S. Government agency debt securities, are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

On May 7, 2023, POINT Biopharma Inc. entered into a Convertible Note Purchase Agreement (the "Convertible Note Agreement") with Ionetix Alpha Corporation ("Ionetix-α"), a subsidiary of IONETIX Corporation. On June 1, 2023, the Company purchased $5.0 million in unsecured promissory notes (the "Note Receivable") convertible into common stock of Ionetix-α at a conversion price that is calculated based on certain conditions as defined in the Convertible Note Agreement. Management assessed all features in the Convertible Note Agreement to determine embedded derivatives requiring bifurcation. In accordance with the Convertible Note Agreement, Ionetix-α has a voluntary redemption option, subject to certain terms and conditions, and may provide notice to the Company upon which the Company can elect to either redeem the Note Receivable at 150% of principal and interest outstanding or convert it into common stock of Ionetix-α. Management concluded that this put option meets the definition of a derivative and it is not clearly and closely related to the Note Receivable, thus requiring bifurcation from the host instrument and recognition at fair value. Further, management concluded the Note Receivable host instrument is to be classified as a loan receivable and therefore is measured at amortized cost but disclosure of fair value is required. Management determined the fair values of both the Note Receivable and the embedded derivative under Level 3 in the fair value hierarchy. Management concluded that the fair value of the Note Receivable as of September 30, 2023 approximated amortized cost and that the fair value of the embedded derivative was nil both at inception of the arrangement and on September 30, 2023. On September 29, 2023, POINT Biopharma Inc. entered into the Amendment of Convertible Note Purchase Agreement (the "Amendment"), whereby in connection with the Amendment, the Company and Ionetix-α agreed to accelerate the purchase of an additional $5.0 million of unsecured promissory notes subject to certain closing conditions. Those conditions were met and the additional purchase was made on October 2, 2023. See Note 16.

We did not have any financial liabilities measured at fair value on a recurring basis as of September 30, 2023. The carrying values of the Company’s cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. There have been no transfers of assets or liabilities between the fair value measurement levels as of September 30, 2023.
12

6. Prepaid expenses and other current assets
Prepaid expenses and other current assets consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Prepaid clinical trial expenses2,812,270 4,011,419 
Prepaid insurance1,390,347 1,310,314 
Receivable on matured short-term investment5,000,000  
Canadian harmonized sales tax receivable206,326 60,222 
Deposit on production equipment 13,738 
Other492,786 215,196 
Total9,901,729 5,610,889 
7. Property, plant and equipment, net
Property, plant and equipment, net consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Land and building19,992,990 18,163,962 
Machinery and equipment11,241,336 5,328,639 
Property, plant and equipment, in development19,827,730 8,434,384 
Facility lease (Note 9)
5,384,707  
Furniture and fixtures938,909 698,728 
Computer equipment237,963 149,892 
57,623,635 32,775,605 
Less: Accumulated depreciation(3,581,282)(1,395,029)
Total54,042,353 31,380,576 

In July 2020, the Company purchased land and a building in Indianapolis, Indiana (which has been expanded to approximately 81,000 square feet) for the purpose of retrofitting the existing building into a state-of-the-art, Current Good Manufacturing Practices ("cGMP") compliant facility that will support the Company’s drug manufacturing operations. The Company commenced the manufacture of clinical supply in the Indianapolis manufacturing facility in January 2022. Construction continues on the facility to expand capacity.

Property, plant and equipment that have finite lives are recorded at cost less accumulated depreciation and impairment losses. Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value:
Asset CategoryEstimated Useful Life
Computer equipment
5 years
Machinery and equipment
7 years
Furniture and fixtures
7 years
Facility lease
7 years
Building
20 years
8. Accrued liabilities
Accrued liabilities consisted of the following:
13

As of September 30, 2023
As of December 31, 2022
$$
Accrued personnel costs5,663,218 7,116,382 
Accrued research and development costs7,766,189 9,645,594 
Accrued corporate legal fees and other professional services907,019 2,068,793 
Accrued costs for purchases of property, plant and equipment75,360 105,741 
Other accrued costs117,568 157,944 
Total14,529,354 19,094,454 
9. Leases
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s current portfolio of leases, the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments. The Company has not incurred any material short-term lease costs or variable lease costs associated with its finance and operating leases.
On February 2, 2023, POINT Biopharma Corp., entered into a Facility Agreement (the "UHN Agreement") with University Health Network (“UHN”), a not-for-profit corporation incorporated under the laws of Canada. Pursuant to the UHN Agreement, the Company was provided access to utilize a 7,700 square foot, licensed research and development space with cGMP manufacturing suites (the “Facility”), which the Company will use to develop and expand its pipeline of next-generation radioligands. The lease commencement date was determined to be April 1, 2023, the date upon which the Company was provided access to the Facility. The lease is accounted for as a finance lease in accordance with ASC 842 as one lease component for the facility, infrastructure and equipment, and the right-of-use asset has been included within property, plant and equipment. Management concluded the lease represents a finance lease on the basis that management believes the lease term covers the remaining economic life of the primary lease component. The initial term of the UHN Agreement will run for five years from the lease commencement date, with an option to renew for additional two-year terms thereafter, subject to certain conditions described in the UHN Agreement. Management included the first option to renew for two years as part of the lease term in determining the right-of-use asset and lease liability. The UHN Agreement does not transfer any title in the Facility to the Company. During the term, the Company shall be responsible for day-to-day management activities and decision-making regarding the Facility. General governance of the Facility will be exercised by the Company and UHN through a joint committee. The joint committee, which will meet quarterly, will have a minimum of six people and will be comprised of an equal number of members from each of the Company and UHN.
On March 10, 2023, the Company entered into a lease for an approximately 103,000 square foot facility in Indianapolis (the "Indianapolis Lease"). The lease commencement date was determined to be July 1, 2023, the date upon which the Company was provided access to the facility. The initial term of the lease will run for 121 months from the lease commencement date, with an option to renew for two ten-year terms thereafter, subject to certain conditions described in the Indianapolis Lease. Management did not include either option to renew as part of the lease term in determining the right-of-use asset and lease liability. Management has accounted for the lease as an operating lease as it believes that the lease term does not cover a substantial portion of the economic life of the primary lease component nor does the present value of the minimum lease payments exceed 90% of the fair value of the facility. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the property to the Company.
On April 12, 2023, the Company entered into an operating lease for laboratory space with a lease term of two years. The lease commencement date was determined to be April 15, 2023, the date upon which the Company was provided access to the laboratory space. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the laboratory space to the Company.

The components of lease expense are as follows:

14

For the nine months ended September 30, 2023
Operating lease expense$303,215 
Finance lease cost
Amortization of right-of-use asset384,622 
Interest on lease liability196,027 
Total finance lease cost$580,649 

As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.

Supplemental cash flow information related to leases is as follows:

For the nine months ended September 30, 2023
Cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow use from operating leases$167,397 
Operating cash flow use from finance lease$196,027 
Financing cash flow use from finance lease$285,949 
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$5,644,563 
Finance lease$5,384,707 

The following table summarizes the weighted average remaining lease terms for the Company’s leases:

As of September 30, 2023
Weighted-average remaining lease term (in years):
Operating leases9.2
Finance lease6.5

Below is information on the weighted average discount rates used at the time that the leases were commenced:

As of September 30, 2023
Weighted-average discount rates:
Operating leases7.8 %
Finance lease7.7 %

The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:

15

Operating LeasesFinance Lease
2023$232,797 $246,755 
2024689,632 987,018 
2025797,739 987,018 
2026746,332 987,018 
2027768,722 987,018 
Thereafter4,732,515 2,220,793 
Total lease payments$7,967,737 $6,415,620 
Less: imputed interest(2,385,189)(1,335,399)
Present value of lease liabilities$5,582,548 $5,080,221 
10. Stockholders’ equity
The Company is authorized to issue 430,000,000 shares of common stock, with a par value of $0.0001 per share ("Common Stock"), as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”).
During the three months ended September 30, 2023, there were no issuances of Common Stock. During the nine months ended September 30, 2023, the Company issued (i) 86,585 shares of Common Stock in connection with the exercise of stock options granted to non-employee consultants, resulting in total cash proceeds of $120,353 and (ii) 29,628 shares of Common Stock in connection with the exercise of stock options granted to employees and directors, resulting in total cash proceeds of $211,569.

During the three months ended September 30, 2022, the Company issued (a) 13,900,000 shares of Common Stock in connection with an underwritten public share offering at the price of $9.00 per share pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission, resulting in total gross proceeds of $125.1 million (excluding approximately $8.2 million of issuance costs) and (b) 30,000 shares of Common Stock in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $41,700. During the nine months ended September 30, 2022, the Company issued 13,933,168 shares of Common Stock, including the 13,930,000 shares of Common Stock discussed above, as well as 3,168 shares of Common Stock in connection with the exercise of stock options issued to non-employee consultants, resulting in total cash proceeds of $4,403.
As of September 30, 2023, the total number of issued and outstanding shares of Common Stock was 105,765,954 (December 31, 2022 — 105,649,741). As of September 30, 2023, there were no issued and outstanding shares of Preferred Stock (December 31, 2022 — $nil).
Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Holders of Common Stock are entitled to receive dividends, if any, as may be declared by the Company’s board of directors (the “Board”). During the three and nine months ended September 30, 2023, no cash dividends were declared or paid by the Company (September 30, 2022 — $nil).
The Board has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law ("DGCL"). During the nine months ended September 30, 2023, no shares of Preferred Stock were issued by the Company.
11. Stock-based compensation
In March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and non-qualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, the Board adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. The Company assumed the outstanding equity awards under the 2020 EIP, but no further grants may be made under the 2020 EIP. The 2021 EIP provides that the
16

number of shares reserved and available for issuance under the 2021 EIP will automatically increase each January 1, beginning on January 1, 2022, by 4% of the number of outstanding shares of Common Stock on the immediately preceding December 31, or such lesser amount as determined by the Board. As of January 1, 2023, the number of shares of Common Stock available under the 2021 EIP increased by 4,225,990 for a total of 9,049,548 shares of Common Stock authorized for issuance under the 2021 EIP as of September 30, 2023.
Stock options
The Company recorded $666,368 and $1,797,759 to research and development expenses and $1,210,064 and $2,798,518 to general and administrative expenses for stock-based compensation for the three and nine months ended September 30, 2023, respectively (September 30, 2022 — $476,481 and $1,220,426 to research and development expenses and $602,575 and $1,326,643 to general and administrative expenses for the three and nine months ended, respectively). The Company did not recognize a tax benefit related to stock-based compensation expense during the three and nine months ended September 30, 2023 as well as during the three and nine months ended September 30, 2022, as the Company had net operating loss carryforwards and recorded a valuation allowance against the deferred tax asset.
The following table summarizes the activity relating to the Company’s stock options.
Number of
Shares
Weighted
Average Exercise
Price Per Share
($)
Weighted-
Average
Remaining
Contractual
Term (in years)
Outstanding as of December 31, 2022
5,592,1735.85
Granted3,294,0717.09
Exercised(116,213)2.86
Forfeited(176,942)7.23
Expired(15,510)8.29
Outstanding as of September 30, 2023
8,577,5796.334.4
Vested and expected to vest as of September 30, 2023
8,577,5796.334.4
Options exercisable as of September 30, 2023
2,985,1145.193.7
During the three months ended September 30, 2023, 150,000 stock options were granted to an employee of the Company, with a weighted average grant date fair value of $4.57 per share. During the nine months ended September 30, 2023, 3,294,071 stock options were granted, including the 150,000 stock options discussed above as well as 3,144,071 stock options granted to employees and directors of the Company, with a weighted average grant date fair value of $3.85 per share. The vesting terms of the options granted to employees of the Company are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in three equal annual installments thereafter. The vesting terms of the options granted to directors of the Company are such that they vest on the one-year anniversary of the date of grant.

During the three months ended September 30, 2022, there were no stock options granted. During the nine months ended September 30, 2022, 1,948,614 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.59 per share. Except as provided below with respect to options granted to directors, the vesting terms of these options are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in three equal annual installments thereafter. On June 6, 2022, the terms of 128,070 stock options granted to directors of the Company during the quarter were amended to reduce the vesting period to one year. This amendment was accounted for as a modification and there was no material impact to stock-based compensation recorded.

The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted:
17

Three months ended September 30, 2023Three months ended September 30, 2022Nine months ended September 30, 2023Nine months ended September 30, 2022
Risk-free interest rate4.47%
3.71% - 4.47%
1.24% - 3.13%
Expected term (in years)4.25
3.50 - 4.25
4.25
Expected volatility66%%
66% - 68%
72% - 75%
Expected dividend yield%%%%
During the three months ended September 30, 2023, there were no stock option exercises. During the nine months ended September 30, 2023, non-employee consultants of the Company exercised 86,585 stock options with an intrinsic value of $700,217, and employees and directors of the Company exercised 29,628 stock options with an intrinsic value of $38,300, for total cash proceeds to the Company of $331,922.
During the three and nine months ended September 30, 2022, non-employee consultants of the Company exercised 30,000 and 33,168 stock options with intrinsic values of $238,300 and $257,601, respectively. The exercises resulted in cash proceeds to the Company of $41,700 and $46,103, respectively.
As of September 30, 2023, the unrecognized stock-based compensation expense related to unvested stock options was $17,944,644 and the estimated weighted average remaining vesting period was 2.9 years.
Performance Share Units
During the year ended December 31, 2022, 146,044 performance share units ("PSUs") were granted to employees of the Company, with a grant date fair value of $6.61 per unit based on the closing share price of the Company's Common Stock on the date of grant. The vesting terms of these PSUs are such that 100% vest upon the regulatory approval of PNT2002 by the FDA. During the three and nine months ended September 30, 2023, the Company did not record any stock-based compensation expense related to these PSUs on the basis that they cannot be considered probable to vest as the regulatory approval requirement is outside the control of the Company and the clinical trial remains ongoing.
12. Commitments and contingencies
Indianapolis facility commitments
The Company is party to certain agreements for the continuing expansion of the manufacturing capabilities of the Indianapolis facility (see Note 7). Effective in the second quarter of 2022, the Company entered into an agreement for the design and build of a commercial manufacturing line. As of September 30, 2023, the Company is committed to aggregate future payments of approximately $22.5 million in connection with these agreements. During the three and nine months ended September 30, 2023, approximately $5.2 million and $15.5 million, respectively, has been recorded within property, plant and equipment in connection with these agreements (three and nine months ended September 30, 2022 — approximately $3.7 million and $7.7 million, respectively).
Clinical trial and commercial commitments
The Company, in the normal course of business, enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain products and product lines during the Company’s clinical phase. These agreements often have minimum purchase commitments and generally terminate upon the termination of the clinical trial. As at September 30, 2023, aggregate remaining minimum commitments amount to approximately $5.4 million with payments ranging from three to eight years or upon completion of the clinical trial, if earlier. The Company recorded research and development expenses in connection with these agreements of approximately $3.1 million and $14.4 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $3.8 million and $8.1 million, respectively).
The Company also has supply agreements with third parties to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of products in the amount of approximately $109.2 million ($148.3 million CAD) with payments ranging from two to nine years. The purchase commitments are contingent upon the completion of certain milestones by the third-party suppliers. During the three and nine months ended September 30, 2023 and September 30, 2022, the Company did not record any research and development expenses in connection with this agreement.

On May 10, 2023, the Company entered into an Irradiation Services Agreement (the "Irradiation Agreement") which expands the Company's reactor network. Pursuant to the Irradiation Agreement, the Company will receive irradiation services to irradiate ytterbium-176 (“176Yb”) and has minimum purchase commitments of approximately $32.4 million over
18

the ten-year contract term. During the three and nine months ended September 30, 2023, the Company did not record any research and development expenses in connection with this agreement.

On September 25, 2023, the Company entered into a Supply Agreement (the "Supply Agreement") for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The Supply Agreement has a term of ten years and has minimum purchase commitments of approximately $107.4 million (€101.8 million) subject to certain conditions in the Supply Agreement, including the successful validation of the supplier-produced 177Lu with the intended compounds. The Company recorded research and development expenses in connection with this agreement of approximately $0.2 million and $0.2 million during the three and nine months ended September 30, 2023, respectively.
The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. As of September 30, 2023, the remaining minimum purchase commitment under this agreement is approximately $23.7 million with payments that range from one to five years. The Company recorded research and development expenses in connection with this agreement of approximately $3.5 million and $14.6 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $6.5 million and $15.4 million, respectively).
License agreements
The Company, in the normal course of business, enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details about the Company’s license agreements, see Note 15 to the 2022 Financial Statements.
On April 17, 2023, POINT Biopharma Inc. entered into first and second amendments (the "Amendments") to that certain Sublicense Agreement, dated November 14, 2019, between POINT Biopharma Inc. and Scintomics GmbH ("Scintomics"). Pursuant to the Amendments, the exclusive, sublicensable, license was expanded to include all geographies worldwide and the Company has increased flexibility in connection with sublicense arrangements.
On September 11, 2023, POINT Biopharma Inc. entered into a collaboration and license agreement between POINT Biopharma Inc. and Athebio AG ("Athebio") (the "Athebio Agreement"). Pursuant to the Agreement, the Company is granted exclusive access to Athebio's intellectual property and capabilities in the designed ankyrin repeat proteins ("DARPins") development. The Company recorded research and development expenses in connection with this agreement of $1.0 million during the three and nine months ended September 30, 2023. In addition, in connection with the Athebio agreement, the Company is committed to enter into a stock purchase agreement by which the Company will invest a total of $5.0 million subject to certain conditions and milestones set forth in the Athebio Agreement.

The Company recorded aggregate research and development expenses in connection with its license agreements of approximately $1.5 million and $5.0 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $0.8 million and $5.3 million, respectively).
13. Net loss per share
Basic loss per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method.
Three months
ended
 September 30, 2023
Three months
ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Net loss$24,774,353 $24,013,069 $66,715,863 $64,973,890 
Weighted-average common shares outstanding-basic and diluted 105,765,954 92,401,484 105,717,330 90,891,031 
Net loss per share-basic and diluted $0.23 $0.26 $0.63 $0.71 
The Company’s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company's PSU's are considered contingently issuable shares for the purpose of the computation of loss per share and have been excluded on the basis that
19

as of September 30, 2023, the performance condition for vesting had not been achieved. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to the holders of Common Stock is the same.
14. Income Taxes
The Company calculates its interim tax provision at the end of each interim period and estimates the annual effective tax rate, which is applied to its ordinary quarterly earnings. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.
The Company has operations in both the United States and Canada, and as such it is subject to tax in both countries. The income tax expense for the three months ended September 30, 2023 and September 30, 2022 was $871,449 and $180,500, respectively and the income tax benefit and expense for the nine months ended September 30, 2023 and September 30, 2022 was $288,491 and $452,021, respectively. The income tax amounts for the three and nine months ended September 30, 2023, include tax benefits related to research and development tax credits partially offset by current federal, state, and Canadian income tax adjustments. The three months ended September 30, 2023 also includes prior year current income tax adjustments in the United States jurisdictions. The income tax expense for the three and nine months ended September 30, 2022, consists of current taxes in Canada.
The Company files income tax returns in the U.S. federal, certain states, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations would have a significant impact on its financial position or results of operations.
As of September 30, 2023, the Company believes no significant changes in the unrecognized tax benefits will occur within the next 12 months.
15. Related party transactions
The Company recognized expenses in connection with related party transactions in the unaudited interim condensed consolidated statements of operations as follows:
Three months ended
September 30, 2023
Three months ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Consulting fees on business activities to Board member $90,161 $90,040 $296,072 $259,132 
Reimbursement to Board member for occupancy costs18,219 17,395 53,532 53,071 
Total$108,380 $107,435 $349,604 $312,203 
Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount.
During the three and nine-month periods ended September 30, 2023 and 2022, the Company received consulting services for research and development from a Board member. As of September 30, 2023, $43,859 is recorded within accrued liabilities in relation to this consulting arrangement.
The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC 842 to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.
16. Subsequent events
Ionetix Amendment of Convertible Note Purchase Agreement
20

On September 29, 2023, POINT Biopharma Inc. entered into the Amendment, whereby on October 2, 2023 the Company purchased an additional $5.0 million of unsecured promissory notes from Ionetix-α. In connection with the Convertible Note Agreement, this additional purchase was originally scheduled for six months from the initial purchase date of June 1, 2023. See Note 5.
Merger Agreement
As previously announced, on October 2, 2023, Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”). Merger Sub commenced the cash tender offer (the “Offer”) to purchase all of the outstanding shares of Common Stock (the “Shares”), at a price of $12.50 per share, net to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement. The Offer commenced on October 13, 2023 and was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 p.m., Eastern Time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.

Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the DGCL) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the HSR Act, (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the U.S. Federal Trade Commission (the “FTC”) and the Antitrust Division of the U.S. Department of Justice (the “Antitrust Division”), initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern Time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. The Company could be required to pay the Parent a termination fee of approximately $54.4 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The consummation of the Offer and the Merger is not subject to a financing condition. For more information on the Offer and the Merger, refer to the Company's Current Report on Form 8-K filed October 3, 2023.
21

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited interim condensed consolidated financial statements and notes thereto for the three and nine months ended September 30, 2023 (the “Q3 2023 Financial Statements”) appearing elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto for the periods ended December 31, 2022 and 2021 (the “2022 Financial Statements”) contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission ("SEC") on March 27, 2023 (the "2022 Form 10-K"). Please also see the section entitled “Cautionary Note Regarding Forward-Looking Statements.”
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negative of any of the foregoing) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These factors include, but not limited to, the following:

risks to the Company with respect to the Offer and the Merger, including: (a) uncertainties as to the timing of the Offer and the Merger, or that the closing of the proposed Merger will not occur including in circumstances which would require the Company to pay the termination fee or other expenses; (b) uncertainties as to how many of POINT’s stockholders will tender their shares in the Offer; (c) the possibility that competing offers will be made; (d) the possibility that various closing conditions for the proposed transactions may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transactions; (e) stockholder litigation that has or may be filed in connection with the proposed Merger, which may affect the timing or occurrence of the proposed Merger or result in significant costs of defense, indemnification and liability; (f) the effects of the proposed transactions on relationships with employees, other business partners or governmental entities; (g) unanticipated difficulties or expenditures relating to the Merger; and (h) risks related to disruption of management’s attention from the Company’s ongoing business operations due to the Merger;
the success, cost and timing of our product development activities and clinical trials, our plans for clinical development of our product candidates and the initiation and completion of any other clinical trials and related preparatory work and the expected timing of the availability of results of the clinical trials;
our ability to recruit and enroll suitable patients in our clinical trials;
the potential attributes and benefits of our product candidates;
our ability to obtain and maintain regulatory approval for our product candidates, and any related restrictions, limitations or warnings in the label of an approved product candidate;
our ability to obtain funding for our operations, including funding necessary to complete further development, approval and, if approved, commercialization of our product candidates;
the period over which we anticipate our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements;
the potential for our business development efforts to maximize the potential value of our portfolio;
our ability to identify, in-license or acquire additional product candidates;
our ability to maintain the license agreements underlying our product candidates;
our ability to compete with other companies currently marketing or engaged in the development of treatments for the indications that we are pursuing for our product candidates;
our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection;
our ability to contract with and rely on third parties to assist in conducting our clinical trials and manufacture our product candidates;
the development and expansion of our own manufacturing facility in Indianapolis, Indiana and the ability of this facility to provide adequate production capacity to meet future clinical and commercial demands for our product candidates;
22

the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;
the rate and degree of market acceptance of our product candidates, if approved;
the pricing and reimbursement of our product candidates, if approved;
regulatory developments in the United States and foreign countries;
the impact of laws and regulations;
our ability to attract and retain key scientific, medical, commercial or management personnel;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our financial performance;
the level of activity in the trading market for our common stock, par value $0.0001 per share ("Common Stock") and the volatility of the market price of our Common Stock;
the effect of the COVID-19 pandemic, the Russo-Ukrainian conflict, Taiwan and China tensions, Israel-Palestine conflict and/or bank failures on the foregoing; and
other factors detailed under the section entitled “Risk Factors” in the 2022 Form 10-K.

These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the 2022 Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak, the Russo-Ukrainian conflict, the Israel-Palestine conflict and/or adverse developments affecting the financial services industry and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We do not undertake any obligation to update or revise any forward-looking statements, which speak only as of the date made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Overview
Introduction
We are a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. We have a pipeline of product candidates and early-stage development programs, in-house manufacturing capabilities, and a secured supply for rare medical isotopes like actinium-225 ("225Ac") and lutetium-177 ("177Lu").

Our team brings decades of combined experience in radioligand clinical development and manufacturing. In a space where manufacturing is often overlooked, the Company has unique capabilities. In addition to our Center of Radioligand Excellence (CORE), a commercial-scale radioligand production campus in Indianapolis, Indiana, we also operate the POINT Institute for Radioligand Innovation (PIRI) in Toronto, Ontario, a state of the art Current Good Manufacturing Practices ("cGMP") R&D center focused on bringing novel programs from discovery to the clinic. Furthermore, management has leveraged their prior relationships to assemble resilient radioisotope supply chains, which even includes processing our own no-carrier-added ("n.c.a") 177Lu isotope in-house.

Our predecessor was incorporated on September 18, 2019 as POINT Theranostics Inc. under the DGCL and subsequently amended its name to “POINT Biopharma Inc.” on November 22, 2019. POINT Biopharma Inc. became a wholly-owned subsidiary of POINT Biopharma Global Inc. pursuant to a merger on June 30, 2021.

Merger Agreement

As previously announced, on October 2, 2023, Parent, Merger Sub, and the Company entered into the Merger Agreement. Merger Sub commenced the Offer to purchase all of the Shares, at the Offer Price, net to the stockholder in cash, without interest and less any applicable withholding taxes and on the terms, upon the terms and subject to the conditions set forth in the Merger Agreement. The Offer commenced on October 13, 2023 and was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 pm, Eastern Time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.

23

Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the DGCL) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the HSR Act, (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. The consummation of the Offer and the Merger is not subject to a financing condition. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the FTC and the Antitrust Division, initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. For more information on the Offer and the Merger, refer to the Company's Current Report on Form 8-K filed October 3, 2023.

Recent Developments
PNT2002: 177Lu-based PSMA-targeted radiopharmaceutical

Enrollment in PNT2002's phase 3 SPLASH trial (NCT04647526) is complete and topline data is expected in the fourth quarter of 2023.

PNT2004: Fibroblast activation protein-alpha (FAP-alpha) inhibitor

The PNT2004 program leverages the D-ala-boroPro FAP targeting warhead, which is a potent and selective FAP inhibitor. PNT6555 is the current clinical lead in the PNT2004 program.

The phase 1 FRONTIER trial (NCT05432193) utilizing 68Ga/177Lu-labelled PNT6555 closed enrollment after the dosing of cohort 3 (12 GBq) in October. There are no plans for expansion of the third cohort, and there were no dose limiting toxicities. Analysis of the dosimetry and clinical data from the FRONTIER trial is underway and includes pancreatic ductal adenocarcinoma, colorectal cancer, cholangiocarcinoma, and esophageal cancer subjects.

Presentation of data from the FRONTIER study is anticipated in the first half of 2024, and based on initial promising data we expect to advance at least one 2nd-generation D-ala-boroPro-based lead into the clinic next year.

PNT2001: 225Ac-labelled next-generation PSMA-targeted radiopharmaceutical

For the phase 1 portion of ACCEL, the first-in-human phase 1/2 clinical trial for PNT2001's actinium-225 program, we expect the first patient dosed in this trial to be in the first quarter of 2024. The trial was designed to enable the parallel exploration of PNT2001 in two populations: patients with later-stage mCRPC and patients with earlier-stage BCR or PSMA-positive oligorecurrent disease.

Manufacturing & Supply Chain Updates

In July 2023, we announced an expanded agreement with ITM Isotope Technologies Munich SE (ITM), which broadens the supply of ITM’s no-carrier-added lutetium-177 (n.c.a. 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline.

In September 2023, we signed a supply agreement with Eckert & Ziegler AG for no-carrier-added lutetium-177 (n.c.a. 177Lu).

Discovery Updates

In September 2023, we announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (“Radio-DARPins”). The collaboration gives POINT exclusive access to Athebio’s intellectual property and capabilities in DARPin development in the radioligand therapy field. Together, the parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities. POINT
24

will be solely responsible for the clinical development and commercialization of Radio-DARPins translated from the discovery collaboration.

Risks & Liquidity

Drug research and development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. We will not generate revenue from product sales unless and until we successfully complete clinical development of, are able to obtain regulatory approval for and successfully commercialize, the product candidates we are currently developing or may develop. We currently do not have any product candidates approved for commercial sale.

Our product candidates, currently under development or that we may develop, will require significant additional research and development efforts, including extensive clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities. There can be no assurance that our research and development activities will be successfully completed, that adequate protection for our licensed or developed technology will be obtained and maintained, that products developed will obtain necessary regulatory approval or that any approved products will be commercially viable.
If we obtain regulatory approval for one or more of our product candidates, we expect to incur significant expenses related to developing our commercialization capabilities to support product sales, marketing, and distribution activities, either alone or in collaboration with others. Prior to the Lantheus License Agreements, the Company had incurred significant net losses and had funded operations primarily through equity financings. Operating losses and negative cash flows were incurred during the three and nine months ended September 30, 2023 and are expected to be incurred in the future.
In September 2022, POINT closed a previously announced underwritten public offering of approximately 15,500,000 shares of Common Stock at a public offering price of $9.00 per share (the "2022 Public Offering"). The gross proceeds to the Company from the 2022 Public Offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $140.0 million. We believe that the net proceeds from the 2022 Public Offering and the Lantheus License Agreements, together with our available resources and existing cash, cash equivalents and investments, are sufficient to fund our operating expenses and capital expenditure requirements into 2026.
We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of our product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of COVID-19, the ability to secure additional capital to fund operations and commercial success of our product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if our drug development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.
We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:
advance our clinical-stage product candidates 177Lu-PNT2002 and 177Lu-PNT6555 through clinical development;
advance our preclinical-stage product candidate 225Ac-PSMA-62, along with candidates developed with our CanSEEKTM Prodrug Platform, into clinical development;
seek to identify, acquire, and develop additional product candidates, including through business development efforts to invest in or in-license other technologies or product candidates;
hire additional clinical, quality control, medical, scientific, and other technical personnel to support our clinical operations;
expand our operational, financial and management systems and increase personnel to support our operations;
meet the requirements and demands of being a public company;
maintain, expand, and protect our intellectual property portfolio;
make milestone, royalty, or other payments due under various in-license or collaboration agreements;
seek regulatory approvals for any product candidates that successfully complete clinical trials; and
undertake any pre-commercialization activities to establish sales, marketing, and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own or jointly with third parties.

25

The Company also has a number of risks and uncertainties related to the Offer and Merger described under “- Merger Agreement” above. These risks and uncertainties are described in more detail in Part II. Item 1A. “Risk Factors” starting on page 34.
COVID-19 Pandemic, macroeconomic and other geopolitical events
The Company is currently operating in a period of significant economic uncertainty, resulting from, among other things, the impact of the COVID-19 pandemic, geopolitical tensions, such as the ongoing military conflict between Russia and Ukraine, the Israel-Palestine conflict and heightened tensions between China and Taiwan, trade uncertainty, including changes in tariffs, sanctions, international treaties, and other trade restrictions, rising inflation and interest rates, and uncertainty and liquidity concerns in the broader financial services industry, including those caused by certain recent banking failures.

We are continuing to monitor the development and potential impact of these global economic and geopolitical events on our business and financial results. To date, we have not experienced any material business disruptions or incurred any impairment losses in the carrying values of our assets as a result of these events and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in the Q3 2023 Financial Statements. However, estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment; as a result, our estimates may change as new events occur and additional information is obtained.
Components of Operating Results
See Item 7 “Management's Discussion and Analysis of Financial Condition and Results of Operations - Components of Operating Results” in our 2022 Form 10-K, for a discussion of the nature of our operating expense line items within our accompanying unaudited interim condensed consolidated statements of operations.
Results of Operations - Three Months Ended September 30
The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022:
For the three
months ended
September 30, 2023
For the three
months ended
September 30, 2022
Change
(In U.S. dollars)$$$%
Revenue
Service revenue2,789,993 — 2,789,993 100.0 %
Total revenue2,789,993  2,789,993 100.0 %
Operating expenses:    
Research and development26,910,286 20,797,406 6,112,880 29.4 %
General and administrative5,505,869 3,839,626 1,666,243 43.4 %
Total operating expenses32,416,155 24,637,032 7,779,123 31.6 %
Loss from operations(29,626,162)(24,637,032)(4,989,130)20.3 %
Other income (expenses):
Investment income5,617,736 1,048,254 4,569,482 435.9 %
Foreign currency gain (loss)105,522 (243,791)349,313 (143.3)%
Total other income (expenses)5,723,258 804,463 4,918,795 611.4 %
Loss before income taxes(23,902,904)(23,832,569)(70,335)0.3 %
Income tax provision(871,449)(180,500)(690,949)(382.8)%
Net loss(24,774,353)(24,013,069)(761,284)3.2 %
Service Revenue
The Company recognized $2.8 million in revenue for services performed in connection with the Lantheus License Agreements for the three months ended September 30, 2023 (three months ended September 30, 2022 — $0).
26

Research and Development
The following table summarizes the components of research and development expenses for the three months ended September 30, 2023 and 2022:
For the three
months ended
September 30, 2023
For the three
months ended
September 30, 2022
Change
(In U.S. dollars)$$$%
Clinical trials6,314,574 9,956,461 (3,641,887)(36.6)%
Salaries and benefits8,186,525 5,033,778 3,152,747 62.6 %
Contract manufacturing7,150,118 3,579,255 3,570,863 99.8 %
Depreciation and overhead3,505,030 1,364,368 2,140,662 156.9 %
Sponsored research & product licenses1,500,000 750,000 750,000 100.0 %
Regulatory consulting254,039 113,544 140,495 123.7 %
Total26,910,286 20,797,406 6,112,880 29.4 %

For the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, the increase in research and development expenses was primarily due to increases in (a) personnel costs as the Company continues to expand its research and development headcount, most notably in our Indianapolis manufacturing facility and the PIRI, (b) costs incurred for contract manufacturing across all of our programs, (c) depreciation and overhead primarily related to our Indianapolis manufacturing facility and (d) our licensing agreements and related sponsored research in connection with our product candidates both preclinical and clinical including an incremental $1 million incurred in connection with the Athebio Agreement. This was partially offset by decreased clinical trial costs as our phase SPLASH trial costs have started to decline as we prepare to provide top line data in the fourth quarter of 2023. For the three months ended September 30, 2023, the Company incurred approximately $8.2 million and $0.5 million of direct costs associated with its PNT2002 and PNT2003 programs, respectively. These figures exclude amounts for salaries and benefits, depreciation and overhead costs which are not allocated by program.

General and administrative
General and administrative expenses increased for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, primarily in connection with increased headcount and personnel costs compared to the prior year period as well as increased consulting and professional fees as the scale of our operations continues to increase.
Other Income (Expenses)
For the three months ended September 30, 2023 and 2022, other income (expenses) consist mainly of (a) interest and other income earned on the Company's cash, cash equivalents and investments and (b) foreign exchange gains and losses primarily associated with foreign currency transactions occurring within the Company’s Canadian subsidiary. The increase in interest and other income in the current period reflects the increase in short and long-term investments primarily in connection with cash received in connection with equity financings and the Lantheus License Agreements.
Income Tax Provision
For the three months ended September 30, 2023, the increase in the income tax provision consists primarily of a) prior year current income tax adjustments in connection with the application of emerging guidance surrounding the section 174 rules around the capitalization of research and development expenses and b) taxes owing in Canada in relation to taxable income generated through management and research and development services performed by the Canadian subsidiary of the Company. This is partially offset by estimated research and development tax credits available for carryback.
27

Results of Operations - Nine Months Ended September 30
The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022:
For the nine
months ended
September 30, 2023
For the nine
months ended
September 30, 2022
Change
(In U.S. dollars)$$$%
Revenue
Service revenue17,113,113 — 17,113,113 100.0 %
Total revenue17,113,113  17,113,113 100.0 %
Operating expenses:   
Research and development85,097,331 54,112,136 30,985,195 57.3 %
General and administrative15,604,401 11,727,969 3,876,432 33.1 %
Total operating expenses100,701,732 65,840,105 34,861,627 52.9 %
Loss from operations(83,588,619)(65,840,105)(17,748,514)27.0 %
Other income (expenses):
Investment income16,717,703 1,605,927 15,111,776 941.0 %
Foreign currency loss(133,438)(287,691)154,253 (53.6)%
Total other income (expenses)16,584,265 1,318,236 15,266,029 1,158.1 %
Loss before income taxes(67,004,354)(64,521,869)(2,482,485)3.8 %
Income tax benefit (provision)288,491 (452,021)740,512 163.8 %
Net loss(66,715,863)(64,973,890)(1,741,973)2.7 %
Service Revenue
The Company recognized $17.1 million in revenue for services performed in connection with the Lantheus License Agreements for the nine months ended September 30, 2023 (nine months ended September 30, 2022 — $0).
Research and Development
The following table summarizes the components of research and development expenses for the nine months ended September 30, 2023 and 2022:
For the nine
months ended
September 30, 2023
For the nine
months ended
September 30, 2022
Change
(In U.S. dollars)$$$%
Clinical trials24,487,852 22,972,208 1,515,644 6.6 %
Salaries and benefits22,677,568 13,085,024 9,592,544 73.3 %
Contract manufacturing22,572,138 9,662,996 12,909,142 133.6 %
Depreciation and overhead9,402,634 2,847,830 6,554,804 230.2 %
Sponsored research & product licenses5,036,390 5,305,325 (268,935)(5.1)%
Regulatory consulting920,749 238,753 681,996 285.6 %
Total85,097,331 54,112,136 30,985,195 57.3 %

For the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, the increase in research and development expenses was due to the same or substantially the same factors as noted above for the three months ended September 30, 2023 with the exception that clinical trial costs increased during the nine month period primarily in connection with randomization phase of the phase 3 SPLASH trial. For the nine months ended September 30, 2023, the Company incurred approximately $31.1 million and $3.2 million of direct costs associated with its PNT2002 and
28

PNT2003 programs, respectively. These figures exclude amounts for salaries and benefits, depreciation and overhead costs which are not allocated by program.

General and administrative
General and administrative expenses increased for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, due to the same or substantially the same factors as noted above for the three months ended September 30, 2023.
Other Income (Expenses)
For the nine months ended September 30, 2023 and 2022, other income (expenses) consists mainly of (a) interest and other income earned on the Company's cash, cash equivalents and investments and (b) foreign exchange gains and losses primarily associated with foreign currency transactions occurring within the Company’s Canadian subsidiary. The increase in the current period reflects the same or substantially the same factors as noted above for the three months ended September 30, 2023.
Income Tax Benefit (Provision)
For the nine months ended September 30, 2023, the Company recorded income tax benefit compared with an income tax provision recorded for the nine months ended September 30, 2022. The recognition of an income tax benefit in the quarter was primarily the result of estimated research and development tax credits available for carryback. This is partially offset by a) prior year current income tax adjustments in connection with the application of emerging guidance surrounding the section 174 rules around the capitalization of research and development expenses and b) taxes owing in Canada in relation to taxable income generated through management and research and development services performed by the Canadian subsidiary of the Company. The income tax provision in the prior year period consisted primarily of taxes owing in Canada in relation to taxable income generated through management and research and development services performed by the Canadian subsidiary of the Company.
Liquidity and Capital Resources
Merger Agreement Impact on Liquidity

The Company expects to complete the Merger near the end of 2023, however, consummation of the Merger is subject to the satisfaction or (to the extent permitted by applicable law) waiver of the conditions to the completion of the Merger. The Company is unable to fully predict the impact that the timing, completion, or termination of the Merger will have on its liquidity, financial condition and results of operations due to numerous uncertainties.

Sources of Liquidity and Capital

Except for the upfront payment received pursuant to the Lantheus License Agreements, the Company has incurred significant net losses and funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to be incurred in future periods. We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if our drug development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.

Net losses totaled $24.8 million and $24.0 million for the three months ended September 30, 2023 and 2022, respectively, and $66.7 million and $65.0 million for the nine months ended September 30, 2023 and 2022, respectively.
In connection with the 2022 Public Offering, (a) on September 16, 2022, we issued 13,900,000 shares of Common Stock resulting in net proceeds of approximately $117.3 million, excluding certain transaction costs incurred in connection with filing the S-3 (defined below), and (b) on October 3, 2022, we issued an additional 1,589,779 shares of Common Stock for net proceeds to the Company of approximately $13.4 million as a result of underwriters exercising their option to purchase additional shares pursuant to the underwriting agreement. On December 22, 2022, we received $260.0 million in connection with the Lantheus License Agreements. We intend to use the net proceeds from these transactions to fulfill our obligations under the Lantheus License Agreements, and for general corporate purposes, funding of development programs, payment of milestones pursuant to our license agreements, general and administrative expenses, licensing of additional product candidates, and supporting our working capital needs.
29

Future Funding Requirements
Our primary use of cash is to fund operating expenses, primarily related to our research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.
Operating losses and negative cash flows are expected to continue to be incurred in the future. We may require additional capital to meet operational needs and capital requirements for clinical trials, for other research and development expenditures, and for business development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and preclinical studies.
Our future funding requirements will depend on many factors, including, but not limited to:
the scope, progress, results and costs of researching and developing our current product candidates, as well as other additional product candidates we may develop and pursue in the future;
the timing of, and the costs involved in, obtaining regulatory and marketing approvals for our product candidates and any other additional product candidates we may develop and pursue in the future;
the number of future product candidates that we may pursue and their development requirements;
subject to receipt of regulatory approval, if any, the costs of commercialization activities for our product candidates, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities;
subject to receipt of regulatory approval, revenue, if any, received from commercial sales of our product candidates or any other additional product candidates we may develop and pursue in the future;
the achievement of milestones that trigger payments under our various license agreements;
the extent to which we in-license or acquire rights to other products, product candidates or technologies;
our ability to establish collaboration arrangements for the development of our product candidates on favorable terms, if at all;
our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
the costs of preparing, filing and prosecuting patent applications, and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and
the costs of operating as a public company.
As of September 30, 2023, we had cash, cash equivalents and investments of approximately $399.0 million, which is anticipated to fund operations into 2026. We have based this estimate on current assumptions that may change or prove to be wrong, which would cause us to utilize our available capital resources sooner than we expect. In addition, our cash, cash equivalents and investments are subject to the economic pressures or uncertainties associated with local or global economic recessions, and ongoing geopolitical events. The failure of one or more of the financial institutions in which our cash, cash equivalents or investments are held, any resulting inability for us to obtain the return of our funds from any of those financial institutions, or any other adverse condition suffered by those financial institutions, could impact access to our cash, cash equivalents or investments and could adversely impact our operating liquidity and financial performance.
On July 11, 2022 the SEC declared effective our shelf registration statement on Form S-3 (the “S-3”) that allows the Company to offer and sell to the public up to $400.0 million of our Common Stock, preferred stock, debt securities, warrants to purchase our Common Stock, preferred stock or debt securities, subscription rights to purchase our Common Stock, preferred stock or debt securities and/or units consisting of some or all of these securities, from time to time in one or more offerings. The details of any future offerings, along with the use of proceeds from any securities offered, will be described in a prospectus supplement or other offering materials, at the time of offering. Also covered under the S-3 as part of the $400.0 million total amount registered is an at-the-market offering (“ATM”) of up to $150.0 million of our Common Stock pursuant to a distribution agreement with Piper Sandler & Co. No shares of Common Stock were issued in connection with the ATM as of September 30, 2023. Pursuant to the S-3 and in connection with the 2022 Public Offering, (a) on September 16, 2022 we issued 13,900,000 shares of Common Stock at the public offering price of $9.00 per share, or an aggregate of $125.1 million, resulting in net proceeds to the Company of approximately $117.3 million, excluding certain transaction costs incurred in connection with filing the S-3, and (b) on October 3, 2022, we issued an additional 1,589,779 shares of Common Stock at the public offering price of $9.00 per share, for net proceeds to the Company of
30

approximately $13.4 million as a result of an underwriters exercising their option to purchase additional shares pursuant to the underwriting agreement.

Until such time as we can generate substantial product revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders' ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Working Capital
Working capital is defined as current assets less current liabilities.
The following table summarizes our total working capital and current assets and liabilities as of September 30, 2023 and December 31, 2022:
As of
September 30,
2023
As of
December 31,
2022
Change
(In U.S. dollars)$$$%
Current assets353,246,546 530,822,730 (177,576,184)(33.5)%
Current liabilities38,666,277 79,738,440 (41,072,163)(51.5)%
Total working capital314,580,269 451,084,290 (136,504,021)(30.3)%
The decrease in working capital as of September 30, 2023, primarily reflects cash used for (a) operating expenses, including personnel costs and research and development costs as we advance our clinical trials and continue to expand our pipeline, and (b) capital expenditures for equipment and machinery used in our manufacturing facility in Indiana. This was partially offset by interest and other income earned on the Company's cash, cash equivalents and investments. The decrease in current liabilities includes the impact of the payment of income taxes during the nine months ended September 30, 2023 of approximately $31.9 million, which had an equal and offsetting impact to current assets.
Cash Flows
The following table summarizes our sources and uses of cash for the nine months ended September 30, 2023 and 2022:
For the nine
months ended
September 30, 2023
For the nine
months ended
September 30, 2022
Change
(In U.S. dollars)$$$%
Net cash flows used in operating activities(124,859,499)(53,397,277)(71,462,222)133.8 %
Net cash flows used in investing activities(140,007,433)(176,537,853)36,530,420 (20.7)%
Net cash flows provided by financing activities45,973 116,902,265 (116,856,292)(100.0)%
Net decrease in cash and cash equivalents(264,820,959)(113,032,865)(151,788,094)134.3 %
Cash flows used in Operating Activities
Net cash flows used in operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash used in operating activities increased for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 primarily due to (a) continued advancement of our clinical
31

trials and expansion of our pipeline, as described above, (b) income taxes paid of approximately $31.9 million and (c) the timing of payments of our accounts payable and accrued liabilities.
We believe that the net proceeds from the Lantheus License Agreements and the 2022 Public Offering, together with our available resources and existing cash and cash equivalents, are sufficient to fund our operating expenses capital expenditure requirements into 2026.
Cash flows used in Investing Activities
For the nine months ended September 30, 2023 and 2022, net cash used in investing activities totaled $140.0 million and $176.5 million, respectively. The decrease in cash used in investing activities relates to a reduction in the Company's investment of its available cash resources into fixed income investments. This was partially offset by (a) increased capital expenditures for purchases in connection with our Indianapolis manufacturing facility and (b) purchase of the Note Receivable from Ionetix-α.
Cash flows provided by Financing Activities
For the nine months ended September 30, 2023, net cash provided by financing activities totaled $46.0 thousand which consists of net proceeds received from the exercise of stock options, partially offset by payments made in connection with the Company's finance lease obligation. For the nine months ended September 30, 2022, net cash provided by financing activities totaled $116.9 million which consisted of the net proceeds received from the (a) issuance of Common Stock in connection with filing the S-3 and (b) exercise of stock options issued to a non-employee consultant.
Contractual Obligations and Other Commitments
The Company, in the normal course of business, enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain product and product lines during the Company’s clinical phase. These agreements often have minimum purchase commitments and generally terminate upon the termination of the clinical trial. For additional information, see Note 12 to the Q3 2023 Financial Statements.
For additional information related to our license agreements, please also see Note 12 to the Q3 2023 Financial Statements and Notes 14 and 15 to the 2022 Financial Statements.
Off-balance Sheet Arrangements
We do not have any off-balance sheet arrangements or holdings in any variable interest entities.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of our Financial Condition and Results of Operations is based on our Q3 2023 Financial Statements, which have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78th Street, LLC, pursuant to the rules and regulations of the SEC.
The preparation of the Q3 2023 Financial Statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Q3 2023 Financial Statements and the reported amounts of expenses during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no significant changes to our critical accounting policies and estimates from the information provided in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our 2022 Form 10-K except as described below:

Leases
32

The Company accounts for leases in accordance with ASC Topic 842, Leases ("ASC 842"). At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less on the consolidated balance sheets. We have also elected to account for the lease and non-lease components as a combined lease component for our current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.

Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the unaudited interim condensed consolidated statements of operations and comprehensive loss.
ITEM 3. – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risks relating to our operations result primarily from interest rate risk and foreign exchange risk. As of September 30, 2023, there were no material changes to our market risks from the information provided in Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our 2022 Form 10-K.

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three and nine months ended September 30, 2023 and 2022.
ITEM 4. – CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Such disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
As of September 30, 2023, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our Chief Executive Officer and Chief Financial Officer have concluded that, based on the evaluation described above, as of September 30, 2023, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
33

PART II - OTHER INFORMATION
ITEM 1. – LEGAL PROCEEDINGS
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. Other than as noted below, we are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
On October 24, 2023, a purported POINT stockholder filed a complaint against POINT and each member of the POINT Board in the United States District Court for the District of Delaware, captioned Clark v. POINT Biopharma Global Inc., et al., Case No. 1:23-cv-01207-UNA (the “Clark Complaint”). On October 25, 2023, a purported POINT stockholder filed a complaint against POINT and each member of the POINT Board in the United States District Court for the District of Delaware, captioned Jones v. POINT Biopharma Global Inc., et al., Case No. 1:23-cv-01213-UNA (the “Jones Complaint”). On October 25, 2023, a purported POINT stockholder filed a complaint against POINT and each member of the POINT Board in the United States District Court for the Southern District of New York, captioned Trinh v. POINT Biopharma Global Inc., et al., Case No. 1:23-cv-09394 (the “Trinh Complaint” and, together with the Clark Complaint and the Jones Complaint, the “Disclosure Complaints”).

The Disclosure Complaints allege, among other things, violations of Sections 14(d) and 14(e) of the Exchange Act and Rule 14d-9 thereunder against all defendants and violations of Section 20(a) of the Exchange Act against the individual defendants. The plaintiffs contend that the Schedule 14D-9 omitted and/or misrepresented material information regarding the transactions. The Complaints seek injunctive relief preventing the consummation of the transactions, rescissory damages or rescission to the extent the transactions are consummated, an order directing the individual defendants to file a Solicitation/Recommendation Statement on Schedule 14D-9 that does not contain any untrue statements of material fact, an award of plaintiff’s expenses including attorneys’ fees and expenses, and such other relief the court may deem just and proper. POINT has also received certain demand letters from purported stockholders making allegations similar to those contained in the Disclosure Complaints.

In addition, on October 27, 2023, POINT received a demand letter, made pursuant to Section 220 of the DGCL, from a purported stockholder seeking to access and inspect certain of POINT’s books and records relating to the transactions contemplated by the Offer and the Merger Agreement. On November 8, 2023, such purported stockholder filed a complaint against POINT in the Court of Chancery of the State of Delaware pursuant to Section 220 of the DGCL, captioned Samson Ghebremariam v. POINT Biopharma Global, Inc. [sic], Case No. 2023-1135-SEM (the “Section 220 Complaint” and collectively with the Disclosure Complaints, the “Complaints”). Pursuant to the Section 220 Complaint, the plaintiff seeks (i) the right to access and inspect certain of POINT’s books and records relating to the transactions contemplated by the Offer and the Merger Agreement, in order to investigate the processes leading thereto and the independence of POINT’s directors and officers in connection therewith and (ii) an award of the plaintiff’s expenses, including reasonable attorneys’ fees.

POINT believes that each of the claims contained in the Complaints and the related demand letters are without merit.
ITEM 1A. – RISK FACTORS
Factors that could cause our actual results to differ materially from those described in this Quarterly Report on Form 10-Q include, but not limited to, any of the risks and uncertainties described in our 2022 Form 10-K. If any of these risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. We are also including the following additional risk factors below related to the Offer and the Merger, which should be read in conjunction with our description of risk factors in Item 1A, "Risk Factors" of our 2022 Form 10-K. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operation.

Risks Related to the Pending Offer and Merger

We may not complete the pending Offer and Merger within the timeframe we anticipate or at all, which could have an adverse effect on our business, financial results and/or operations.

As described above, on October 2, 2023, we entered into the Merger Agreement, with Parent and Merger Sub. Merger Sub commenced a cash tender offer to purchase all of the Shares, at a price of $12.50 per share, net to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement. The Offer commenced on October 13, 2023 and was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 p.m., Eastern Time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.
34


If the Offer and the Merger are not completed within the expected timeframe or at all, we may be subject to a number of material risks in addition to the risks of continuing to operate our business. The price of our Common Stock may decline to the extent that current market prices of our Common Stock reflect a market assumption that the Merger will be completed on a timely basis or at all. We could be required to pay Parent a termination fee of approximately $54.4 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The failure to complete the transaction also may result in negative publicity and negatively affect our relationship with our stockholders, employees, collaborators and suppliers. We may also be required to devote significant time and resources to litigation related to any failure to complete the Merger or related to any enforcement proceeding commenced against us to perform our obligations under the Merger Agreement.

Our ability to complete the Merger is subject to certain closing conditions that could adversely affect us or cause the Merger to be abandoned.

Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the DGCL) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the HSR Act, (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the FTC and the Antitrust Division, initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. The consummation of the Offer and the Merger is not subject to a financing condition. We cannot provide any assurance that the conditions to the consummation of the Offer and/or the Merger will be satisfied or waived, or will not result in the abandonment or delay of the Offer and the Merger. If we do not consummate the Offer and Merger, the price of our Common Stock may decline significantly from the current market price, which may reflect a market assumption that the Offer and Merger will be consummated. Any of these events could have a material adverse effect on our business, operating results and financial condition and could cause a decline in the price of our Common Stock.

Stockholder litigation could prevent or delay the consummation of the Offer and Merger or otherwise negatively impact our business, operating results and financial condition.

We may incur additional costs in connection with the defense or settlement of any existing and future stockholder litigation
in connection with the Offer and Merger. These lawsuits or other future litigation may adversely affect our ability to complete the Offer and Merger. We could incur significant costs in connection with any such litigation, including costs associated with the indemnification of our directors and officers.

Furthermore, one of the conditions to the consummation of the Offer and the Merger is the absence of any governmental order or law preventing the consummation of the Merger. Consequently, if a plaintiff were to secure injunctive or other relief prohibiting, delaying or otherwise adversely affecting our ability to complete the consummation of the Offer and the Merger, then such injunctive or other relief may prevent the Offer and the Merger from becoming effective within the expected time frame or at all.

The Offer and the Merger will involve substantial costs and will require substantial management resources.

In connection with the consummation of the Offer and the Merger, management and financial resources have been diverted and will continue to be diverted towards the completion of the Offer and the Merger. We expect to incur substantial costs and expenses relating to, as well as the direction of management resources towards, the Offer and the Merger. Such costs, fees and expenses include fees and expenses payable to financial advisors, other professional fees and expenses, fees and costs relating to regulatory filings and filings with the SEC and notices and other transaction-related costs, fees and expenses. Further, if the Merger Agreement is terminated by us under specified circumstances, we will be required to pay Parent a termination fee of approximately $54.4 million. If the Merger is not completed, we will have incurred substantial expenses and expended substantial management resources for which we will have received little or no benefit if the closing of the Merger does not occur.

35

The Merger Agreement contains provisions that could discourage a potential competing acquirer.

The Merger Agreement provides that, upon the terms and subject to the conditions thereof, we and our representatives cannot solicit or initiate discussions with third parties regarding other proposals to acquire the Company and we are subject to restrictions on our ability to respond to any such proposal, except as permitted under the terms of the Merger Agreement. In the event that we receive an acquisition proposal from a third party, we must notify Parent of such proposal and negotiate in good faith with Parent prior to terminating the Merger Agreement or effecting a change in the recommendation of the Board to our stockholders with respect to the Offer and the Merger. The Merger Agreement also contains certain termination rights for Parent and us and further provides that, upon termination of the Merger Agreement under specified circumstances, including certain terminations in connection with an alternative business combination transaction as permitted by the terms of the Merger Agreement, we will be required to pay Parent a termination fee of approximately $54.4 million. These provisions could discourage a potential third-party acquirer that might have an interest in acquiring all or a significant portion of us from considering or proposing that acquisition, even if it were prepared to pay consideration with a higher per share cash or market value than the market value proposed to be received or realized in the transaction. These provisions also might result in a potential third-party acquirer proposing to pay a lower price to our stockholders than it might otherwise have proposed to pay due to the added expense of the termination fee that may become payable in certain circumstances. If the Merger Agreement is terminated and we determine to seek another business combination, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Offer and Merger.

The pendency of the transactions with Parent and Merger Sub could adversely affect our business, financial results and/or operations.

Our efforts to complete the transactions with Parent and Merger Sub could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our business, financial results and/or operations. Uncertainty as to whether the Offer and the Merger will be completed may affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the transactions are pending because employees may experience uncertainty about their roles following consummation of the Merger. A substantial amount of our management’s and employees’ attention is being directed toward the completion of the transactions and thus is being diverted from our day-to-day operations. Uncertainty as to our future could adversely affect our business and our relationship with collaborators and suppliers. Changes to or termination of existing business relationships could adversely affect our results of operations and financial condition, as well as the market price of our Common Stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transactions or termination of the Merger Agreement.

Our executive officers and directors may have interests in the Offer and the Merger that are different from, or in addition to, those of our stockholders generally.

Our executive officers and directors may have interests in the Offer and the Merger that are different from, or are in addition to, those of our stockholders generally. These interests include direct or indirect ownership of our Shares and equity awards, the acceleration of equity awards upon consummation of the transactions and other interests. Such interests of our directors and executive officers are set forth in further detail in the Schedule 14D-9 filed with the SEC on October 13, 2023.

If the Merger occurs, our stockholders will not be able to participate in any financial upside to our business after the Merger.

Pursuant to the Merger Agreement, on October 13, 2023, Merger Sub commenced the Offer to purchase, subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, any and all of the issued and outstanding Shares, at a price of $12.50 per Share, to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement. In the Merger, each Share issued and outstanding immediately prior to the Effective Time that is not tendered and accepted pursuant to the Offer (other than the Shares owned by the Company or any subsidiary of the Company, Shares held by Parent, Merger Sub or any other subsidiary of Parent, and Shares as to which appraisal rights have been perfected in accordance with applicable law) will be canceled and converted into the right to receive the Offer Price in cash and without interest, less any applicable tax withholding. Our stockholders will not receive any shares of Parent or Merger Sub common stock in connection with the Offer or the Merger. As a result, if our business following the consummation of the Merger performs well, our current stockholders will not receive any benefit from the performance of our business following the consummation of the Merger.

In certain instances, the Merger Agreement requires us to pay a termination fee to Parent, which could require us to use available cash that would have otherwise been available for general corporate purposes.

36

Under the terms of the Merger Agreement, we may be required to pay Parent a termination fee of approximately $54.4 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement, including, but not limited to, our entry into an agreement with respect to a superior proposal or a change in the recommendation of our Board. If the Merger Agreement is terminated under such circumstances, the termination fee we may be required to pay under the Merger Agreement may require us to use available cash that would have otherwise been available for general corporate purposes and other uses.

The Offer consideration payable to holders of our Common Stock will not be adjusted for changes in our business, assets liabilities, prospects, outlook, financial condition or results of operations, or in the event of any change in the price of our Common Stock.

The Offer consideration payable to holders of our common stock will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial condition or results of operations, or changes in the market price of, analyst estimates of, or projections relating to, our Common Stock. For example, if we experienced an improvement in our business, assets, liabilities, prospects, outlook, financial condition or results of operations prior to the consummation of the Offer and Merger, there would be no adjustment to the amount of the proposed Offer consideration.

While the Merger Agreement is in effect, we are subject to restrictions on our business activities.

While the Merger Agreement is in effect, we are subject to restrictions on our business activities, generally requiring us to conduct our business in the ordinary course, consistent with past practice, and subjecting us to a variety of specified limitations absent Parent’s prior consent. These limitations include, among other things, restrictions on our ability to acquire other businesses and assets, dispose of our assets, make investments, enter into certain contracts, repurchase or issue securities, pay dividends, make capital expenditures, take certain actions relating to intellectual property, amend our organizational documents and incur indebtedness. These restrictions could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may as a result materially and adversely affect our business, results of operations and financial condition.

We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transactions with Parent.

We have incurred, and will continue to incur, significant costs and expenses, including fees for professional services and other transaction costs, in connection with the transactions contemplated by the Merger Agreement. We are obligated to pay these costs and expenses whether or not the transactions are completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses, any of which could materially and adversely affect our business, financial condition and results of operations.

If the Merger is not consummated, we may need to raise additional capital to continue our operations and execute our operating plans.

If the Merger is not consummated, we may need to raise additional capital or we may need to delay, scale back or eliminate some planned operations or reduce expenses to remain a going concern, any of which would have a significant negative impact on our prospects and financial condition, as well as the trading price of our Common Stock. There can be no assurance that we can raise capital when needed or on terms favorable to us and our stockholders. Macroeconomic conditions and heightened global uncertainties may adversely affect general commercial activity and the U.S. and global economies and financial markets, which increases uncertainty around our ability to access the capital markets when needed and on acceptable terms.
ITEM 2. – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
We did not have any unregistered sales of equity securities during the quarter ended September 30, 2023.

Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended September 30, 2023.
ITEM 3. – DEFAULTS UPON SENIOR SECURITIES
None.
37

ITEM 4. – MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. – OTHER INFORMATION
None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended September 30, 2023.

ITEM 6. – EXHIBITS
The following exhibits are filed as part of this Quarterly Report on Form 10-Q.
Exhibit Index
Exhibit
Number
Description
2.1†
3.1
3.2
10.1
10.2
10.3
31.1*
31.2*
32*
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*    Filed herewith.
†    Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
38

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
POINT BIOPHARMA GLOBAL INC.
Date: November 13, 2023
By:/s/Joe McCann
Dr. Joe McCann, Ph.D.
Chief Executive Officer
(Principal Executive Officer)
By:/s/Bill Demers
Bill Demers
Chief Financial Officer
(Principal Financial Officer)

39
EX-31.1 2 exhibit311-10qx09302023.htm EX-31.1 Document



Exhibit 31.1
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joe McCann, certify that:
1.I have reviewed this quarterly report on Form 10-Q of POINT Biopharma Global Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.




Exhibit 31.1
Date: November 13, 2023
By:/s/Joe McCann
Dr. Joe McCann, Ph.D.
Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 exhibit312-10qx09302023.htm EX-31.2 Document



Exhibit 31.2
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Bill Demers, certify that:
1.I have reviewed this quarterly report on Form 10-Q of POINT Biopharma Global Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.




Exhibit 31.2
Date: November 13, 2023
By:/s/Bill Demers
Bill Demers
Chief Financial Officer (Principal Financial Officer)
EX-32 4 exhibit32-10qx09302023.htm EX-32 Document



Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of POINT Biopharma Global Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2023By:/s/Joe McCann
Dr. Joe McCann, Ph.D.
Chief Executive Officer,
(Principal Executive Officer)
Date: November 13, 2023By:/s/Bill Demers
Bill Demers
Chief Financial Officer,
(Principal Financial Officer)
*This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-101.SCH 5 pnt-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Interim Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Interim Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Unaudited Interim Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Nature of business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Cash, cash equivalents and investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Prepaid expenses and other current assets link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Property, plant and equipment, net link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accrued liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Cash, cash equivalents and investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Prepaid expenses and other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Property, plant and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Accrued liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Related party transaction (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Nature of business - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue - Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Cash, cash equivalents and investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Property, plant and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Property, plant and equipment, net - Estimated Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Leases - Operating Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stockholders' equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stock-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Commitments and contingencies - Property in development commitment (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Net loss per share - Summary of basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Related party transactions - Schedule of Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Related party transactions -Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 pnt-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 pnt-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 pnt-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Deferred and non-current income taxes Deferred Income Taxes and Tax Credits Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Summary of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities Total Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Note receivable Financing Receivable, after Allowance for Credit Loss, Noncurrent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Cash, Cash Equivalents and Investments Cash, Cash Equivalents and Investments [Table Text Block] Number of people required in committee Collaborative Arrangement, Number of People Required In Committee Collaborative Arrangement, Number of People Required In Committee MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Shares Performance Shares [Member] Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Commitments and contingencies (Note 12) Commitments and Contingencies Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Minimum purchase commitments Long-Term Purchase Commitment, Amount Property, in development commitment Property In Development Commitment [Member] Represents the commitment related to property, in development. Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vesting ratably over the remaining three years Share-based Payment Arrangement, Tranche Four [Member] Share-based Payment Arrangement, Tranche Four Stockholders' equity Equity [Text Block] Issuance of shares of Common Stock, net of direct and incremental costs paid Proceeds from issuance of shares of common stock Proceeds from Issuance of Common Stock Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Weighted-average remaining lease term (in years): Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Director Director [Member] Total property, plant and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Current liabilities Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Type [Domain] Subsequent Event Type [Domain] Purchase of note receivable Purchase of note receivable Payments to Acquire Notes Receivable Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cash dividend paid Payments of Ordinary Dividends, Common Stock Diluted net loss per common share (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-current assets Assets, Noncurrent [Abstract] Change in accrued interest and dividends within investments Increase (Decrease) in Accrued Interest Receivable, Net Other income (expenses) Other Nonoperating Income (Expense) [Abstract] Issuance of shares of Common Stock in connection with stock option exercises Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol U.S. Government agency debt securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense Options granted in period, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] 2025 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Board member Share Based Compensation To Board Member [Member] Share Based Compensation To Board Member Company Selected Measure Name Company Selected Measure Name Number of renewal options Lessee, Operating Lease, Number of Renewal Options Lessee, Operating Lease, Number of Renewal Options Machinery and equipment Machinery and Equipment [Member] Due between one and five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Leases Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] Property, plant and equipment, net Total Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization LIABILITIES & STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period License Agreement License Agreement [Member] License Agreement Supply agreements in connection Supply Agreements In Connection [Member] Represents the supply agreements in connection. Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders’ equity Equity, Attributable to Parent [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Total Contract with Customer, Liability Issuance of shares of common stock in connection with stock option exercises (in shares) Stock options exercised (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Receivable for investment maturities Transfer from Investments Summary of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Related party expenses Related Party Transaction, Amounts of Transaction Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Revenue Recognition, Milestone Method [Table] Revenue Recognition, Milestone Method [Table] UHN UHN [Member] UHN Other Commitments [Table] Other Commitments [Table] Summary of significant accounting policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Land and building Land and Building [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Summary of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued liabilities Increase (Decrease) in Accrued Liabilities Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Number of options granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Receivable on matured short-term investment Investment Receivable, Current Investment Receivable, Current Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Supply agreements in connection with clinical trials Supply Agreements In Connection With Clinical Trials [Member] Represents the supply agreements in connection with clinical trials. Total aggregate remaining minimum commitment Aggregated Remaining Long Term Purchase Commitment Amount The aggregate remaining minimum amount the entity agreed to spend under the long-term purchase commitment. Right-of-use assets obtained in exchange for lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Measurement Frequency [Axis] Measurement Frequency [Axis] Income taxes receivable and payable Increase (Decrease) in Income Taxes Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Accounts payable Increase (Decrease) in Accounts Payable, Trade Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Cost and fees on issuance of common shares Payments of Stock Issuance Costs Depreciation on property, plant and equipment Depreciation Number of wholly-owned subsidiaries Number Of Wholly-Owned Subsidiaries Represents the number of wholly-owned subsidiaries. Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Operating Lease Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Milestone payment Collaborative Arrangement, Milestone Payment Collaborative Arrangement, Milestone Payment Going concern Going Concern [Policy Text Block] Disclosure of accounting policy related to going concern. Other Performance Measure, Amount Other Performance Measure, Amount Good Manufacturing Practices Good Manufacturing Practices [Member] Good Manufacturing Practices Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Annual net sales milestone payment Collaborative Arrangement, Annual Net Sales Milestone Payment Collaborative Arrangement, Annual Net Sales Milestone Payment Schedule of Lease Expense and Supplemental Cash Flow Lease, Cost [Table Text Block] Research and development Research and Development Expense [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type [Axis] Award Type [Axis] Grants in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Income taxes receivable Income Taxes Receivable, Current Non-cash investment activities: Noncash Investing and Financing Items [Abstract] Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of shares authorized for issuance under plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized General and administrative General and Administrative Expense [Member] Property, plant and equipment, gross Property, Plant and Equipment, Gross Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Related party transactions Related Party Transactions Disclosure [Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Total cash, cash equivalents and investments Cash, Cash Equivalents, And Investments Cash, Cash Equivalents, And Investments Leases Lessee, Finance Leases [Text Block] Entity File Number Entity File Number Operating lease current liability Operating Lease, Liability, Current Revenue recognized for future performance Contract with Customer, Liability, Revenue Recognized For Future Performance Contract with Customer, Liability, Revenue Recognized For Future Performance Interest on lease liability Finance Lease, Interest Expense Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Percentage of fair value Operating Lease, Present Value of Minimum Lease Payments, Maximum Percentage of Fair Value Operating Lease, Present Value of Minimum Lease Payments, Maximum Percentage of Fair Value Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Operating lease expense Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Summary of Assumptions Used to Determine the Grant Date Fair Value of Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total Assets, Fair Value Disclosure Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock options Employee Stock Option [Member] Period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One 2026 Finance Lease, Liability, to be Paid, Year Three Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation Share-Based Payment Arrangement [Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] 2024 Finance Lease, Liability, to be Paid, Year One Weighted Average Exercise Price Per Share ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Income taxes payable Taxes Payable, Current Subsequent Event Subsequent Event [Member] Weighted-average discount rates: Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Income Statement [Abstract] Income Statement [Abstract] Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Issuance of shares of Common Stock, net of direct and incremental costs (in shares) Number of shares issued during period (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Accrued costs for purchases of property, plant and equipment Accrued Costs For Purchases Of Property, Plant, And Equipment, Current Accrued Costs For Purchases Of Property, Plant, And Equipment, Current Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Supply Agreement To Purchase n.c.a. Lu Supply Agreement To Purchase n.c.a. Lu [Member] Supply Agreement To Purchase n.c.a. Lu Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Future payments relating to the construction and retrofit of the building Other Commitment, to be Paid, Year One Other Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Square-foot of building Square Foot of Building Represents the square-foot of building. Net loss per basic and diluted common share: Earnings Per Share, Diluted [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Other Commitments [Domain] Other Commitments [Domain] Total finance lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Accrued personnel costs Accrued Personnel Costs, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for personnel costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Number of votes per share Number of Votes Per Common Share Represents the number of votes per share. Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Issuance of common stock in connection with an underwritten public share offering and exercise of stock options (in shares) Stock Issued During Period, Shares, New Issues and Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Stock Issued During Period, Shares, New Issues and Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (Accumulated deficit) Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Stock Purchase Agreement Stock Purchase Agreement [Member] Stock Purchase Agreement Leases [Abstract] Other Commitments [Line Items] Other Commitments [Line Items] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Total lease payments Finance Lease, Liability, to be Paid Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Accrued liabilities Accrued Liabilities [Text Block] The Entire Disclosure On Current Accrued Expenses. License Agreements, PNT2003 Agreement License Agreements, PNT2003 Agreement [Member] License Agreements, PNT2003 Agreement Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Operating cash flow use from operating leases Operating Lease, Payments Net unrealized loss on available-for-sale debt securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Risks and uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] License Agreements, PNT2002 Agreement License Agreements, PNT2002 Agreement [Member] License Agreements, PNT2002 Agreement Total non-current assets Assets, Noncurrent Prepaid expenses and other current assets Prepaid Expense And Other Assets, Current [Text Block] The entire disclosure of prepaid expenses and other current assets. Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Common shares, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Present value of lease liabilities Operating Lease, Liability 2023 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities Liabilities Employees and Directors Employees and Directors [Member] Employees and Directors Prepaid clinical trial expenses Prepaid Clinical Trial Expenses, Current Represents the prepaid clinical trial expenses that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vesting [Domain] Vesting [Domain] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] Property, plant and equipment, net Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Title of Individual [Axis] Title of Individual [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accrued research and development costs Accrued Research and Development Costs, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock, par value $0.0001 per share, 430,000,000 authorized, 105,765,954 and 105,649,741 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued General and administrative General and Administrative Expense Due between one and five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accrued corporate legal fees and other professional services Accrued Professional Fees, Current Facility lease Facility Lease [Member] Facility Lease Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Preferred shares Preferred Stock [Member] Payments on finance lease Payments on finance lease Finance Lease, Principal Payments Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Total other income (expenses) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Agreement in connection with the SPLASH clinical phase study Agreement In Connection With Splash Clinical Phase Study [Member] Represents the agreement in connection with the SPLASH clinical phase study. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Preferred shares, shares authorized (in shares) Preferred Stock, Shares Authorized Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Building Building [Member] Prepaid insurance Prepaid Insurance Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Term for total aggregate remaining minimum commitment Long-Term Purchase Commitment, Period 2027 Finance Lease, Liability, to be Paid, Year Four Asset backed securities Asset-Backed Securities [Member] Summary of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Current Debt Securities, Available-for-Sale, Current Other accrued costs Other Accrued Liabilities, Current Purchase of investments, net of sales and maturities Payments to Acquire Other Investments Nature of business Nature of Operations [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Commercial paper Commercial Paper [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Lease Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Termination fee Merger Agreement, Termination Fee Merger Agreement, Termination Fee Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Reimbursement to Board member for occupancy costs Reimbursement To Board Member For Occupancy Costs [Member] Represents the information pertaining to reimbursement to Board member for occupancy costs. Entity Emerging Growth Company Entity Emerging Growth Company Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Rent expense Operating Lease, Expense Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Long-term income taxes payable Accrued Income Taxes, Noncurrent Non-current Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] Facility lease Finance Lease, Right-of-Use Asset, before Accumulated Amortization City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net loss per share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Financial Assets and Liabilities Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Total stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Initial lease term Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Cash Cash Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividend declared Dividends, Common Stock, Cash ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Foreign currency gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax Operating lease liabilities Increase (Decrease) in Operating Lease Liability Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Net loss: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash paid for income taxes Income Taxes Paid, Net Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums (accretion of discounts) on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic net loss per common share (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Non-employee consultant Share Based Compensation To Non Employee Consultant [Member] These member stand for share based compensation to non-employee consultant. Unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Labratory Space Labratory Space [Member] Labratory Space Intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Revenue recognized Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Common stock, authorized (in shares) Common Stock, Shares Authorized Fair Value Available-for-sale debt securities: Debt Securities, Available-for-Sale Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Less: Accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Commercial paper Commercial Paper, at Carrying Value Annual increase in shares authorized, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Title of Individual [Domain] Title of Individual [Domain] Compensation Amount Outstanding Recovery Compensation Amount Other Commitments [Axis] Other Commitments [Axis] Additional paid-in capital Additional Paid in Capital Subsequent Event Type [Axis] Subsequent Event Type [Axis] Issuance of shares of Common Stock in connection with stock option exercises Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Present value of lease liabilities Finance Lease, Liability Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Total Prepaid Expense and Other Assets, Current Insider Trading Arrangements [Line Items] Related Party [Axis] Related Party, Type [Axis] Consulting fees on business activities to Board member Consulting Fees On Business Activities To Related Parties [Member] Represents the information pertaining to consulting fees on business activities to Board member. Upfront payment Collaborative Arrangement, Upfront Payment Collaborative Arrangement, Upfront Payment Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Vesting on 1st year anniversary Share-Based Payment Arrangement, Tranche Two [Member] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Finance lease Finance Lease, Weighted Average Discount Rate, Percent Finance lease liability, net of current portion Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax (provision) benefit Income tax (benefit) expense Income Tax Expense (Benefit) Vesting [Axis] Vesting [Axis] Fair value measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Cash and Cash Equivalents [Abstract] Issuance of shares of Common Stock, net of direct and incremental costs Stock Issued During Period, Value, New Issues Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Operating leases Operating Lease, Weighted Average Remaining Lease Term Revenue Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Royalty rate Collaborative Arrangement, Royalty Rate Collaborative Arrangement, Royalty Rate Net rentable area Net Rentable Area Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Amendment Flag Amendment Flag Money market mutual fund Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Operating leases Operating Lease, Weighted Average Discount Rate, Percent Investment income Interest Income (Expense), Net Employee Employee [Member] These member stand for employee. Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Canadian harmonized sales tax receivable Canadian Harmonized Sales Tax Receivable, Current Represents the Canadian harmonized sales tax receivable that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Deposit on production equipment Deposit on Production Equipment Deposit on Production Equipment Estimated Useful Life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Finance lease Finance Lease, Weighted Average Remaining Lease Term Diluted weighted average common shares outstanding (in shares) Weighted-average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Investment committed Other Commitment Realized gain on available-for-sale debt investments Debt Securities, Available-for-Sale, Realized Gain (Loss) Schedule of Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Finance lease Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Supply agreement to purchase certain products Supply Agreement To Purchase Certain Products [Member] Represents the supply agreement to purchase certain products. Money market funds Money Market Funds, at Carrying Value Number of additional shares available (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses Operating Expenses [Abstract] Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Revenue Revenue from Contract with Customer [Text Block] Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Additional Paid-in Capital Additional Paid-in Capital [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] Athebio Athebio [Member] Athebio Eli Lilly Eli Lilly [Member] Eli Lilly Category of Item Purchased [Axis] Category of Item Purchased [Axis] Options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent events Subsequent Events [Text Block] Fair Value, Recurring Fair Value, Recurring [Member] Operating cash flow use from finance lease Finance Lease, Interest Payment on Liability Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Short-term investments Short-Term Investments Property, plant and equipment, in development Construction in Progress [Member] Total operating expenses Operating Expenses Amortization of right-of-use asset Finance Lease, Right-of-Use Asset, Amortization Cash, cash equivalents and investments Cash and Cash Equivalents Disclosure [Text Block] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Finance lease current liability Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Indianapolis Lease Indianapolis Lease [Member] Indianapolis Lease Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic weighted average common shares outstanding (in shares) Weighted-average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) Revenue Revenues [Abstract] Leases Lessor, Leases [Policy Text Block] Public Share Offering Public Share Offering [Member] Public Share Offering Debt instrument, redemption price, percentage of principal and interest outstanding Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Lantheus Holdings, Inc. Lantheus Holdings, Inc. [Member] Lantheus Holdings, Inc. Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted- Average Remaining Contractual Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Schedule of Available-For-Sale Investments Debt Securities, Available-for-Sale [Table Text Block] Revenue Recognition, Milestone Method [Line Items] Revenue Recognition, Milestone Method [Line Items] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] EX-101.PRE 9 pnt-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
9 Months Ended
Sep. 30, 2023
Nov. 08, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-39311  
Entity Registrant Name POINT BIOPHARMA GLOBAL INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-0800493  
Entity Address, Address Line One 4850 West 78th Street  
Entity Address, City or Town Indianapolis,  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46268  
City Area Code 317  
Local Phone Number 543-9957  
Title of 12(b) Security Common Stock  
Trading Symbol PNT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   106,569,231
Entity Central Index Key 0001811764  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Interim Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 21,607,412 $ 286,428,371
Short-term investments 317,555,936 238,783,470
Prepaid expenses and other current assets 9,901,729 5,610,889
Income taxes receivable 4,181,469 0
Total current assets 353,246,546 530,822,730
Non-current assets    
Long-term investments 59,793,161 16,119,430
Note receivable 5,116,667 0
Property, plant and equipment, net 54,042,353 31,380,576
Operating lease right-of-use asset 5,505,693 0
Total non-current assets 124,457,874 47,500,006
Total assets 477,704,420 578,322,736
Current liabilities    
Accounts payable 8,886,750 7,703,150
Accrued liabilities 14,529,354 19,094,454
Deferred revenue 12,586,443 23,242,290
Income taxes payable 736,729 29,698,546
Finance lease current liability 987,018 0
Operating lease current liability 939,983 0
Total current liabilities 38,666,277 79,738,440
Deferred revenue, net of current portion 3,720,881 10,178,147
Long-term income taxes payable 2,389,109 1,452,356
Finance lease liability, net of current portion 4,093,202 0
Operating lease liability, net of current portion 4,642,565 0
Total liabilities 53,512,034 91,368,943
Commitments and contingencies (Note 12)
Stockholders’ equity    
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 105,765,954 and 105,649,741 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 10,576 10,565
Additional paid-in capital 453,319,762 448,391,574
(Accumulated deficit) Retained earnings (27,707,358) 39,008,505
Accumulated other comprehensive loss (1,430,594) (456,851)
Total stockholders’ equity 424,192,386 486,953,793
Total liabilities and stockholders’ equity $ 477,704,420 $ 578,322,736
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Interim Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 430,000,000 430,000,000
Common stock, shares issued (in shares) 105,765,954 105,649,741
Common stock, shares outstanding (in shares) 105,765,954 105,649,741
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue        
Revenue $ 2,789,993 $ 0 $ 17,113,113 $ 0
Operating expenses        
Research and development 26,910,286 20,797,406 85,097,331 54,112,136
General and administrative 5,505,869 3,839,626 15,604,401 11,727,969
Total operating expenses 32,416,155 24,637,032 100,701,732 65,840,105
Loss from operations (29,626,162) (24,637,032) (83,588,619) (65,840,105)
Other income (expenses)        
Investment income 5,617,736 1,048,254 16,717,703 1,605,927
Foreign currency gain (loss) 105,522 (243,791) (133,438) (287,691)
Total other income (expenses) 5,723,258 804,463 16,584,265 1,318,236
Loss before income taxes (23,902,904) (23,832,569) (67,004,354) (64,521,869)
Income tax (provision) benefit (871,449) (180,500) 288,491 (452,021)
Net loss $ (24,774,353) $ (24,013,069) $ (66,715,863) $ (64,973,890)
Net loss per basic and diluted common share:        
Basic net loss per common share (in dollars per share) $ (0.23) $ (0.26) $ (0.63) $ (0.71)
Diluted net loss per common share (in dollars per share) $ (0.23) $ (0.26) $ (0.63) $ (0.71)
Basic weighted average common shares outstanding (in shares) 105,765,954 92,401,484 105,717,330 90,891,031
Diluted weighted average common shares outstanding (in shares) 105,765,954 92,401,484 105,717,330 90,891,031
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (24,774,353) $ (24,013,069) $ (66,715,863) $ (64,973,890)
Other comprehensive loss, net of tax        
Net unrealized loss on available-for-sale debt securities (361,611) (266,320) (973,743) (608,698)
Total comprehensive loss $ (25,135,964) $ (24,279,389) $ (67,689,606) $ (65,582,588)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   90,121,794      
Beginning balance at Dec. 31, 2021 $ 255,213,086 $ 9,012 $ 314,488,782 $ (59,284,708) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of common stock in connection with stock option exercises (in shares)   678      
Issuance of shares of Common Stock in connection with stock option exercises 942   942    
Stock-based compensation 440,450   440,450    
Net loss (16,380,574)     (16,380,574)  
Ending balance (in shares) at Mar. 31, 2022   90,122,472      
Ending balance at Mar. 31, 2022 239,273,904 $ 9,012 314,930,174 (75,665,282) 0
Beginning balance (in shares) at Dec. 31, 2021   90,121,794      
Beginning balance at Dec. 31, 2021 255,213,086 $ 9,012 314,488,782 (59,284,708) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of Common Stock, net of direct and incremental costs (in shares)   13,933,168      
Net loss (64,973,890)        
Ending balance (in shares) at Sep. 30, 2022   104,054,962      
Ending balance at Sep. 30, 2022 309,079,832 $ 10,405 433,936,723 (124,258,598) (608,698)
Beginning balance (in shares) at Mar. 31, 2022   90,122,472      
Beginning balance at Mar. 31, 2022 239,273,904 $ 9,012 314,930,174 (75,665,282) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of common stock in connection with stock option exercises (in shares)   2,490      
Issuance of shares of Common Stock in connection with stock option exercises 3,461   3,461    
Stock-based compensation 1,027,563   1,027,563    
Net loss (24,580,247)     (24,580,247)  
Other comprehensive income (loss), net of tax (342,378)       (342,378)
Ending balance (in shares) at Jun. 30, 2022   90,124,962      
Ending balance at Jun. 30, 2022 215,382,303 $ 9,012 315,961,198 (100,245,529) (342,378)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of Common Stock, net of direct and incremental costs (in shares)   13,900,000      
Issuance of shares of Common Stock, net of direct and incremental costs 116,856,162 $ 1,390 116,854,772    
Issuance of shares of common stock in connection with stock option exercises (in shares)   30,000      
Issuance of shares of Common Stock in connection with stock option exercises 41,700 $ 3 41,697    
Stock-based compensation 1,079,056   1,079,056    
Net loss (24,013,069)     (24,013,069)  
Other comprehensive income (loss), net of tax (266,320)       (266,320)
Ending balance (in shares) at Sep. 30, 2022   104,054,962      
Ending balance at Sep. 30, 2022 $ 309,079,832 $ 10,405 433,936,723 (124,258,598) (608,698)
Beginning balance (in shares) at Dec. 31, 2022 105,649,741 105,649,741      
Beginning balance at Dec. 31, 2022 $ 486,953,793 $ 10,565 448,391,574 39,008,505 (456,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of common stock in connection with stock option exercises (in shares)   32,936      
Issuance of shares of Common Stock in connection with stock option exercises 145,864 $ 3 145,861    
Stock-based compensation 1,009,496   1,009,496    
Net loss (16,530,671)     (16,530,671)  
Other comprehensive income (loss), net of tax 201,294       201,294
Ending balance (in shares) at Mar. 31, 2023   105,682,677      
Ending balance at Mar. 31, 2023 $ 471,779,776 $ 10,568 449,546,931 22,477,834 (255,557)
Beginning balance (in shares) at Dec. 31, 2022 105,649,741 105,649,741      
Beginning balance at Dec. 31, 2022 $ 486,953,793 $ 10,565 448,391,574 39,008,505 (456,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (66,715,863)        
Ending balance (in shares) at Sep. 30, 2023 105,765,954 105,765,954      
Ending balance at Sep. 30, 2023 $ 424,192,386 $ 10,576 453,319,762 (27,707,358) (1,430,594)
Beginning balance (in shares) at Mar. 31, 2023   105,682,677      
Beginning balance at Mar. 31, 2023 471,779,776 $ 10,568 449,546,931 22,477,834 (255,557)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of common stock in connection with stock option exercises (in shares)   83,277      
Issuance of shares of Common Stock in connection with stock option exercises 186,058 $ 8 186,050    
Stock-based compensation 1,710,349   1,710,349    
Net loss (25,410,839)     (25,410,839)  
Other comprehensive income (loss), net of tax (813,426)       (813,426)
Ending balance (in shares) at Jun. 30, 2023   105,765,954      
Ending balance at Jun. 30, 2023 $ 447,451,918 $ 10,576 451,443,330 (2,933,005) (1,068,983)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of Common Stock, net of direct and incremental costs (in shares) 0        
Stock-based compensation $ 1,876,432   1,876,432    
Net loss (24,774,353)     (24,774,353)  
Other comprehensive income (loss), net of tax $ (361,611)       (361,611)
Ending balance (in shares) at Sep. 30, 2023 105,765,954 105,765,954      
Ending balance at Sep. 30, 2023 $ 424,192,386 $ 10,576 $ 453,319,762 $ (27,707,358) $ (1,430,594)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net loss: $ (66,715,863) $ (64,973,890)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation on property, plant and equipment 2,186,253 980,995
Deferred and non-current income taxes 936,753 (65,592)
Stock-based compensation expense 4,596,277 2,547,069
Non-cash lease expense 196,772 0
Amortization of premiums (accretion of discounts) on investments, net (9,457,635) (435,238)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 709,160 318,586
Accounts payable (1,060,594) 1,261,082
Accrued liabilities (4,534,719) 6,926,449
Deferred revenue (17,113,113) 0
Income taxes receivable and payable (33,143,286) 110,745
Operating lease liabilities (62,014) 0
Change in accrued interest and dividends within investments (1,397,490) (67,483)
Net cash used in operating activities (124,859,499) (53,397,277)
Cash flows from investing activities    
Purchase of investments, net of sales and maturities (117,757,923) (165,841,488)
Purchase of property, plant and equipment (17,249,510) (10,696,365)
Purchase of note receivable (5,000,000) 0
Net cash used in investing activities (140,007,433) (176,537,853)
Cash flows from financing activities    
Issuance of shares of Common Stock in connection with stock option exercises 331,922 46,103
Payments on finance lease (285,949) 0
Issuance of shares of Common Stock, net of direct and incremental costs paid 0 116,856,162
Net cash provided by financing activities 45,973 116,902,265
Net decrease in cash and cash equivalents (264,820,959) (113,032,865)
Cash and cash equivalents, beginning of period 286,428,371 238,815,991
Cash and cash equivalents, end of period 21,607,412 125,783,126
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 31,924,135 411,424
Non-cash investment activities:    
Receivable for investment maturities 5,000,000 0
Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities $ 3,623,314 $ 1,142,278
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Nature of business
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of business Nature of business
POINT Biopharma Global Inc., together with its consolidated subsidiaries ("POINT" or the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere.
The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78th Street, LLC, each located in the U.S., and POINT Biopharma Corp., located in Canada (collectively the "Subsidiaries"). The Company’s headquarters is located at 4850 West 78th Street, Indianapolis, Indiana, 46268.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and the Subsidiaries, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023 (the “2022 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2022 Financial Statements.
These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
COVID-19 Pandemic, macroeconomics and other geopolitical events
The Company is currently operating in a period of significant economic uncertainty, resulting from, among other things, the impact of the COVID-19 pandemic, geopolitical tensions, such as the ongoing military conflict between Russia and Ukraine, the Israel-Palestine conflict and heightened tensions between China and Taiwan, trade uncertainty, including changes in tariffs, sanctions, international treaties, and other trade restrictions, rising inflation and interest rates, and uncertainty and liquidity concerns in the broader financial services industry, including those caused by certain recent banking failures.

The Company is continuing to monitor the development and potential impact of these global economic and geopolitical events on its business and unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of these events and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. However, estimates and assumptions about future events and their effects cannot be determined with certainty, and therefore, require the exercise of judgment; as a result, the Company’s estimates may change as new events occur and additional information is obtained.
Risks and uncertainties
Except for the upfront payment received pursuant to the Lantheus License Agreements (as defined in Note 3 below), the Company has incurred significant net losses and has funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to continue to be incurred in future periods. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from public health crisis or military conflicts and adverse developments affecting the financial services industry, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
The Company also has a number of risks and uncertainties related to the Offer and Merger described in Note 16. These risks and uncertainties are described in more detail in Part II. Item 1A. “Risk Factors” starting on page 34.
Use of estimates
The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the allocation of consideration and the recognition of revenues in respect of the performance obligations under the Lantheus License Agreements, the accrual of research and development expenses, incremental borrowing rates determined in connection with finance and operating lease obligations, the valuations of stock options, the expected recoverability of and the estimated useful lives of our long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experiences. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Leases
The Company accounts for leases in accordance with ASC Topic 842, Leases ("ASC 842"). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less in the consolidated balance sheets. The Company has also elected to account for the lease and non-lease components as a combined lease component for its current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.

Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

Recent accounting pronouncements
The Company has evaluated accounting pronouncements recently issued but not yet adopted and believes that the accounting pronouncements currently do not apply to the Company’s operations and are not expected to have a material impact on the Company’s unaudited interim condensed consolidated financial statements or disclosures.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue RevenueIn November 2022, POINT announced strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. ("Lantheus") for exclusive worldwide rights for POINT's programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003), excluding certain territories (Japan, South Korea, Singapore, Indonesia, and China including Hong Kong, Macau and Taiwan) (the "PNT2002 Agreement" and the "PNT2003 Agreement", respectively, and collectively the "Lantheus License Agreements"). The collaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in Prostate-Specific Membrane Antigen ("PSMA") PET and radiopharmaceuticals.
In December 2022, closing conditions for the Lantheus transaction, including antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended, the "HSR Act"), were satisfied. POINT received a $250.0 million upfront payment under the PNT2002 Agreement and will receive an additional payment of up to $250.0 million upon U.S. regulatory approval. In addition, once certain return on investment financial thresholds have been achieved and other conditions satisfied, POINT will be eligible to receive royalties of 20% on all net sales (prior to which there is a period of sales in which the royalty may be based on only a portion of the gross profit), and contingent upon the satisfaction of certain net sales milestones, additional payments of up to $1.3 billion. POINT received a $10.0 million upfront payment under the PNT2003 Agreement, and will receive up to an additional $30.0 million upon U.S. regulatory approval. The PNT2003 Agreement also provides that POINT will receive royalties of 15% on net sales and, contingent upon the satisfaction of certain net sales milestones, an additional payment of up to $275.0 million.

In connection with the PNT2002 Agreement, the Company is responsible for completing the Company's multi-center, randomized, open label phase 3 Study evaluating metastatic castration-resistant Prostate cancer using 177Lu-PNT2002 PSMA therapy After Second-line Hormonal treatment (“SPLASH") trial and the parties will work together to file the New Drug Application (“NDA”), with the costs incurred in connection with the U.S. Food and Drug Administration ("FDA") submission being borne by Lantheus. Thereafter, Lantheus will be responsible for all additional clinical and regulatory costs in the U.S., as well as all costs for development, clinical trials and regulatory approval in the rest of its territories outside the U.S., except Asia.
To determine the appropriate amount of revenue to be recognized under ASC Topic 606, Revenue from Contracts with Customers, the Company performs the following steps: (i) identify the promised goods or services in the contract, (ii) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract, (iii) measure the transaction price, including the constraint on variable consideration, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when (or as) the Company satisfies each performance obligation.
In connection with the PNT2002 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the SPLASH trial, support the NDA submission and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2002 Agreement to be the $250.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.
In connection with the PNT2003 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the necessary submissions for regulatory approval and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2003 Agreement to be the $10.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.
The Company does not include variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will occur. Variable consideration in the PNT2002 Agreement and PNT2003 Agreement consists of:
Potential future regulatory milestone payments. The Company concluded that this variable consideration is constrained considering that achievement of the milestones is outside its control and contingent upon the future success of clinical trials and regulatory approval by the FDA and in respect of other territories outside the U.S.
Potential future milestone payments in connection with certain sales targets as well as any future royalties. The Company concluded that these payments qualify for the royalty exception. Under the royalty exception, sales-based royalties are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). That is, an entity does not estimate the amount of a sales-based royalty at contract inception; rather, revenue
would be recognized when the subsequent sales occur (under the assumption that the associated performance obligation has been satisfied or partially satisfied).
Potential payments for the manufacturing and supply of commercial product. The Company concluded that this variable consideration is constrained as it is contingent upon future regulatory approvals and the execution of a manufacturing and supply agreement.
The estimate of the Company’s variable consideration to be included in the transaction price is updated at each reporting date as a change in estimate. For the potential future regulatory milestone payments, the Company utilizes the most likely amount approach to determine the amounts recognized and timing of recognition. For the potential payments for manufacturing and supply of commercial product, the Company utilizes the expected value approach to determine the amounts recognized and timing of recognition. Once the constraint is removed, the milestone payments will be accounted for and allocated to the performance obligations.
For the licenses conveyed to Lantheus, the Company recognized revenue upon execution and regulatory approval of the Lantheus License Agreements. The Company concluded that the licenses represent that of functional intellectual property as each has significant standalone functionality and derives a substantial portion of its utility from that standalone functionality.
For the obligations to complete the SPLASH trial, support the NDA submission and participate in joint steering activities in connection with the PNT2002 Agreement as well as the obligations to complete the necessary submissions for regulatory approval and participate in joint steering activities for the PNT2003 Agreement, the Company recognizes revenue using the cost-to-cost method, which it concluded best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion.
The following table presents the Company’s contract liabilities as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Deferred revenue
Deferred revenue, current$12,586,443 $23,242,290 
Deferred revenue, net of current portion3,720,881 10,178,147 
Total$16,307,324 $33,420,437 
At inception of the Lantheus License Agreements, deferred revenue of $34.8 million was recognized in connection with future performance. During the three and nine months ended September 30, 2023, the Company recognized $2.8 million and $17.1 million in revenue for services performed (three and nine months ended September 30, 2022 — $nil and $nil, respectively). The current portion of deferred revenue reflects the Company’s estimate of the revenue it expects to recognize within the next 12 months. The Company expects to recognize the remainder of the deferred revenue balance in subsequent periods through the year ending December 31, 2028. No contract assets were recognized in connection with the Lantheus License Agreements, including costs incurred in obtaining the agreements.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments
9 Months Ended
Sep. 30, 2023
Cash and Cash Equivalents [Abstract]  
Cash, cash equivalents and investments Cash, cash equivalents and investments
Cash, cash equivalents and investments consisted of the following:
As of September 30, 2023As of December 31, 2022
Cash$11,446,728 $12,429,627 
Cash equivalents:
Money market funds6,852,616 273,998,744 
Commercial paper3,308,068 — 
Total cash and cash equivalents21,607,412 286,428,371 
Short-term investments
Commercial paper107,567,350 115,156,455 
Corporate bonds93,787,733 45,219,042 
U.S. Government agency debt securities35,942,645 42,577,762 
Asset backed securities80,258,208 35,830,211 
Total short-term investments317,555,936 238,783,470 
Long-term investments
U.S. Government agency debt securities16,098,662 — 
Asset backed securities8,634,828 16,119,430 
Corporate bonds35,059,671 — 
Total long-term investments59,793,161 16,119,430 
Total cash, cash equivalents and investments$398,956,509 $541,331,271 
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of September 30, 2023 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$107,597,155 $981 $(30,786)$107,567,350 $107,567,350 $— 
Corporate bonds129,438,4505,918(596,964)128,847,40493,787,73335,059,671 
Asset backed securities89,554,665204 (661,833)88,893,03680,258,2088,634,828 
U.S. Government agency debt securities52,186,023— (144,716)52,041,30735,942,64516,098,662 
Total available-for-sale securities$378,776,293 $7,103 $(1,434,299)$377,349,097 $317,555,936 $59,793,161 

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of December 31, 2022 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$115,156,455 $— $— $115,156,455 $115,156,455 $— 
Asset backed securities52,019,619 26,527 (96,505)51,949,641 35,830,211 16,119,430 
Corporate bonds45,468,482 — (249,440)45,219,042 45,219,042 — 
U.S. Government agency debt securities42,715,195 — (137,433)42,577,762 42,577,762 — 
Total available-for-sale securities$255,359,751 $26,527 $(483,378)$254,902,900 $238,783,470 $16,119,430 
The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of September 30, 2023:
Amortized CostFair Value
Due within one year$318,607,866 $317,555,936 
Due between one and five years60,168,427 59,793,161 
Total$378,776,293 $377,349,097 

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2022:

Amortized CostFair Value
Maturing within one year$239,236,498 $238,783,470 
Maturing between one and five years16,123,253 16,119,430 
Total$255,359,751 $254,902,900 

The primary objective of our investment portfolio is to maintain safety of principal balances, provide sufficient levels of liquidity and enhance overall returns in an efficient manner with acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

During the three and nine months ended September 30, 2023, we had $611 of realized gains on available-for-sale investments.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value measurements
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The following tables present information about the Company’s financial assets and liabilities as of September 30, 2023 and December 31, 2022, that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
Level 1Level 2Level 3Total
September 30, 2023
Cash equivalents:
Money market mutual fund$6,852,616 $— $— $6,852,616 
Commercial paper— 3,308,068 — 3,308,068 
Available-for-sale debt securities:
Commercial paper— 107,567,350 — 107,567,350 
Corporate bonds— 128,847,404 — 128,847,404 
Asset backed securities— 88,893,036 — 88,893,036 
U.S. Government agency debt securities52,041,307 — — 52,041,307 
Total$58,893,923 $328,615,858 $ $387,509,781 

Level 1Level 2Level 3Total
December 31, 2022
Cash equivalents:
Money market mutual fund$273,998,744 $— $— $273,998,744 
Commercial paper— — — — 
Available-for-sale debt securities:
Commercial paper— 115,156,455 — 115,156,455 
Asset backed securities— 51,949,641 — 51,949,641 
Corporate bonds— 45,219,042 — 45,219,042 
U.S. Government agency debt securities42,577,762 — — 42,577,762 
Total$316,576,506 $212,325,138 $ $528,901,644 

Certain of our available-for-sale debt securities, including U.S. Government agency debt securities, are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

On May 7, 2023, POINT Biopharma Inc. entered into a Convertible Note Purchase Agreement (the "Convertible Note Agreement") with Ionetix Alpha Corporation ("Ionetix-α"), a subsidiary of IONETIX Corporation. On June 1, 2023, the Company purchased $5.0 million in unsecured promissory notes (the "Note Receivable") convertible into common stock of Ionetix-α at a conversion price that is calculated based on certain conditions as defined in the Convertible Note Agreement. Management assessed all features in the Convertible Note Agreement to determine embedded derivatives requiring bifurcation. In accordance with the Convertible Note Agreement, Ionetix-α has a voluntary redemption option, subject to certain terms and conditions, and may provide notice to the Company upon which the Company can elect to either redeem the Note Receivable at 150% of principal and interest outstanding or convert it into common stock of Ionetix-α. Management concluded that this put option meets the definition of a derivative and it is not clearly and closely related to the Note Receivable, thus requiring bifurcation from the host instrument and recognition at fair value. Further, management concluded the Note Receivable host instrument is to be classified as a loan receivable and therefore is measured at amortized cost but disclosure of fair value is required. Management determined the fair values of both the Note Receivable and the embedded derivative under Level 3 in the fair value hierarchy. Management concluded that the fair value of the Note Receivable as of September 30, 2023 approximated amortized cost and that the fair value of the embedded derivative was nil both at inception of the arrangement and on September 30, 2023. On September 29, 2023, POINT Biopharma Inc. entered into the Amendment of Convertible Note Purchase Agreement (the "Amendment"), whereby in connection with the Amendment, the Company and Ionetix-α agreed to accelerate the purchase of an additional $5.0 million of unsecured promissory notes subject to certain closing conditions. Those conditions were met and the additional purchase was made on October 2, 2023. See Note 16.

We did not have any financial liabilities measured at fair value on a recurring basis as of September 30, 2023. The carrying values of the Company’s cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. There have been no transfers of assets or liabilities between the fair value measurement levels as of September 30, 2023.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid expenses and other current assets
9 Months Ended
Sep. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Prepaid expenses and other current assets Prepaid expenses and other current assets
Prepaid expenses and other current assets consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Prepaid clinical trial expenses2,812,270 4,011,419 
Prepaid insurance1,390,347 1,310,314 
Receivable on matured short-term investment5,000,000 — 
Canadian harmonized sales tax receivable206,326 60,222 
Deposit on production equipment— 13,738 
Other492,786 215,196 
Total9,901,729 5,610,889 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Property, plant and equipment, net
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Property, plant and equipment, net Property, plant and equipment, net
Property, plant and equipment, net consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Land and building19,992,990 18,163,962 
Machinery and equipment11,241,336 5,328,639 
Property, plant and equipment, in development19,827,730 8,434,384 
Facility lease (Note 9)
5,384,707 — 
Furniture and fixtures938,909 698,728 
Computer equipment237,963 149,892 
57,623,635 32,775,605 
Less: Accumulated depreciation(3,581,282)(1,395,029)
Total54,042,353 31,380,576 

In July 2020, the Company purchased land and a building in Indianapolis, Indiana (which has been expanded to approximately 81,000 square feet) for the purpose of retrofitting the existing building into a state-of-the-art, Current Good Manufacturing Practices ("cGMP") compliant facility that will support the Company’s drug manufacturing operations. The Company commenced the manufacture of clinical supply in the Indianapolis manufacturing facility in January 2022. Construction continues on the facility to expand capacity.

Property, plant and equipment that have finite lives are recorded at cost less accumulated depreciation and impairment losses. Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value:
Asset CategoryEstimated Useful Life
Computer equipment
5 years
Machinery and equipment
7 years
Furniture and fixtures
7 years
Facility lease
7 years
Building
20 years
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued liabilities
9 Months Ended
Sep. 30, 2023
Accrued Liabilities, Current [Abstract]  
Accrued liabilities Accrued liabilitiesAccrued liabilities consisted of the following:
As of September 30, 2023
As of December 31, 2022
$$
Accrued personnel costs5,663,218 7,116,382 
Accrued research and development costs7,766,189 9,645,594 
Accrued corporate legal fees and other professional services907,019 2,068,793 
Accrued costs for purchases of property, plant and equipment75,360 105,741 
Other accrued costs117,568 157,944 
Total14,529,354 19,094,454 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases Leases
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s current portfolio of leases, the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments. The Company has not incurred any material short-term lease costs or variable lease costs associated with its finance and operating leases.
On February 2, 2023, POINT Biopharma Corp., entered into a Facility Agreement (the "UHN Agreement") with University Health Network (“UHN”), a not-for-profit corporation incorporated under the laws of Canada. Pursuant to the UHN Agreement, the Company was provided access to utilize a 7,700 square foot, licensed research and development space with cGMP manufacturing suites (the “Facility”), which the Company will use to develop and expand its pipeline of next-generation radioligands. The lease commencement date was determined to be April 1, 2023, the date upon which the Company was provided access to the Facility. The lease is accounted for as a finance lease in accordance with ASC 842 as one lease component for the facility, infrastructure and equipment, and the right-of-use asset has been included within property, plant and equipment. Management concluded the lease represents a finance lease on the basis that management believes the lease term covers the remaining economic life of the primary lease component. The initial term of the UHN Agreement will run for five years from the lease commencement date, with an option to renew for additional two-year terms thereafter, subject to certain conditions described in the UHN Agreement. Management included the first option to renew for two years as part of the lease term in determining the right-of-use asset and lease liability. The UHN Agreement does not transfer any title in the Facility to the Company. During the term, the Company shall be responsible for day-to-day management activities and decision-making regarding the Facility. General governance of the Facility will be exercised by the Company and UHN through a joint committee. The joint committee, which will meet quarterly, will have a minimum of six people and will be comprised of an equal number of members from each of the Company and UHN.
On March 10, 2023, the Company entered into a lease for an approximately 103,000 square foot facility in Indianapolis (the "Indianapolis Lease"). The lease commencement date was determined to be July 1, 2023, the date upon which the Company was provided access to the facility. The initial term of the lease will run for 121 months from the lease commencement date, with an option to renew for two ten-year terms thereafter, subject to certain conditions described in the Indianapolis Lease. Management did not include either option to renew as part of the lease term in determining the right-of-use asset and lease liability. Management has accounted for the lease as an operating lease as it believes that the lease term does not cover a substantial portion of the economic life of the primary lease component nor does the present value of the minimum lease payments exceed 90% of the fair value of the facility. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the property to the Company.
On April 12, 2023, the Company entered into an operating lease for laboratory space with a lease term of two years. The lease commencement date was determined to be April 15, 2023, the date upon which the Company was provided access to the laboratory space. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the laboratory space to the Company.

The components of lease expense are as follows:
For the nine months ended September 30, 2023
Operating lease expense$303,215 
Finance lease cost
Amortization of right-of-use asset384,622 
Interest on lease liability196,027 
Total finance lease cost$580,649 

As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.

Supplemental cash flow information related to leases is as follows:

For the nine months ended September 30, 2023
Cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow use from operating leases$167,397 
Operating cash flow use from finance lease$196,027 
Financing cash flow use from finance lease$285,949 
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$5,644,563 
Finance lease$5,384,707 

The following table summarizes the weighted average remaining lease terms for the Company’s leases:

As of September 30, 2023
Weighted-average remaining lease term (in years):
Operating leases9.2
Finance lease6.5

Below is information on the weighted average discount rates used at the time that the leases were commenced:

As of September 30, 2023
Weighted-average discount rates:
Operating leases7.8 %
Finance lease7.7 %

The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:
Operating LeasesFinance Lease
2023$232,797 $246,755 
2024689,632 987,018 
2025797,739 987,018 
2026746,332 987,018 
2027768,722 987,018 
Thereafter4,732,515 2,220,793 
Total lease payments$7,967,737 $6,415,620 
Less: imputed interest(2,385,189)(1,335,399)
Present value of lease liabilities$5,582,548 $5,080,221 
Leases Leases
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s current portfolio of leases, the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments. The Company has not incurred any material short-term lease costs or variable lease costs associated with its finance and operating leases.
On February 2, 2023, POINT Biopharma Corp., entered into a Facility Agreement (the "UHN Agreement") with University Health Network (“UHN”), a not-for-profit corporation incorporated under the laws of Canada. Pursuant to the UHN Agreement, the Company was provided access to utilize a 7,700 square foot, licensed research and development space with cGMP manufacturing suites (the “Facility”), which the Company will use to develop and expand its pipeline of next-generation radioligands. The lease commencement date was determined to be April 1, 2023, the date upon which the Company was provided access to the Facility. The lease is accounted for as a finance lease in accordance with ASC 842 as one lease component for the facility, infrastructure and equipment, and the right-of-use asset has been included within property, plant and equipment. Management concluded the lease represents a finance lease on the basis that management believes the lease term covers the remaining economic life of the primary lease component. The initial term of the UHN Agreement will run for five years from the lease commencement date, with an option to renew for additional two-year terms thereafter, subject to certain conditions described in the UHN Agreement. Management included the first option to renew for two years as part of the lease term in determining the right-of-use asset and lease liability. The UHN Agreement does not transfer any title in the Facility to the Company. During the term, the Company shall be responsible for day-to-day management activities and decision-making regarding the Facility. General governance of the Facility will be exercised by the Company and UHN through a joint committee. The joint committee, which will meet quarterly, will have a minimum of six people and will be comprised of an equal number of members from each of the Company and UHN.
On March 10, 2023, the Company entered into a lease for an approximately 103,000 square foot facility in Indianapolis (the "Indianapolis Lease"). The lease commencement date was determined to be July 1, 2023, the date upon which the Company was provided access to the facility. The initial term of the lease will run for 121 months from the lease commencement date, with an option to renew for two ten-year terms thereafter, subject to certain conditions described in the Indianapolis Lease. Management did not include either option to renew as part of the lease term in determining the right-of-use asset and lease liability. Management has accounted for the lease as an operating lease as it believes that the lease term does not cover a substantial portion of the economic life of the primary lease component nor does the present value of the minimum lease payments exceed 90% of the fair value of the facility. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the property to the Company.
On April 12, 2023, the Company entered into an operating lease for laboratory space with a lease term of two years. The lease commencement date was determined to be April 15, 2023, the date upon which the Company was provided access to the laboratory space. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the laboratory space to the Company.

The components of lease expense are as follows:
For the nine months ended September 30, 2023
Operating lease expense$303,215 
Finance lease cost
Amortization of right-of-use asset384,622 
Interest on lease liability196,027 
Total finance lease cost$580,649 

As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.

Supplemental cash flow information related to leases is as follows:

For the nine months ended September 30, 2023
Cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow use from operating leases$167,397 
Operating cash flow use from finance lease$196,027 
Financing cash flow use from finance lease$285,949 
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$5,644,563 
Finance lease$5,384,707 

The following table summarizes the weighted average remaining lease terms for the Company’s leases:

As of September 30, 2023
Weighted-average remaining lease term (in years):
Operating leases9.2
Finance lease6.5

Below is information on the weighted average discount rates used at the time that the leases were commenced:

As of September 30, 2023
Weighted-average discount rates:
Operating leases7.8 %
Finance lease7.7 %

The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:
Operating LeasesFinance Lease
2023$232,797 $246,755 
2024689,632 987,018 
2025797,739 987,018 
2026746,332 987,018 
2027768,722 987,018 
Thereafter4,732,515 2,220,793 
Total lease payments$7,967,737 $6,415,620 
Less: imputed interest(2,385,189)(1,335,399)
Present value of lease liabilities$5,582,548 $5,080,221 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' equity
9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' equity Stockholders’ equity
The Company is authorized to issue 430,000,000 shares of common stock, with a par value of $0.0001 per share ("Common Stock"), as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”).
During the three months ended September 30, 2023, there were no issuances of Common Stock. During the nine months ended September 30, 2023, the Company issued (i) 86,585 shares of Common Stock in connection with the exercise of stock options granted to non-employee consultants, resulting in total cash proceeds of $120,353 and (ii) 29,628 shares of Common Stock in connection with the exercise of stock options granted to employees and directors, resulting in total cash proceeds of $211,569.

During the three months ended September 30, 2022, the Company issued (a) 13,900,000 shares of Common Stock in connection with an underwritten public share offering at the price of $9.00 per share pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission, resulting in total gross proceeds of $125.1 million (excluding approximately $8.2 million of issuance costs) and (b) 30,000 shares of Common Stock in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $41,700. During the nine months ended September 30, 2022, the Company issued 13,933,168 shares of Common Stock, including the 13,930,000 shares of Common Stock discussed above, as well as 3,168 shares of Common Stock in connection with the exercise of stock options issued to non-employee consultants, resulting in total cash proceeds of $4,403.
As of September 30, 2023, the total number of issued and outstanding shares of Common Stock was 105,765,954 (December 31, 2022 — 105,649,741). As of September 30, 2023, there were no issued and outstanding shares of Preferred Stock (December 31, 2022 — $nil).
Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Holders of Common Stock are entitled to receive dividends, if any, as may be declared by the Company’s board of directors (the “Board”). During the three and nine months ended September 30, 2023, no cash dividends were declared or paid by the Company (September 30, 2022 — $nil).
The Board has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law ("DGCL"). During the nine months ended September 30, 2023, no shares of Preferred Stock were issued by the Company.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensationIn March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and non-qualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, the Board adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. The Company assumed the outstanding equity awards under the 2020 EIP, but no further grants may be made under the 2020 EIP. The 2021 EIP provides that the
number of shares reserved and available for issuance under the 2021 EIP will automatically increase each January 1, beginning on January 1, 2022, by 4% of the number of outstanding shares of Common Stock on the immediately preceding December 31, or such lesser amount as determined by the Board. As of January 1, 2023, the number of shares of Common Stock available under the 2021 EIP increased by 4,225,990 for a total of 9,049,548 shares of Common Stock authorized for issuance under the 2021 EIP as of September 30, 2023.
Stock options
The Company recorded $666,368 and $1,797,759 to research and development expenses and $1,210,064 and $2,798,518 to general and administrative expenses for stock-based compensation for the three and nine months ended September 30, 2023, respectively (September 30, 2022 — $476,481 and $1,220,426 to research and development expenses and $602,575 and $1,326,643 to general and administrative expenses for the three and nine months ended, respectively). The Company did not recognize a tax benefit related to stock-based compensation expense during the three and nine months ended September 30, 2023 as well as during the three and nine months ended September 30, 2022, as the Company had net operating loss carryforwards and recorded a valuation allowance against the deferred tax asset.
The following table summarizes the activity relating to the Company’s stock options.
Number of
Shares
Weighted
Average Exercise
Price Per Share
($)
Weighted-
Average
Remaining
Contractual
Term (in years)
Outstanding as of December 31, 2022
5,592,1735.85
Granted3,294,0717.09
Exercised(116,213)2.86
Forfeited(176,942)7.23
Expired(15,510)8.29
Outstanding as of September 30, 2023
8,577,5796.334.4
Vested and expected to vest as of September 30, 2023
8,577,5796.334.4
Options exercisable as of September 30, 2023
2,985,1145.193.7
During the three months ended September 30, 2023, 150,000 stock options were granted to an employee of the Company, with a weighted average grant date fair value of $4.57 per share. During the nine months ended September 30, 2023, 3,294,071 stock options were granted, including the 150,000 stock options discussed above as well as 3,144,071 stock options granted to employees and directors of the Company, with a weighted average grant date fair value of $3.85 per share. The vesting terms of the options granted to employees of the Company are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in three equal annual installments thereafter. The vesting terms of the options granted to directors of the Company are such that they vest on the one-year anniversary of the date of grant.

During the three months ended September 30, 2022, there were no stock options granted. During the nine months ended September 30, 2022, 1,948,614 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.59 per share. Except as provided below with respect to options granted to directors, the vesting terms of these options are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in three equal annual installments thereafter. On June 6, 2022, the terms of 128,070 stock options granted to directors of the Company during the quarter were amended to reduce the vesting period to one year. This amendment was accounted for as a modification and there was no material impact to stock-based compensation recorded.

The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted:
Three months ended September 30, 2023Three months ended September 30, 2022Nine months ended September 30, 2023Nine months ended September 30, 2022
Risk-free interest rate4.47%
3.71% - 4.47%
1.24% - 3.13%
Expected term (in years)4.25
3.50 - 4.25
4.25
Expected volatility66%—%
66% - 68%
72% - 75%
Expected dividend yield—%—%—%—%
During the three months ended September 30, 2023, there were no stock option exercises. During the nine months ended September 30, 2023, non-employee consultants of the Company exercised 86,585 stock options with an intrinsic value of $700,217, and employees and directors of the Company exercised 29,628 stock options with an intrinsic value of $38,300, for total cash proceeds to the Company of $331,922.
During the three and nine months ended September 30, 2022, non-employee consultants of the Company exercised 30,000 and 33,168 stock options with intrinsic values of $238,300 and $257,601, respectively. The exercises resulted in cash proceeds to the Company of $41,700 and $46,103, respectively.
As of September 30, 2023, the unrecognized stock-based compensation expense related to unvested stock options was $17,944,644 and the estimated weighted average remaining vesting period was 2.9 years.
Performance Share Units
During the year ended December 31, 2022, 146,044 performance share units ("PSUs") were granted to employees of the Company, with a grant date fair value of $6.61 per unit based on the closing share price of the Company's Common Stock on the date of grant. The vesting terms of these PSUs are such that 100% vest upon the regulatory approval of PNT2002 by the FDA. During the three and nine months ended September 30, 2023, the Company did not record any stock-based compensation expense related to these PSUs on the basis that they cannot be considered probable to vest as the regulatory approval requirement is outside the control of the Company and the clinical trial remains ongoing.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Indianapolis facility commitments
The Company is party to certain agreements for the continuing expansion of the manufacturing capabilities of the Indianapolis facility (see Note 7). Effective in the second quarter of 2022, the Company entered into an agreement for the design and build of a commercial manufacturing line. As of September 30, 2023, the Company is committed to aggregate future payments of approximately $22.5 million in connection with these agreements. During the three and nine months ended September 30, 2023, approximately $5.2 million and $15.5 million, respectively, has been recorded within property, plant and equipment in connection with these agreements (three and nine months ended September 30, 2022 — approximately $3.7 million and $7.7 million, respectively).
Clinical trial and commercial commitments
The Company, in the normal course of business, enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain products and product lines during the Company’s clinical phase. These agreements often have minimum purchase commitments and generally terminate upon the termination of the clinical trial. As at September 30, 2023, aggregate remaining minimum commitments amount to approximately $5.4 million with payments ranging from three to eight years or upon completion of the clinical trial, if earlier. The Company recorded research and development expenses in connection with these agreements of approximately $3.1 million and $14.4 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $3.8 million and $8.1 million, respectively).
The Company also has supply agreements with third parties to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of products in the amount of approximately $109.2 million ($148.3 million CAD) with payments ranging from two to nine years. The purchase commitments are contingent upon the completion of certain milestones by the third-party suppliers. During the three and nine months ended September 30, 2023 and September 30, 2022, the Company did not record any research and development expenses in connection with this agreement.

On May 10, 2023, the Company entered into an Irradiation Services Agreement (the "Irradiation Agreement") which expands the Company's reactor network. Pursuant to the Irradiation Agreement, the Company will receive irradiation services to irradiate ytterbium-176 (“176Yb”) and has minimum purchase commitments of approximately $32.4 million over
the ten-year contract term. During the three and nine months ended September 30, 2023, the Company did not record any research and development expenses in connection with this agreement.

On September 25, 2023, the Company entered into a Supply Agreement (the "Supply Agreement") for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The Supply Agreement has a term of ten years and has minimum purchase commitments of approximately $107.4 million (€101.8 million) subject to certain conditions in the Supply Agreement, including the successful validation of the supplier-produced 177Lu with the intended compounds. The Company recorded research and development expenses in connection with this agreement of approximately $0.2 million and $0.2 million during the three and nine months ended September 30, 2023, respectively.
The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. As of September 30, 2023, the remaining minimum purchase commitment under this agreement is approximately $23.7 million with payments that range from one to five years. The Company recorded research and development expenses in connection with this agreement of approximately $3.5 million and $14.6 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $6.5 million and $15.4 million, respectively).
License agreements
The Company, in the normal course of business, enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details about the Company’s license agreements, see Note 15 to the 2022 Financial Statements.
On April 17, 2023, POINT Biopharma Inc. entered into first and second amendments (the "Amendments") to that certain Sublicense Agreement, dated November 14, 2019, between POINT Biopharma Inc. and Scintomics GmbH ("Scintomics"). Pursuant to the Amendments, the exclusive, sublicensable, license was expanded to include all geographies worldwide and the Company has increased flexibility in connection with sublicense arrangements.
On September 11, 2023, POINT Biopharma Inc. entered into a collaboration and license agreement between POINT Biopharma Inc. and Athebio AG ("Athebio") (the "Athebio Agreement"). Pursuant to the Agreement, the Company is granted exclusive access to Athebio's intellectual property and capabilities in the designed ankyrin repeat proteins ("DARPins") development. The Company recorded research and development expenses in connection with this agreement of $1.0 million during the three and nine months ended September 30, 2023. In addition, in connection with the Athebio agreement, the Company is committed to enter into a stock purchase agreement by which the Company will invest a total of $5.0 million subject to certain conditions and milestones set forth in the Athebio Agreement.

The Company recorded aggregate research and development expenses in connection with its license agreements of approximately $1.5 million and $5.0 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $0.8 million and $5.3 million, respectively).
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net loss per share Net loss per share
Basic loss per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method.
Three months
ended
 September 30, 2023
Three months
ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Net loss$24,774,353 $24,013,069 $66,715,863 $64,973,890 
Weighted-average common shares outstanding-basic and diluted 105,765,954 92,401,484 105,717,330 90,891,031 
Net loss per share-basic and diluted $0.23 $0.26 $0.63 $0.71 
The Company’s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company's PSU's are considered contingently issuable shares for the purpose of the computation of loss per share and have been excluded on the basis that
as of September 30, 2023, the performance condition for vesting had not been achieved. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to the holders of Common Stock is the same.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company calculates its interim tax provision at the end of each interim period and estimates the annual effective tax rate, which is applied to its ordinary quarterly earnings. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.
The Company has operations in both the United States and Canada, and as such it is subject to tax in both countries. The income tax expense for the three months ended September 30, 2023 and September 30, 2022 was $871,449 and $180,500, respectively and the income tax benefit and expense for the nine months ended September 30, 2023 and September 30, 2022 was $288,491 and $452,021, respectively. The income tax amounts for the three and nine months ended September 30, 2023, include tax benefits related to research and development tax credits partially offset by current federal, state, and Canadian income tax adjustments. The three months ended September 30, 2023 also includes prior year current income tax adjustments in the United States jurisdictions. The income tax expense for the three and nine months ended September 30, 2022, consists of current taxes in Canada.
The Company files income tax returns in the U.S. federal, certain states, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations would have a significant impact on its financial position or results of operations.
As of September 30, 2023, the Company believes no significant changes in the unrecognized tax benefits will occur within the next 12 months.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Related party transactions
9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related party transactions Related party transactions
The Company recognized expenses in connection with related party transactions in the unaudited interim condensed consolidated statements of operations as follows:
Three months ended
September 30, 2023
Three months ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Consulting fees on business activities to Board member $90,161 $90,040 $296,072 $259,132 
Reimbursement to Board member for occupancy costs18,219 17,395 53,532 53,071 
Total$108,380 $107,435 $349,604 $312,203 
Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount.
During the three and nine-month periods ended September 30, 2023 and 2022, the Company received consulting services for research and development from a Board member. As of September 30, 2023, $43,859 is recorded within accrued liabilities in relation to this consulting arrangement.
The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC 842 to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent events
9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent events Subsequent eventsIonetix Amendment of Convertible Note Purchase Agreement
On September 29, 2023, POINT Biopharma Inc. entered into the Amendment, whereby on October 2, 2023 the Company purchased an additional $5.0 million of unsecured promissory notes from Ionetix-α. In connection with the Convertible Note Agreement, this additional purchase was originally scheduled for six months from the initial purchase date of June 1, 2023. See Note 5.
Merger Agreement
As previously announced, on October 2, 2023, Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”). Merger Sub commenced the cash tender offer (the “Offer”) to purchase all of the outstanding shares of Common Stock (the “Shares”), at a price of $12.50 per share, net to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement. The Offer commenced on October 13, 2023 and was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 p.m., Eastern Time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.

Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the DGCL) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the HSR Act, (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the U.S. Federal Trade Commission (the “FTC”) and the Antitrust Division of the U.S. Department of Justice (the “Antitrust Division”), initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern Time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. The Company could be required to pay the Parent a termination fee of approximately $54.4 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The consummation of the Offer and the Merger is not subject to a financing condition. For more information on the Offer and the Merger, refer to the Company's Current Report on Form 8-K filed October 3, 2023.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure                
Net loss $ (24,774,353) $ (25,410,839) $ (16,530,671) $ (24,013,069) $ (24,580,247) $ (16,380,574) $ (66,715,863) $ (64,973,890)
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and the Subsidiaries, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023 (the “2022 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2022 Financial Statements.
Going concern These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
Risks and uncertainties
Risks and uncertainties
Except for the upfront payment received pursuant to the Lantheus License Agreements (as defined in Note 3 below), the Company has incurred significant net losses and has funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to continue to be incurred in future periods. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from public health crisis or military conflicts and adverse developments affecting the financial services industry, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
The Company also has a number of risks and uncertainties related to the Offer and Merger described in Note 16. These risks and uncertainties are described in more detail in Part II. Item 1A. “Risk Factors” starting on page 34.
Use of estimates
Use of estimates
The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the allocation of consideration and the recognition of revenues in respect of the performance obligations under the Lantheus License Agreements, the accrual of research and development expenses, incremental borrowing rates determined in connection with finance and operating lease obligations, the valuations of stock options, the expected recoverability of and the estimated useful lives of our long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experiences. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Leases
Leases
The Company accounts for leases in accordance with ASC Topic 842, Leases ("ASC 842"). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less in the consolidated balance sheets. The Company has also elected to account for the lease and non-lease components as a combined lease component for its current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.

Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.
Recent accounting pronouncements
Recent accounting pronouncements
The Company has evaluated accounting pronouncements recently issued but not yet adopted and believes that the accounting pronouncements currently do not apply to the Company’s operations and are not expected to have a material impact on the Company’s unaudited interim condensed consolidated financial statements or disclosures.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue (Tables)
9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Contract Liabilities
The following table presents the Company’s contract liabilities as of September 30, 2023 and December 31, 2022:
September 30, 2023December 31, 2022
Deferred revenue
Deferred revenue, current$12,586,443 $23,242,290 
Deferred revenue, net of current portion3,720,881 10,178,147 
Total$16,307,324 $33,420,437 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments (Tables)
9 Months Ended
Sep. 30, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Cash Equivalents and Investments
Cash, cash equivalents and investments consisted of the following:
As of September 30, 2023As of December 31, 2022
Cash$11,446,728 $12,429,627 
Cash equivalents:
Money market funds6,852,616 273,998,744 
Commercial paper3,308,068 — 
Total cash and cash equivalents21,607,412 286,428,371 
Short-term investments
Commercial paper107,567,350 115,156,455 
Corporate bonds93,787,733 45,219,042 
U.S. Government agency debt securities35,942,645 42,577,762 
Asset backed securities80,258,208 35,830,211 
Total short-term investments317,555,936 238,783,470 
Long-term investments
U.S. Government agency debt securities16,098,662 — 
Asset backed securities8,634,828 16,119,430 
Corporate bonds35,059,671 — 
Total long-term investments59,793,161 16,119,430 
Total cash, cash equivalents and investments$398,956,509 $541,331,271 
Schedule of Available-For-Sale Investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of September 30, 2023 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$107,597,155 $981 $(30,786)$107,567,350 $107,567,350 $— 
Corporate bonds129,438,4505,918(596,964)128,847,40493,787,73335,059,671 
Asset backed securities89,554,665204 (661,833)88,893,03680,258,2088,634,828 
U.S. Government agency debt securities52,186,023— (144,716)52,041,30735,942,64516,098,662 
Total available-for-sale securities$378,776,293 $7,103 $(1,434,299)$377,349,097 $317,555,936 $59,793,161 

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of December 31, 2022 were as follows:

Amortized CostUnrealized GainsUnrealized LossesFair ValueCurrentNon-current
Commercial paper$115,156,455 $— $— $115,156,455 $115,156,455 $— 
Asset backed securities52,019,619 26,527 (96,505)51,949,641 35,830,211 16,119,430 
Corporate bonds45,468,482 — (249,440)45,219,042 45,219,042 — 
U.S. Government agency debt securities42,715,195 — (137,433)42,577,762 42,577,762 — 
Total available-for-sale securities$255,359,751 $26,527 $(483,378)$254,902,900 $238,783,470 $16,119,430 
The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of September 30, 2023:
Amortized CostFair Value
Due within one year$318,607,866 $317,555,936 
Due between one and five years60,168,427 59,793,161 
Total$378,776,293 $377,349,097 

The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2022:

Amortized CostFair Value
Maturing within one year$239,236,498 $238,783,470 
Maturing between one and five years16,123,253 16,119,430 
Total$255,359,751 $254,902,900 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value measurements (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value The following tables present information about the Company’s financial assets and liabilities as of September 30, 2023 and December 31, 2022, that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:
Level 1Level 2Level 3Total
September 30, 2023
Cash equivalents:
Money market mutual fund$6,852,616 $— $— $6,852,616 
Commercial paper— 3,308,068 — 3,308,068 
Available-for-sale debt securities:
Commercial paper— 107,567,350 — 107,567,350 
Corporate bonds— 128,847,404 — 128,847,404 
Asset backed securities— 88,893,036 — 88,893,036 
U.S. Government agency debt securities52,041,307 — — 52,041,307 
Total$58,893,923 $328,615,858 $ $387,509,781 

Level 1Level 2Level 3Total
December 31, 2022
Cash equivalents:
Money market mutual fund$273,998,744 $— $— $273,998,744 
Commercial paper— — — — 
Available-for-sale debt securities:
Commercial paper— 115,156,455 — 115,156,455 
Asset backed securities— 51,949,641 — 51,949,641 
Corporate bonds— 45,219,042 — 45,219,042 
U.S. Government agency debt securities42,577,762 — — 42,577,762 
Total$316,576,506 $212,325,138 $ $528,901,644 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid expenses and other current assets (Tables)
9 Months Ended
Sep. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Summary of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Prepaid clinical trial expenses2,812,270 4,011,419 
Prepaid insurance1,390,347 1,310,314 
Receivable on matured short-term investment5,000,000 — 
Canadian harmonized sales tax receivable206,326 60,222 
Deposit on production equipment— 13,738 
Other492,786 215,196 
Total9,901,729 5,610,889 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Property, plant and equipment, net (Tables)
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Summary of Property, Plant and Equipment, Net
Property, plant and equipment, net consisted of the following:
As of September 30, 2023
 
As of December 31, 2022
$ $
Land and building19,992,990 18,163,962 
Machinery and equipment11,241,336 5,328,639 
Property, plant and equipment, in development19,827,730 8,434,384 
Facility lease (Note 9)
5,384,707 — 
Furniture and fixtures938,909 698,728 
Computer equipment237,963 149,892 
57,623,635 32,775,605 
Less: Accumulated depreciation(3,581,282)(1,395,029)
Total54,042,353 31,380,576 
Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value:
Asset CategoryEstimated Useful Life
Computer equipment
5 years
Machinery and equipment
7 years
Furniture and fixtures
7 years
Facility lease
7 years
Building
20 years
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued liabilities (Tables)
9 Months Ended
Sep. 30, 2023
Accrued Liabilities, Current [Abstract]  
Summary of Accrued Liabilities Accrued liabilities consisted of the following:
As of September 30, 2023
As of December 31, 2022
$$
Accrued personnel costs5,663,218 7,116,382 
Accrued research and development costs7,766,189 9,645,594 
Accrued corporate legal fees and other professional services907,019 2,068,793 
Accrued costs for purchases of property, plant and equipment75,360 105,741 
Other accrued costs117,568 157,944 
Total14,529,354 19,094,454 
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Lease Expense and Supplemental Cash Flow The components of lease expense are as follows:
For the nine months ended September 30, 2023
Operating lease expense$303,215 
Finance lease cost
Amortization of right-of-use asset384,622 
Interest on lease liability196,027 
Total finance lease cost$580,649 

As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.

Supplemental cash flow information related to leases is as follows:

For the nine months ended September 30, 2023
Cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow use from operating leases$167,397 
Operating cash flow use from finance lease$196,027 
Financing cash flow use from finance lease$285,949 
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$5,644,563 
Finance lease$5,384,707 

The following table summarizes the weighted average remaining lease terms for the Company’s leases:

As of September 30, 2023
Weighted-average remaining lease term (in years):
Operating leases9.2
Finance lease6.5

Below is information on the weighted average discount rates used at the time that the leases were commenced:

As of September 30, 2023
Weighted-average discount rates:
Operating leases7.8 %
Finance lease7.7 %
Operating Lease Maturity The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:
Operating LeasesFinance Lease
2023$232,797 $246,755 
2024689,632 987,018 
2025797,739 987,018 
2026746,332 987,018 
2027768,722 987,018 
Thereafter4,732,515 2,220,793 
Total lease payments$7,967,737 $6,415,620 
Less: imputed interest(2,385,189)(1,335,399)
Present value of lease liabilities$5,582,548 $5,080,221 
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity
The following table summarizes the activity relating to the Company’s stock options.
Number of
Shares
Weighted
Average Exercise
Price Per Share
($)
Weighted-
Average
Remaining
Contractual
Term (in years)
Outstanding as of December 31, 2022
5,592,1735.85
Granted3,294,0717.09
Exercised(116,213)2.86
Forfeited(176,942)7.23
Expired(15,510)8.29
Outstanding as of September 30, 2023
8,577,5796.334.4
Vested and expected to vest as of September 30, 2023
8,577,5796.334.4
Options exercisable as of September 30, 2023
2,985,1145.193.7
Summary of Assumptions Used to Determine the Grant Date Fair Value of Stock Options Granted The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted:
Three months ended September 30, 2023Three months ended September 30, 2022Nine months ended September 30, 2023Nine months ended September 30, 2022
Risk-free interest rate4.47%
3.71% - 4.47%
1.24% - 3.13%
Expected term (in years)4.25
3.50 - 4.25
4.25
Expected volatility66%—%
66% - 68%
72% - 75%
Expected dividend yield—%—%—%—%
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share (Tables)
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss per Share
Three months
ended
 September 30, 2023
Three months
ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Net loss$24,774,353 $24,013,069 $66,715,863 $64,973,890 
Weighted-average common shares outstanding-basic and diluted 105,765,954 92,401,484 105,717,330 90,891,031 
Net loss per share-basic and diluted $0.23 $0.26 $0.63 $0.71 
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Related party transaction (Tables)
9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The Company recognized expenses in connection with related party transactions in the unaudited interim condensed consolidated statements of operations as follows:
Three months ended
September 30, 2023
Three months ended
September 30, 2022
Nine months
ended
 September 30, 2023
Nine months
ended
September 30, 2022
Consulting fees on business activities to Board member $90,161 $90,040 $296,072 $259,132 
Reimbursement to Board member for occupancy costs18,219 17,395 53,532 53,071 
Total$108,380 $107,435 $349,604 $312,203 
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Nature of business - Narrative (Details)
9 Months Ended
Sep. 30, 2023
subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of wholly-owned subsidiaries 4
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue Recognition, Milestone Method [Line Items]          
Revenue recognized for future performance $ 34.8        
Revenue recognized   $ 2.8 $ 0.0 $ 17.1 $ 0.0
Lantheus Holdings, Inc. | License Agreements, PNT2002 Agreement          
Revenue Recognition, Milestone Method [Line Items]          
Upfront payment 250.0        
Milestone payment $ 250.0        
Royalty rate 20.00%        
Annual net sales milestone payment $ 1,300.0        
Lantheus Holdings, Inc. | License Agreements, PNT2003 Agreement          
Revenue Recognition, Milestone Method [Line Items]          
Upfront payment 10.0        
Milestone payment $ 30.0        
Royalty rate 15.00%        
Annual net sales milestone payment $ 275.0        
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Contract Liabilities (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Deferred revenue, current $ 12,586,443 $ 23,242,290
Deferred revenue, net of current portion 3,720,881 10,178,147
Total $ 16,307,324 $ 33,420,437
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]    
Cash $ 11,446,728 $ 12,429,627
Money market funds 6,852,616 273,998,744
Commercial paper 3,308,068 0
Total cash and cash equivalents 21,607,412 286,428,371
Short-term investments 317,555,936 238,783,470
Long-term investments 59,793,161 16,119,430
Total cash, cash equivalents and investments 398,956,509 541,331,271
Commercial paper    
Cash and Cash Equivalents [Line Items]    
Short-term investments 107,567,350 115,156,455
Corporate bonds    
Cash and Cash Equivalents [Line Items]    
Short-term investments 93,787,733 45,219,042
Long-term investments 35,059,671 0
U.S. Government agency debt securities    
Cash and Cash Equivalents [Line Items]    
Short-term investments 35,942,645 42,577,762
Long-term investments 16,098,662 0
Asset backed securities    
Cash and Cash Equivalents [Line Items]    
Short-term investments 80,258,208 35,830,211
Long-term investments $ 8,634,828 $ 16,119,430
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 378,776,293 $ 255,359,751
Unrealized Gains 7,103 26,527
Unrealized Losses (1,434,299) (483,378)
Fair Value 377,349,097 254,902,900
Current 317,555,936 238,783,470
Non-current 59,793,161 16,119,430
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 107,597,155 115,156,455
Unrealized Gains 981 0
Unrealized Losses (30,786) 0
Fair Value 107,567,350 115,156,455
Current 107,567,350 115,156,455
Non-current 0 0
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 129,438,450 52,019,619
Unrealized Gains 5,918 26,527
Unrealized Losses (596,964) (96,505)
Fair Value 128,847,404 51,949,641
Current 93,787,733 35,830,211
Non-current 35,059,671 16,119,430
Asset backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 89,554,665 45,468,482
Unrealized Gains 204 0
Unrealized Losses (661,833) (249,440)
Fair Value 88,893,036 45,219,042
Current 80,258,208 45,219,042
Non-current 8,634,828 0
U.S. Government agency debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 52,186,023 42,715,195
Unrealized Gains 0 0
Unrealized Losses (144,716) (137,433)
Fair Value 52,041,307 42,577,762
Current 35,942,645 42,577,762
Non-current $ 16,098,662 $ 0
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Amortized Cost    
Due within one year $ 318,607,866 $ 239,236,498
Due between one and five years 60,168,427 16,123,253
Amortized Cost 378,776,293 255,359,751
Fair Value    
Due within one year 317,555,936 238,783,470
Due between one and five years 59,793,161 16,119,430
Fair Value $ 377,349,097 $ 254,902,900
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, cash equivalents and investments - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Cash and Cash Equivalents [Abstract]    
Realized gain on available-for-sale debt investments $ 611 $ 611
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details) - USD ($)
9 Months Ended
Oct. 02, 2023
Jun. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     $ 377,349,097   $ 254,902,900
Purchase of note receivable   $ 5,000,000 5,000,000 $ 0  
Debt instrument, redemption price, percentage of principal and interest outstanding   150.00%      
Subsequent Event          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Purchase of note receivable $ 5,000,000        
Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Total     387,509,781   528,901,644
Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Total     58,893,923   316,576,506
Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Total     328,615,858   212,325,138
Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Total     0   0
Commercial paper          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     107,567,350   115,156,455
Commercial paper | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     107,567,350   115,156,455
Commercial paper | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Commercial paper | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     107,567,350   115,156,455
Commercial paper | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Corporate bonds          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     128,847,404   51,949,641
Corporate bonds | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     128,847,404   51,949,641
Corporate bonds | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Corporate bonds | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     128,847,404   51,949,641
Corporate bonds | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Asset backed securities          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     88,893,036   45,219,042
Asset backed securities | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     88,893,036   45,219,042
Asset backed securities | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Asset backed securities | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     88,893,036   45,219,042
Asset backed securities | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
U.S. Government agency debt securities          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     52,041,307   42,577,762
U.S. Government agency debt securities | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     52,041,307   42,577,762
U.S. Government agency debt securities | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     52,041,307   42,577,762
U.S. Government agency debt securities | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
U.S. Government agency debt securities | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Available-for-sale debt securities:     0   0
Money market mutual fund | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     6,852,616   273,998,744
Money market mutual fund | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     6,852,616   273,998,744
Money market mutual fund | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     0   0
Money market mutual fund | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     0   0
Commercial paper | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     3,308,068   0
Commercial paper | Fair Value, Recurring | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     0   0
Commercial paper | Fair Value, Recurring | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     3,308,068   0
Commercial paper | Fair Value, Recurring | Level 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash equivalents:     $ 0   $ 0
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid expenses and other current assets (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]    
Prepaid clinical trial expenses $ 2,812,270 $ 4,011,419
Prepaid insurance 1,390,347 1,310,314
Receivable on matured short-term investment 5,000,000 0
Canadian harmonized sales tax receivable 206,326 60,222
Deposit on production equipment 0 13,738
Other 492,786 215,196
Total $ 9,901,729 $ 5,610,889
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Property, plant and equipment, net (Details)
ft² in Thousands
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jul. 31, 2020
ft²
Property, Plant and Equipment [Line Items]      
Facility lease $ 5,384,707 $ 0  
Total property, plant and equipment, gross 57,623,635 32,775,605  
Less: Accumulated depreciation (3,581,282) (1,395,029)  
Total 54,042,353 31,380,576  
Good Manufacturing Practices      
Property, Plant and Equipment [Line Items]      
Square-foot of building | ft²     81
Land and building      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 19,992,990 18,163,962  
Machinery and equipment      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 11,241,336 5,328,639  
Property, plant and equipment, in development      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 19,827,730 8,434,384  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 938,909 698,728  
Computer equipment      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 237,963 $ 149,892  
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Property, plant and equipment, net - Estimated Useful Life (Details)
Sep. 30, 2023
Computer equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 5 years
Machinery and equipment  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 7 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 7 years
Facility lease  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 7 years
Building  
Property, Plant and Equipment [Line Items]  
Estimated Useful Life 20 years
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued liabilities (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Accrued Liabilities, Current [Abstract]    
Accrued personnel costs $ 5,663,218 $ 7,116,382
Accrued research and development costs 7,766,189 9,645,594
Accrued corporate legal fees and other professional services 907,019 2,068,793
Accrued costs for purchases of property, plant and equipment 75,360 105,741
Other accrued costs 117,568 157,944
Total $ 14,529,354 $ 19,094,454
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Narrative (Details)
Apr. 12, 2023
Mar. 10, 2023
ft²
renewal
Feb. 02, 2023
ft²
people
Lessee, Lease, Description [Line Items]      
Percentage of fair value   0.90  
UHN      
Lessee, Lease, Description [Line Items]      
Net rentable area     7,700
Initial lease term     5 years
Renewal term     2 years
UHN | Minimum      
Lessee, Lease, Description [Line Items]      
Number of people required in committee | people     6
Indianapolis Lease      
Lessee, Lease, Description [Line Items]      
Net rentable area   103,000  
Initial lease term   121 months  
Renewal term   10 years  
Number of renewal options | renewal   2  
Labratory Space      
Lessee, Lease, Description [Line Items]      
Initial lease term 2 years    
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Schedule of Lease Expense (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Leases [Abstract]    
Operating lease expense $ 303,215 $ 0
Amortization of right-of-use asset 384,622  
Interest on lease liability 196,027  
Total finance lease cost $ 580,649 $ 0
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Supplemental Cash Flow Information (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flow use from operating leases $ 167,397  
Operating cash flow use from finance lease 196,027  
Payments on finance lease 285,949 $ 0
Right-of-use assets obtained in exchange for lease obligations:    
Operating leases 5,644,563  
Finance lease $ 5,384,707  
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Weighted Average Remaining Lease Term and Discount Rates (Details)
Sep. 30, 2023
Weighted-average remaining lease term (in years):  
Operating leases 9 years 2 months 12 days
Finance lease 6 years 6 months
Weighted-average discount rates:  
Operating leases 7.80%
Finance lease 7.70%
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Operating Lease Maturity (Details)
Sep. 30, 2023
USD ($)
Operating Leases  
2023 $ 232,797
2024 689,632
2025 797,739
2026 746,332
2027 768,722
Thereafter 4,732,515
Total lease payments 7,967,737
Less: imputed interest (2,385,189)
Present value of lease liabilities 5,582,548
Finance Lease  
2023 246,755
2024 987,018
2025 987,018
2026 987,018
2027 987,018
Thereafter 2,220,793
Total lease payments 6,415,620
Less: imputed interest (1,335,399)
Present value of lease liabilities $ 5,080,221
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' equity (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
shares
Mar. 31, 2023
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2022
shares
Mar. 31, 2022
shares
Sep. 30, 2023
USD ($)
vote
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Dec. 31, 2021
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Common stock, authorized (in shares) 430,000,000           430,000,000   430,000,000  
Common shares, par value (in dollars per share) | $ / shares $ 0.0001           $ 0.0001   $ 0.0001  
Number of shares issued during period (in shares) 0                  
Proceeds from issuance of shares of common stock | $             $ 0 $ 116,856,162    
Cost and fees on issuance of common shares | $       $ 8,200,000            
Common stock, shares issued (in shares) 105,765,954           105,765,954   105,649,741  
Common stock, shares outstanding (in shares) 105,765,954           105,765,954   105,649,741  
Preferred stock, shares outstanding (in shares) 0           0   0  
Preferred stock, shares issued (in shares) 0           0   0  
Number of votes per share | vote             1      
Cash dividend declared | $ $ 0     0     $ 0 0    
Cash dividend paid | $ $ 0     $ 0     $ 0 $ 0    
Public Share Offering                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Sale of stock, price per share (in dollars per share) | $ / shares       $ 9.00       $ 9.00    
Preferred shares                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Preferred shares, shares authorized (in shares) 20,000,000           20,000,000      
Preferred stock, par value (in dollars per share) | $ / shares $ 0.0001           $ 0.0001      
Number of shares issued during period (in shares)             0      
Common Stock                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Number of shares issued during period (in shares)       13,900,000       13,933,168    
Issuance of shares of common stock in connection with stock option exercises (in shares)   83,277 32,936 30,000 2,490 678        
Proceeds from issuance of shares of common stock | $       $ 125,100,000            
Issuance of common stock in connection with an underwritten public share offering and exercise of stock options (in shares)               13,930,000    
Common stock, shares outstanding (in shares) 105,765,954 105,765,954 105,682,677 104,054,962 90,124,962 90,122,472 105,765,954 104,054,962 105,649,741 90,121,794
Common Stock | Non-employee consultant                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Issuance of shares of common stock in connection with stock option exercises (in shares)             86,585 3,168    
Proceeds from issuance of shares of common stock | $       $ 41,700     $ 120,353 $ 4,403    
Common Stock | Board member                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Issuance of shares of common stock in connection with stock option exercises (in shares)             29,628      
Proceeds from issuance of shares of common stock | $             $ 211,569      
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based compensation - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2023
Jun. 06, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Annual increase in shares authorized, percentage         4.00%    
Number of additional shares available (in shares) 4,225,990            
Number of shares authorized for issuance under plan (in shares)     9,049,548   9,049,548    
Proceeds from issuance of shares of common stock         $ 0 $ 116,856,162  
Unrecognized stock-based compensation     $ 17,944,644   $ 17,944,644    
Period for recognition         2 years 10 months 24 days    
Non-employee consultant              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Proceeds from issuance of shares of common stock       $ 41,700 $ 331,922 $ 46,103  
Vesting on 1st year anniversary | Employees and Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage           25.00%  
Vesting ratably over the remaining three years | Employees and Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage           75.00%  
Stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of options granted (in shares)       0 3,294,071    
Stock options exercised (in shares)     0   116,213    
Stock options | Employee              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of options granted (in shares)     150,000        
Options granted in period, weighted average grant date fair value (in dollars per share)     $ 4.57        
Stock options | Employees and Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of options granted (in shares)         3,144,071 1,948,614  
Options granted in period, weighted average grant date fair value (in dollars per share)         $ 3.85 $ 4.59  
Stock options exercised (in shares)         29,628    
Intrinsic value         $ 38,300    
Stock options | Director              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of options granted (in shares)   128,070          
Vesting period   1 year          
Stock options | Non-employee consultant              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock options exercised (in shares)       30,000 86,585 33,168  
Intrinsic value       $ 238,300 $ 700,217 $ 257,601  
Stock options | Vesting on 1st year anniversary | Employee              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage     25.00%        
Vesting period         1 year    
Stock options | Vesting on 1st year anniversary | Employees and Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period           1 year  
Stock options | Vesting on 1st year anniversary | Director              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period         1 year    
Stock options | Vesting ratably over the remaining three years | Employee              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage     75.00%        
Vesting period     3 years   3 years    
Stock options | Vesting ratably over the remaining three years | Employees and Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period           3 years  
Performance Shares              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage             100.00%
Grants in period (in shares)             146,044
Grant date fair value (in dollars per share)             $ 6.61
Research and development              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based compensation expense     $ 666,368 476,481 $ 1,797,759 $ 1,220,426  
General and administrative              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based compensation expense     $ 1,210,064 $ 602,575 $ 2,798,518 $ 1,326,643  
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) - Stock options - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Number of Shares      
Beginning balance (in shares)     5,592,173
Granted (in shares)   0 3,294,071
Exercised (in shares) 0   (116,213)
Forfeited (in shares)     (176,942)
Expired (in shares)     (15,510)
Ending balance (in shares) 8,577,579   8,577,579
Vested and expected to vest (in shares) 8,577,579   8,577,579
Options exercisable (in shares) 2,985,114   2,985,114
Weighted Average Exercise Price Per Share ($)      
Beginning balance (in dollars per share)     $ 5.85
Granted (in dollars per share)     7.09
Exercised (in dollars per share)     2.86
Forfeited (in dollars per share)     7.23
Expired (in dollars per share)     8.29
Ending balance (in dollars per share) $ 6.33   6.33
Vested and expected to vest (in dollars per share) 6.33   6.33
Options exercisable (in dollars per share) $ 5.19   $ 5.19
Weighted- Average Remaining Contractual Term (in years)      
Outstanding (in years)     4 years 4 months 24 days
Vested and expected to vest (in years)     4 years 4 months 24 days
Options exercisable (in years)     3 years 8 months 12 days
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest rate 4.47% 0.00%    
Expected term (in years) 4 years 3 months      
Expected volatility 66.00% 0.00%    
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest rate     0.0371% 0.0124%
Expected term (in years)     3 years 6 months 4 years 3 months
Expected volatility     0.66% 0.72%
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest rate     0.0447% 0.0313%
Expected term (in years)     4 years 3 months  
Expected volatility     0.68% 0.75%
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies - Property in development commitment (Details) - Property, in development commitment - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Other Commitments [Line Items]        
Future payments relating to the construction and retrofit of the building $ 22.5   $ 22.5  
Total aggregate remaining minimum commitment $ 5.2 $ 3.7 $ 15.5 $ 7.7
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details)
€ in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 25, 2023
USD ($)
Sep. 25, 2023
EUR (€)
May 10, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
CAD ($)
Sep. 30, 2022
USD ($)
Sep. 11, 2023
USD ($)
Athebio | Stock Purchase Agreement                  
Long-term Purchase Commitment [Line Items]                  
Investment committed                 $ 5,000,000
Research and development | Athebio                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment       $ 1,000,000   $ 1,000,000      
Research and development | License Agreement                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment       1,500,000 $ 800,000 5,000,000   $ 5,300,000  
Supply agreements in connection with clinical trials                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment           5,400,000      
Supply agreements in connection | Research and development                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment       3,100,000 3,800,000 14,400,000   8,100,000  
Supply agreement to purchase certain products                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment     10 years            
Minimum purchase commitments     $ 32,400,000     109,200,000 $ 148.3    
Supply agreement to purchase certain products | Research and development                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment       0   0      
Minimum purchase commitments       0 0 0   0  
Supply Agreement To Purchase n.c.a. Lu                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment 10 years 10 years              
Minimum purchase commitments $ 107,400,000 € 101.8              
Supply Agreement To Purchase n.c.a. Lu | Research and development                  
Long-term Purchase Commitment [Line Items]                  
Minimum purchase commitments       200,000   200,000      
Agreement in connection with the SPLASH clinical phase study                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment           23,700,000      
Agreement in connection with the SPLASH clinical phase study | Research and development                  
Long-term Purchase Commitment [Line Items]                  
Total aggregate remaining minimum commitment       $ 3,500,000 $ 6,500,000 $ 14,600,000   $ 15,400,000  
Maximum | Supply agreements in connection with clinical trials                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           8 years 8 years    
Maximum | Supply agreement to purchase certain products                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           9 years 9 years    
Maximum | Agreement in connection with the SPLASH clinical phase study                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           5 years 5 years    
Minimum | Supply agreements in connection with clinical trials                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           3 years 3 years    
Minimum | Supply agreement to purchase certain products                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           2 years 2 years    
Minimum | Agreement in connection with the SPLASH clinical phase study                  
Long-term Purchase Commitment [Line Items]                  
Term for total aggregate remaining minimum commitment           1 year 1 year    
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share - Summary of basic and diluted net loss per share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]                
Net loss $ 24,774,353 $ 25,410,839 $ 16,530,671 $ 24,013,069 $ 24,580,247 $ 16,380,574 $ 66,715,863 $ 64,973,890
Weighted-average common shares outstanding - basic (in shares) 105,765,954     92,401,484     105,717,330 90,891,031
Weighted-average common shares outstanding - diluted (in shares) 105,765,954     92,401,484     105,717,330 90,891,031
Net loss per share - basic (in dollars per share) $ 0.23     $ 0.26     $ 0.63 $ 0.71
Net loss per share - diluted (in dollars per share) $ 0.23     $ 0.26     $ 0.63 $ 0.71
XML 70 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ 871,449 $ 180,500 $ (288,491) $ 452,021
XML 71 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Related party transactions - Schedule of Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Related Party Transaction [Line Items]        
Related party expenses $ 108,380 $ 107,435 $ 349,604 $ 312,203
Consulting fees on business activities to Board member        
Related Party Transaction [Line Items]        
Related party expenses 90,161 90,040 296,072 259,132
Reimbursement to Board member for occupancy costs        
Related Party Transaction [Line Items]        
Related party expenses $ 18,219 $ 17,395 $ 53,532 $ 53,071
XML 72 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Related party transactions -Narrative (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Accrued liabilities $ 14,529,354 $ 19,094,454
Director    
Related Party Transaction [Line Items]    
Accrued liabilities 43,859  
Related Party    
Related Party Transaction [Line Items]    
Rent expense $ 6,000  
XML 73 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent events (Details) - USD ($)
9 Months Ended
Oct. 02, 2023
Jun. 01, 2023
Sep. 30, 2023
Sep. 30, 2022
Oct. 13, 2023
Subsequent Event [Line Items]          
Purchase of note receivable   $ 5,000,000 $ 5,000,000 $ 0  
Subsequent Event          
Subsequent Event [Line Items]          
Purchase of note receivable $ 5,000,000        
Termination fee         $ 54,400,000
Subsequent Event | Eli Lilly          
Subsequent Event [Line Items]          
Business acquisition, share price (in dollars per share) $ 12.50        
XML 74 pnt-20230930_htm.xml IDEA: XBRL DOCUMENT 0001811764 2023-01-01 2023-09-30 0001811764 2023-11-08 0001811764 2023-09-30 0001811764 2022-12-31 0001811764 2023-07-01 2023-09-30 0001811764 2022-07-01 2022-09-30 0001811764 2022-01-01 2022-09-30 0001811764 us-gaap:CommonStockMember 2022-12-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001811764 us-gaap:RetainedEarningsMember 2022-12-31 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001811764 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001811764 2023-01-01 2023-03-31 0001811764 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001811764 us-gaap:CommonStockMember 2023-03-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001811764 us-gaap:RetainedEarningsMember 2023-03-31 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001811764 2023-03-31 0001811764 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001811764 2023-04-01 2023-06-30 0001811764 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001811764 us-gaap:CommonStockMember 2023-06-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001811764 us-gaap:RetainedEarningsMember 2023-06-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001811764 2023-06-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001811764 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001811764 us-gaap:CommonStockMember 2023-09-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001811764 us-gaap:RetainedEarningsMember 2023-09-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001811764 us-gaap:CommonStockMember 2021-12-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001811764 us-gaap:RetainedEarningsMember 2021-12-31 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001811764 2021-12-31 0001811764 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001811764 2022-01-01 2022-03-31 0001811764 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001811764 us-gaap:CommonStockMember 2022-03-31 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001811764 us-gaap:RetainedEarningsMember 2022-03-31 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001811764 2022-03-31 0001811764 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001811764 2022-04-01 2022-06-30 0001811764 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001811764 us-gaap:CommonStockMember 2022-06-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001811764 us-gaap:RetainedEarningsMember 2022-06-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001811764 2022-06-30 0001811764 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001811764 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001811764 us-gaap:CommonStockMember 2022-09-30 0001811764 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001811764 us-gaap:RetainedEarningsMember 2022-09-30 0001811764 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001811764 2022-09-30 0001811764 pnt:LantheusHoldingsIncMember pnt:LicenseAgreementsPNT2002AgreementMember 2022-12-01 2022-12-31 0001811764 pnt:LantheusHoldingsIncMember pnt:LicenseAgreementsPNT2002AgreementMember 2022-12-31 0001811764 pnt:LantheusHoldingsIncMember pnt:LicenseAgreementsPNT2003AgreementMember 2022-12-01 2022-12-31 0001811764 pnt:LantheusHoldingsIncMember pnt:LicenseAgreementsPNT2003AgreementMember 2022-12-31 0001811764 2022-12-01 2022-12-31 0001811764 us-gaap:CommercialPaperMember 2023-09-30 0001811764 us-gaap:CommercialPaperMember 2022-12-31 0001811764 us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001811764 us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001811764 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001811764 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001811764 us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001811764 us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001811764 2023-06-01 2023-06-01 0001811764 us-gaap:SubsequentEventMember 2023-10-02 2023-10-02 0001811764 us-gaap:LandAndBuildingMember 2023-09-30 0001811764 us-gaap:LandAndBuildingMember 2022-12-31 0001811764 us-gaap:MachineryAndEquipmentMember 2023-09-30 0001811764 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001811764 us-gaap:ConstructionInProgressMember 2023-09-30 0001811764 us-gaap:ConstructionInProgressMember 2022-12-31 0001811764 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001811764 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001811764 us-gaap:ComputerEquipmentMember 2023-09-30 0001811764 us-gaap:ComputerEquipmentMember 2022-12-31 0001811764 pnt:GoodManufacturingPracticesMember 2020-07-31 0001811764 pnt:FacilityLeaseMember 2023-09-30 0001811764 us-gaap:BuildingMember 2023-09-30 0001811764 pnt:UHNMember 2023-02-02 0001811764 pnt:UHNMember srt:MinimumMember 2023-02-02 0001811764 pnt:IndianapolisLeaseMember 2023-03-10 0001811764 2023-03-10 0001811764 pnt:LabratorySpaceMember 2023-04-12 0001811764 us-gaap:PreferredStockMember 2023-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001811764 pnt:ShareBasedCompensationToBoardMemberMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001811764 pnt:PublicShareOfferingMember 2022-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001811764 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001811764 us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001811764 2023-01-01 2023-01-01 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001811764 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001811764 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001811764 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001811764 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001811764 us-gaap:EmployeeStockOptionMember 2022-12-31 0001811764 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001811764 us-gaap:EmployeeStockOptionMember 2023-09-30 0001811764 pnt:EmployeeMember us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001811764 pnt:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001811764 pnt:EmployeeMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-07-01 2023-09-30 0001811764 pnt:EmployeeMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-09-30 0001811764 pnt:EmployeeMember us-gaap:EmployeeStockOptionMember pnt:ShareBasedPaymentArrangementTrancheFourMember 2023-07-01 2023-09-30 0001811764 pnt:EmployeeMember us-gaap:EmployeeStockOptionMember pnt:ShareBasedPaymentArrangementTrancheFourMember 2023-01-01 2023-09-30 0001811764 srt:DirectorMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-09-30 0001811764 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001811764 pnt:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001811764 pnt:EmployeesAndDirectorsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-09-30 0001811764 pnt:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-09-30 0001811764 pnt:EmployeesAndDirectorsMember pnt:ShareBasedPaymentArrangementTrancheFourMember 2022-01-01 2022-09-30 0001811764 pnt:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember pnt:ShareBasedPaymentArrangementTrancheFourMember 2022-01-01 2022-09-30 0001811764 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2022-06-06 2022-06-06 0001811764 srt:MinimumMember 2023-01-01 2023-09-30 0001811764 srt:MaximumMember 2023-01-01 2023-09-30 0001811764 srt:MinimumMember 2022-01-01 2022-09-30 0001811764 srt:MaximumMember 2022-01-01 2022-09-30 0001811764 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember 2023-01-01 2023-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember 2022-07-01 2022-09-30 0001811764 pnt:ShareBasedCompensationToNonEmployeeConsultantMember 2022-01-01 2022-09-30 0001811764 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001811764 pnt:PropertyInDevelopmentCommitmentMember 2023-09-30 0001811764 pnt:PropertyInDevelopmentCommitmentMember 2023-07-01 2023-09-30 0001811764 pnt:PropertyInDevelopmentCommitmentMember 2023-01-01 2023-09-30 0001811764 pnt:PropertyInDevelopmentCommitmentMember 2022-07-01 2022-09-30 0001811764 pnt:PropertyInDevelopmentCommitmentMember 2022-01-01 2022-09-30 0001811764 pnt:SupplyAgreementsInConnectionWithClinicalTrialsMember 2023-01-01 2023-09-30 0001811764 srt:MinimumMember pnt:SupplyAgreementsInConnectionWithClinicalTrialsMember 2023-01-01 2023-09-30 0001811764 srt:MaximumMember pnt:SupplyAgreementsInConnectionWithClinicalTrialsMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementsInConnectionMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementsInConnectionMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementsInConnectionMember 2022-07-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementsInConnectionMember 2022-01-01 2022-09-30 0001811764 pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-01-01 2023-09-30 0001811764 srt:MinimumMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-01-01 2023-09-30 0001811764 srt:MaximumMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2022-01-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2022-07-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-01-01 2023-09-30 0001811764 pnt:SupplyAgreementToPurchaseCertainProductsMember 2023-05-10 2023-05-10 0001811764 pnt:SupplyAgreementToPurchaseNcaLuMember 2023-09-25 2023-09-25 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseNcaLuMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:SupplyAgreementToPurchaseNcaLuMember 2023-01-01 2023-09-30 0001811764 pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2023-01-01 2023-09-30 0001811764 srt:MinimumMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2023-01-01 2023-09-30 0001811764 srt:MaximumMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2022-07-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AgreementInConnectionWithSplashClinicalPhaseStudyMember 2022-01-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AthebioMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:AthebioMember 2023-07-01 2023-09-30 0001811764 pnt:StockPurchaseAgreementMember pnt:AthebioMember 2023-09-11 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:LicenseAgreementMember 2023-07-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:LicenseAgreementMember 2023-01-01 2023-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:LicenseAgreementMember 2022-07-01 2022-09-30 0001811764 us-gaap:ResearchAndDevelopmentExpenseMember pnt:LicenseAgreementMember 2022-01-01 2022-09-30 0001811764 pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember 2023-07-01 2023-09-30 0001811764 pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember 2022-07-01 2022-09-30 0001811764 pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember 2023-01-01 2023-09-30 0001811764 pnt:ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember 2022-01-01 2022-09-30 0001811764 pnt:ReimbursementToBoardMemberForOccupancyCostsMember 2023-07-01 2023-09-30 0001811764 pnt:ReimbursementToBoardMemberForOccupancyCostsMember 2022-07-01 2022-09-30 0001811764 pnt:ReimbursementToBoardMemberForOccupancyCostsMember 2023-01-01 2023-09-30 0001811764 pnt:ReimbursementToBoardMemberForOccupancyCostsMember 2022-01-01 2022-09-30 0001811764 srt:DirectorMember 2023-09-30 0001811764 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001811764 pnt:EliLillyMember us-gaap:SubsequentEventMember 2023-10-02 0001811764 us-gaap:SubsequentEventMember 2023-10-13 shares iso4217:USD iso4217:USD shares pnt:subsidiary pure utr:sqft pnt:people pnt:renewal pnt:vote iso4217:CAD iso4217:EUR 0001811764 --12-31 2023 Q3 false P3Y P3Y P3Y P3Y P2Y P1Y 10-Q true 2023-09-30 false 001-39311 POINT BIOPHARMA GLOBAL INC. DE 85-0800493 4850 West 78th Street Indianapolis, IN 46268 317 543-9957 Common Stock PNT NASDAQ Yes Yes Non-accelerated Filer true true false false 106569231 21607412 286428371 317555936 238783470 9901729 5610889 4181469 0 353246546 530822730 59793161 16119430 5116667 0 54042353 31380576 5505693 0 124457874 47500006 477704420 578322736 8886750 7703150 14529354 19094454 12586443 23242290 736729 29698546 987018 0 939983 0 38666277 79738440 3720881 10178147 2389109 1452356 4093202 0 4642565 0 53512034 91368943 0.0001 0.0001 430000000 430000000 105765954 105765954 105649741 105649741 10576 10565 453319762 448391574 -27707358 39008505 -1430594 -456851 424192386 486953793 477704420 578322736 2789993 0 17113113 0 2789993 0 17113113 0 26910286 20797406 85097331 54112136 5505869 3839626 15604401 11727969 32416155 24637032 100701732 65840105 -29626162 -24637032 -83588619 -65840105 5617736 1048254 16717703 1605927 105522 -243791 -133438 -287691 5723258 804463 16584265 1318236 -23902904 -23832569 -67004354 -64521869 871449 180500 -288491 452021 -24774353 -24013069 -66715863 -64973890 -0.23 -0.23 -0.26 -0.26 -0.63 -0.63 -0.71 -0.71 105765954 105765954 92401484 92401484 105717330 105717330 90891031 90891031 -24774353 -24013069 -66715863 -64973890 -361611 -266320 -973743 -608698 -25135964 -24279389 -67689606 -65582588 105649741 10565 448391574 39008505 -456851 486953793 32936 3 145861 145864 1009496 1009496 -16530671 -16530671 201294 201294 105682677 10568 449546931 22477834 -255557 471779776 83277 8 186050 186058 1710349 1710349 -25410839 -25410839 -813426 -813426 105765954 10576 451443330 -2933005 -1068983 447451918 1876432 1876432 -24774353 -24774353 -361611 -361611 105765954 10576 453319762 -27707358 -1430594 424192386 90121794 9012 314488782 -59284708 0 255213086 678 942 942 440450 440450 -16380574 -16380574 90122472 9012 314930174 -75665282 0 239273904 2490 3461 3461 1027563 1027563 -24580247 -24580247 -342378 -342378 90124962 9012 315961198 -100245529 -342378 215382303 13900000 1390 116854772 116856162 30000 3 41697 41700 1079056 1079056 -24013069 -24013069 -266320 -266320 104054962 10405 433936723 -124258598 -608698 309079832 -66715863 -64973890 2186253 980995 936753 -65592 4596277 2547069 196772 0 9457635 435238 -709160 -318586 -1060594 1261082 -4534719 6926449 -17113113 0 -33143286 110745 -62014 0 1397490 67483 -124859499 -53397277 117757923 165841488 17249510 10696365 5000000 0 -140007433 -176537853 331922 46103 285949 0 0 116856162 45973 116902265 -264820959 -113032865 286428371 238815991 21607412 125783126 31924135 411424 5000000 0 3623314 1142278 Nature of business<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">POINT Biopharma Global Inc., together with its consolidated subsidiaries ("POINT" or the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, LLC, each located in the U.S., and POINT Biopharma Corp., located in Canada (collectively the "Subsidiaries"). The Company’s headquarters is located at 4850 West 78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, Indianapolis, Indiana, 46268.</span></div> 4 Summary of significant accounting policies<div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interim Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and include the accounts of the Company and the Subsidiaries, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023 (the “2022 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2022 Financial Statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Presentation of Financial Statements—Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Pandemic, macroeconomics and other geopolitical events</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently operating in a period of significant economic uncertainty, resulting from, among other things, the impact of the COVID-19 pandemic, geopolitical tensions, such as the ongoing military conflict between Russia and Ukraine, the Israel-Palestine conflict and heightened tensions between China and Taiwan, trade uncertainty, including changes in tariffs, sanctions, international treaties, and other trade restrictions, rising inflation and interest rates, and uncertainty and liquidity concerns in the broader financial services industry, including those caused by certain recent banking failures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is continuing to monitor the development and potential impact of these global economic and geopolitical events on its business and unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of these events and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. However, estimates and assumptions about future events and their effects cannot be determined with certainty, and therefore, require the exercise of judgment; as a result, the Company’s estimates may change as new events occur and additional information is obtained. </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks and uncertainties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except for the upfront payment received pursuant to the Lantheus License Agreements (as defined in Note 3 below), the Company has incurred significant net losses and has funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to continue to be incurred in future periods. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from public health crisis or military conflicts and adverse developments affecting the financial services industry, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has a number of risks and uncertainties related to the Offer and Merger described in Note 16. These risks and uncertainties are described in more detail in Part II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Item 1A. “Risk Factors” starting on page 34.</span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the allocation of consideration and the recognition of revenues in respect of the performance obligations under the Lantheus License Agreements, the accrual of research and development expenses, incremental borrowing rates determined in connection with finance and operating lease obligations, the valuations of stock options, the expected recoverability of and the estimated useful lives of our long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experiences. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">("ASC 842"). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less in the consolidated balance sheets. The Company has also elected to account for the lease and non-lease components as a combined lease component for its current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent accounting pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has evaluated accounting pronouncements recently issued but not yet adopted and believes that the accounting pronouncements currently do not apply to the Company’s operations and are not expected to have a material impact on the Company’s unaudited interim condensed consolidated financial statements or disclosures.</span></div> <div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interim Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and include the accounts of the Company and the Subsidiaries, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023 (the “2022 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2022 Financial Statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Presentation of Financial Statements—Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span> <div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks and uncertainties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except for the upfront payment received pursuant to the Lantheus License Agreements (as defined in Note 3 below), the Company has incurred significant net losses and has funded operations primarily through equity financings. Operating losses and negative cash flows were incurred in the nine months ended September 30, 2023 and are expected to continue to be incurred in future periods. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from public health crisis or military conflicts and adverse developments affecting the financial services industry, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has a number of risks and uncertainties related to the Offer and Merger described in Note 16. These risks and uncertainties are described in more detail in Part II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Item 1A. “Risk Factors” starting on page 34.</span></div> <div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the allocation of consideration and the recognition of revenues in respect of the performance obligations under the Lantheus License Agreements, the accrual of research and development expenses, incremental borrowing rates determined in connection with finance and operating lease obligations, the valuations of stock options, the expected recoverability of and the estimated useful lives of our long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experiences. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></div> <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">("ASC 842"). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize leases with an original term of one year or less in the consolidated balance sheets. The Company has also elected to account for the lease and non-lease components as a combined lease component for its current lease portfolio. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Options to renew or early terminate a lease are included in the initial lease term of a lease when there is reasonable certainty that the option will be applied.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The Company's incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease in a similar economic environment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease expense for operating leases is recognized on a straight-line basis over the lease term and included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent accounting pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has evaluated accounting pronouncements recently issued but not yet adopted and believes that the accounting pronouncements currently do not apply to the Company’s operations and are not expected to have a material impact on the Company’s unaudited interim condensed consolidated financial statements or disclosures.</span></div> RevenueIn November 2022, POINT announced strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. ("Lantheus") for exclusive worldwide rights for POINT's programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003), excluding certain territories (Japan, South Korea, Singapore, Indonesia, and China including Hong Kong, Macau and Taiwan) (the "PNT2002 Agreement" and the "PNT2003 Agreement", respectively, and collectively the "Lantheus License Agreements"). The collaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in Prostate-Specific Membrane Antigen ("PSMA") PET and radiopharmaceuticals.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2022, closing conditions for the Lantheus transaction, including antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended, the "HSR Act"), were satisfied. POINT received a $250.0 million upfront payment under the PNT2002 Agreement and will receive an additional payment of up to $250.0 million upon U.S. regulatory approval. In addition, once certain return on investment financial thresholds have been achieved and other conditions satisfied, POINT will be eligible to receive royalties of 20% on all net sales (prior to which there is a period of sales in which the royalty may be based on only a portion of the gross profit), and contingent upon the satisfaction of certain net sales milestones, additional payments of up to $1.3 billion. POINT received a $10.0 million upfront payment under the PNT2003 Agreement, and will receive up to an additional $30.0 million upon U.S. regulatory approval. The PNT2003 Agreement also provides that POINT will receive royalties of 15% on net sales and, contingent upon the satisfaction of certain net sales milestones, an additional payment of up to $275.0 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the PNT2002 Agreement, the Company is responsible for completing the Company's multi-center, randomized, open label phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">tudy evaluating metastatic castration-resistant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rostate cancer using 177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">u-PNT2002 PSMA therapy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">econd-line </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ormonal treatment (“SPLASH") trial and the parties will work together to file the New Drug Application (“NDA”), with the costs incurred in connection with the U.S. Food and Drug Administration ("FDA") submission being borne by Lantheus. Thereafter, Lantheus will be responsible for all additional clinical and regulatory costs in the U.S., as well as all costs for development, clinical trials and regulatory approval in the rest of its territories outside the U.S., except Asia.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To determine the appropriate amount of revenue to be recognized under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Company performs the following steps: (i) identify the promised goods or services in the contract, (ii) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract, (iii) measure the transaction price, including the constraint on variable consideration, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the PNT2002 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the SPLASH trial, support the NDA submission and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2002 Agreement to be the $250.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the PNT2003 Agreement, the Company identified the following performance conditions: (i) the license it conveyed to Lantheus with respect to certain intellectual property, (ii) service provided to complete the necessary submissions for regulatory approval and participate in joint steering activities and (iii) manufacturing activities. The Company determined the transaction price under ASC Topic 606 at the inception of the PNT2003 Agreement to be the $10.0 million upfront payment and has allocated this to the first two performance obligations based on a relative standalone selling price basis. The standalone selling prices for the first two performance obligations were determined using the adjusted market assessment approach and the expected cost plus a margin assessment approach, respectively. The Company concluded that variable consideration associated with the product manufacturing relates solely to the manufacturing activities performance obligation on the basis that it believes that the expected margin associated with this consideration is in line with market standards and specifically relates to the Company's efforts to satisfy its manufacturing obligations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not include variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will occur. Variable consideration in the PNT2002 Agreement and PNT2003 Agreement consists of:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Potential future regulatory milestone payments. The Company concluded that this variable consideration is constrained considering that achievement of the milestones is outside its control and contingent upon the future success of clinical trials and regulatory approval by the FDA and in respect of other territories outside the U.S.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Potential future milestone payments in connection with certain sales targets as well as any future royalties. The Company concluded that these payments qualify for the royalty exception. Under the royalty exception, sales-based royalties are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). That is, an entity does not estimate the amount of a sales-based royalty at contract inception; rather, revenue </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">would be recognized when the subsequent sales occur (under the assumption that the associated performance obligation has been satisfied or partially satisfied). </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Potential payments for the manufacturing and supply of commercial product. The Company concluded that this variable consideration is constrained as it is contingent upon future regulatory approvals and the execution of a manufacturing and supply agreement.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The estimate of the Company’s variable consideration to be included in the transaction price is updated at each reporting date as a change in estimate. For the potential future regulatory milestone payments, the Company utilizes the most likely amount approach to determine the amounts recognized and timing of recognition. For the potential payments for manufacturing and supply of commercial product, the Company utilizes the expected value approach to determine the amounts recognized and timing of recognition. Once the constraint is removed, the milestone payments will be accounted for and allocated to the performance obligations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the licenses conveyed to Lantheus, the Company recognized revenue upon execution and regulatory approval of the Lantheus License Agreements. The Company concluded that the licenses represent that of functional intellectual property as each has significant standalone functionality and derives a substantial portion of its utility from that standalone functionality.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the obligations to complete the SPLASH trial, support the NDA submission and participate in joint steering activities in connection with the PNT2002 Agreement as well as the obligations to complete the necessary submissions for regulatory approval and participate in joint steering activities for the PNT2003 Agreement, the Company recognizes revenue using the cost-to-cost method, which it concluded best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company’s contract liabilities as of September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,586,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,242,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,720,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,178,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">16,307,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">33,420,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At inception of the Lantheus License Agreements, deferred revenue of $34.8 million was recognized in connection with future performance. During the three and nine months ended September 30, 2023, the Company recognized $2.8 million and $17.1 million in revenue for services performed (three and nine months ended September 30, 2022 — $nil and $nil, respectively). The current portion of deferred revenue reflects the Company’s estimate of the revenue it expects to recognize within the next 12 months. The Company expects to recognize the remainder of the deferred revenue balance in subsequent periods through the year ending December 31, 2028. No contract assets were recognized in connection with the Lantheus License Agreements, including costs incurred in obtaining the agreements.</span></div> 250000000 250000000 0.20 1300000000 10000000 30000000 0.15 275000000 250000000 10000000 <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company’s contract liabilities as of September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,586,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,242,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,720,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,178,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">16,307,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">33,420,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12586443 23242290 3720881 10178147 16307324 33420437 34800000 2800000 17100000 0 0 Cash, cash equivalents and investments<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and investments consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,446,728 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,429,627 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,428,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,787,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,942,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,258,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,830,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,555,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,783,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,098,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634,828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,793,161 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,956,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">541,331,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Available-for-sale investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of September 30, 2023 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,597,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,438,450</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(596,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,847,404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,787,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,059,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,554,665</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,893,036</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,258,208</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,634,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,186,023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,041,307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,942,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">378,776,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,434,299)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">377,349,097</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">317,555,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,793,161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of December 31, 2022 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,019,619 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,505)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,830,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,468,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,715,195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">255,359,751</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26,527</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(483,378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254,902,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238,783,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,119,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,607,866 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,555,936 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due between one and five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,168,427 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,793,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">378,776,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,349,097</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing within one year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,236,498 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,783,470 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing between one and five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,123,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,359,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,902,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary objective of our investment portfolio is to maintain safety of principal balances, provide sufficient levels of liquidity and enhance overall returns in an efficient manner with acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended September 30, 2023, we had $611 of realized gains on available-for-sale investments.</span></div> <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and investments consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,446,728 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,429,627 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607,412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,428,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,787,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,942,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,258,208 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,830,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,555,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,783,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,098,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634,828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,793,161 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,956,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">541,331,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11446728 12429627 6852616 273998744 3308068 0 21607412 286428371 107567350 115156455 93787733 45219042 35942645 42577762 80258208 35830211 317555936 238783470 16098662 0 8634828 16119430 35059671 0 59793161 16119430 398956509 541331271 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of September 30, 2023 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,597,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,438,450</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(596,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,847,404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,787,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,059,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,554,665</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,893,036</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,258,208</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,634,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,186,023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,041,307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,942,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">378,776,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,434,299)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">377,349,097</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">317,555,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,793,161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as of December 31, 2022 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,019,619 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,505)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,830,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,468,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,715,195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">255,359,751</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26,527</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(483,378)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254,902,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238,783,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,119,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,607,866 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,555,936 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due between one and five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,168,427 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,793,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">378,776,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,349,097</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing within one year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,236,498 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,783,470 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing between one and five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,123,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119,430 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,359,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,902,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 107597155 981 30786 107567350 107567350 0 129438450 5918 596964 128847404 93787733 35059671 89554665 204 661833 88893036 80258208 8634828 52186023 0 144716 52041307 35942645 16098662 378776293 7103 1434299 377349097 317555936 59793161 115156455 0 0 115156455 115156455 0 52019619 26527 96505 51949641 35830211 16119430 45468482 0 249440 45219042 45219042 0 42715195 0 137433 42577762 42577762 0 255359751 26527 483378 254902900 238783470 16119430 318607866 317555936 60168427 59793161 378776293 377349097 239236498 238783470 16123253 16119430 255359751 254902900 611 611 Fair value measurements<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about the Company’s financial assets and liabilities as of September 30, 2023 and December 31, 2022, that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,847,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,847,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,893,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,893,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,041,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,041,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,893,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,615,858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387,509,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316,576,506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212,325,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">528,901,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our available-for-sale debt securities, including U.S. Government agency debt securities, are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On May 7, 2023, POINT Biopharma Inc. entered into a Convertible Note Purchase Agreement (the "Convertible Note Agreement") with Ionetix Alpha Corporation ("Ionetix-α"), a subsidiary of IONETIX Corporation. On June 1, 2023, the Company purchased $5.0 million in unsecured promissory notes (the "Note Receivable") convertible into common stock of Ionetix-α at a conversion price that is calculated based on certain conditions as defined in the Convertible Note Agreement. Management assessed all features in the Convertible Note Agreement to determine embedded derivatives requiring bifurcation. In accordance with the Convertible Note Agreement, Ionetix-α has a voluntary redemption option, subject to certain terms and conditions, and may provide notice to the Company upon which the Company can elect to either redeem the Note Receivable at 150% of principal and interest outstanding or convert it into common stock of Ionetix-α. Management concluded that this put option meets the definition of a derivative and it is not clearly and closely related to the Note Receivable, thus requiring bifurcation from the host instrument and recognition at fair value. Further, management concluded the Note Receivable host instrument is to be classified as a loan receivable and therefore is measured at amortized cost but disclosure of fair value is required. Management determined the fair values of both the Note Receivable and the embedded derivative under Level 3 in the fair value hierarchy. Management concluded that the fair value of the Note Receivable as of September 30, 2023 approximated amortized cost and that the fair value of the embedded derivative was nil both at inception of the arrangement and on September 30, 2023. On September 29, 2023, POINT Biopharma Inc. entered into the Amendment of Convertible Note Purchase Agreement (the "Amendment"), whereby in connection with the Amendment, the Company and Ionetix-α agreed to accelerate the purchase of an additional $5.0 million of unsecured promissory notes subject to certain closing conditions. Those conditions were met and the additional purchase was made on October 2, 2023. See Note 16.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We did not have any financial liabilities measured at fair value on a recurring basis as of September 30, 2023. The carrying values of the Company’s cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. There have been no transfers of assets or liabilities between the fair value measurement levels as of September 30, 2023.</span></div> The following tables present information about the Company’s financial assets and liabilities as of September 30, 2023 and December 31, 2022, that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,068 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,567,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,847,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,847,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,893,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,893,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,041,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,041,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,893,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,615,858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387,509,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual fund</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,998,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,156,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,949,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,219,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316,576,506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212,325,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">528,901,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6852616 0 0 6852616 0 3308068 0 3308068 0 107567350 0 107567350 0 128847404 0 128847404 0 88893036 0 88893036 52041307 0 0 52041307 58893923 328615858 0 387509781 273998744 0 0 273998744 0 0 0 0 0 115156455 0 115156455 0 51949641 0 51949641 0 45219042 0 45219042 42577762 0 0 42577762 316576506 212325138 0 528901644 5000000 1.50 5000000 Prepaid expenses and other current assets<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,812,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,011,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid insurance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390,347 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,310,314 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivable on matured short-term investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Canadian harmonized sales tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deposit on production equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">492,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">215,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">9,901,729</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,610,889</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,812,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,011,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid insurance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390,347 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,310,314 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Receivable on matured short-term investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Canadian harmonized sales tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deposit on production equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">492,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">215,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">9,901,729</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,610,889</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2812270 4011419 1390347 1310314 5000000 0 206326 60222 0 13738 492786 215196 9901729 5610889 Property, plant and equipment, net<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment, net consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land and building</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,992,990 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,163,962 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,241,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,328,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, in development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,827,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,434,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Note 9)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,384,707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">938,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">698,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">149,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">57,623,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">32,775,605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,581,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,395,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">54,042,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">31,380,576</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, the Company purchased land and a building in Indianapolis, Indiana (which has been expanded to approximately 81,000 square feet) for the purpose of retrofitting the existing building into a state-of-the-art, Current Good Manufacturing Practices ("cGMP") compliant facility that will support the Company’s drug manufacturing operations. The Company commenced the manufacture of clinical supply in the Indianapolis manufacturing facility in January 2022. Construction continues on the facility to expand capacity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property, plant and equipment that have finite lives are recorded at cost less accumulated depreciation and impairment losses. Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility lease</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20 years</span></div></td></tr></table></div> <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment, net consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land and building</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,992,990 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,163,962 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,241,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,328,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, in development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,827,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,434,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Note 9)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,384,707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">938,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">698,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">237,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">149,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">57,623,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">32,775,605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,581,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,395,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">54,042,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">31,380,576</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility lease</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20 years</span></div></td></tr></table> 19992990 18163962 11241336 5328639 19827730 8434384 5384707 0 938909 698728 237963 149892 57623635 32775605 3581282 1395029 54042353 31380576 81000 P5Y P7Y P7Y P7Y P20Y Accrued liabilitiesAccrued liabilities consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued personnel costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,663,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,116,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,766,189 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,645,594 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued corporate legal fees and other professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">907,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,068,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued costs for purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">157,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">14,529,354</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">19,094,454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Accrued liabilities consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued personnel costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,663,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,116,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,766,189 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,645,594 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued corporate legal fees and other professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">907,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,068,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued costs for purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">117,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">157,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">14,529,354</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">19,094,454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5663218 7116382 7766189 9645594 907019 2068793 75360 105741 117568 157944 14529354 19094454 Leases<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s current portfolio of leases, the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments. The Company has not incurred any material short-term lease costs or variable lease costs associated with its finance and operating leases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023, POINT Biopharma Corp., entered into a Facility Agreement (the "UHN Agreement") with University Health Network (“UHN”), a not-for-profit corporation incorporated under the laws of Canada. Pursuant to the UHN Agreement, the Company was provided access to utilize a 7,700 square foot, licensed research and development space with cGMP manufacturing suites (the “Facility”), which the Company will use to develop and expand its pipeline of next-generation radioligands. The lease commencement date was determined to be April 1, 2023, the date upon which the Company was provided access to the Facility. The lease is accounted for as a finance lease in accordance with ASC 842 as one lease component for the facility, infrastructure and equipment, and the right-of-use asset has been included within property, plant and equipment. Management concluded the lease represents a finance lease on the basis that management believes the lease term covers the remaining economic life of the primary lease component. The initial term of the UHN Agreement will run for five years from the lease commencement date, with an option to renew for additional two-year terms thereafter, subject to certain conditions described in the UHN Agreement. Management included the first option to renew for two years as part of the lease term in determining the right-of-use asset and lease liability. The UHN Agreement does not transfer any title in the Facility to the Company. During the term, the Company shall be responsible for day-to-day management activities and decision-making regarding the Facility. General governance of the Facility will be exercised by the Company and UHN through a joint committee. The joint committee, which will meet quarterly, will have a minimum of six people and will be comprised of an equal number of members from each of the Company and UHN.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 10, 2023, the Company entered into a lease for an approximately 103,000 square foot facility in Indianapolis (the "Indianapolis Lease"). The lease commencement date was determined to be July 1, 2023, the date upon which the Company was provided access to the facility. The initial term of the lease will run for 121 months from the lease commencement date, with an option to renew for two ten-year terms thereafter, subject to certain conditions described in the Indianapolis Lease. Management did not include either option to renew as part of the lease term in determining the right-of-use asset and lease liability. Management has accounted for the lease as an operating lease as it believes that the lease term does not cover a substantial portion of the economic life of the primary lease component nor does the present value of the minimum lease payments exceed 90% of the fair value of the facility. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the property to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 12, 2023, the Company entered into an operating lease for laboratory space with a lease term of two years. The lease commencement date was determined to be April 15, 2023, the date upon which the Company was provided access to the laboratory space. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the laboratory space to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">303,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">384,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">580,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow use from finance lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,644,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,384,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the weighted average remaining lease terms for the Company’s leases:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.5</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below is information on the weighted average discount rates used at the time that the leases were commenced:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rates:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">232,797 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">246,755 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">689,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">797,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">746,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">768,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,732,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,220,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">7,967,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">6,415,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,385,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,335,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,582,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,080,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Leases<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s current portfolio of leases, the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments. The Company has not incurred any material short-term lease costs or variable lease costs associated with its finance and operating leases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023, POINT Biopharma Corp., entered into a Facility Agreement (the "UHN Agreement") with University Health Network (“UHN”), a not-for-profit corporation incorporated under the laws of Canada. Pursuant to the UHN Agreement, the Company was provided access to utilize a 7,700 square foot, licensed research and development space with cGMP manufacturing suites (the “Facility”), which the Company will use to develop and expand its pipeline of next-generation radioligands. The lease commencement date was determined to be April 1, 2023, the date upon which the Company was provided access to the Facility. The lease is accounted for as a finance lease in accordance with ASC 842 as one lease component for the facility, infrastructure and equipment, and the right-of-use asset has been included within property, plant and equipment. Management concluded the lease represents a finance lease on the basis that management believes the lease term covers the remaining economic life of the primary lease component. The initial term of the UHN Agreement will run for five years from the lease commencement date, with an option to renew for additional two-year terms thereafter, subject to certain conditions described in the UHN Agreement. Management included the first option to renew for two years as part of the lease term in determining the right-of-use asset and lease liability. The UHN Agreement does not transfer any title in the Facility to the Company. During the term, the Company shall be responsible for day-to-day management activities and decision-making regarding the Facility. General governance of the Facility will be exercised by the Company and UHN through a joint committee. The joint committee, which will meet quarterly, will have a minimum of six people and will be comprised of an equal number of members from each of the Company and UHN.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 10, 2023, the Company entered into a lease for an approximately 103,000 square foot facility in Indianapolis (the "Indianapolis Lease"). The lease commencement date was determined to be July 1, 2023, the date upon which the Company was provided access to the facility. The initial term of the lease will run for 121 months from the lease commencement date, with an option to renew for two ten-year terms thereafter, subject to certain conditions described in the Indianapolis Lease. Management did not include either option to renew as part of the lease term in determining the right-of-use asset and lease liability. Management has accounted for the lease as an operating lease as it believes that the lease term does not cover a substantial portion of the economic life of the primary lease component nor does the present value of the minimum lease payments exceed 90% of the fair value of the facility. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the property to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 12, 2023, the Company entered into an operating lease for laboratory space with a lease term of two years. The lease commencement date was determined to be April 15, 2023, the date upon which the Company was provided access to the laboratory space. The lease is recorded on the interim condensed consolidated balance sheet as an operating lease right-of-use asset with a related operating lease liability as of September 30, 2023. The agreement does not transfer any title in the laboratory space to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">303,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">384,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">580,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow use from finance lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,644,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,384,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the weighted average remaining lease terms for the Company’s leases:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.5</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below is information on the weighted average discount rates used at the time that the leases were commenced:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rates:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">232,797 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">246,755 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">689,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">797,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">746,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">768,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,732,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,220,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">7,967,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">6,415,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,385,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,335,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,582,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,080,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7700 P5Y P2Y P2Y 6 103000 P121M 2 P10Y 0.90 P2Y The components of lease expense are as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">303,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">384,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">580,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, there were no operating or finance leases recognized in the condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the nine months ended September 30, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">167,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow use from finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow use from finance lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,644,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,384,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the weighted average remaining lease terms for the Company’s leases:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.5</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below is information on the weighted average discount rates used at the time that the leases were commenced:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rates:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div> 303215 384622 196027 580649 0 0 167397 196027 285949 5644563 5384707 P9Y2M12D P6Y6M 0.078 0.077 The following table summarizes the future maturities of the Company's lease liabilities as of September 30, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">232,797 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">246,755 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">689,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">797,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">746,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">768,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">987,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,732,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,220,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">7,967,737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">6,415,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,385,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,335,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,582,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">5,080,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 232797 246755 689632 987018 797739 987018 746332 987018 768722 987018 4732515 2220793 7967737 6415620 2385189 1335399 5582548 5080221 Stockholders’ equity<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is authorized to issue 430,000,000 shares of common stock, with a par value of $0.0001 per share ("Common Stock"), as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2023, there were no issuances of Common Stock. During the nine months ended September 30, 2023, the Company issued (i) 86,585 shares of Common Stock in connection with the exercise of stock options granted to non-employee consultants, resulting in total cash proceeds of $120,353 and (ii) 29,628 shares of Common Stock in connection with the exercise of stock options granted to employees and directors, resulting in total cash proceeds of $211,569.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September 30, 2022, the Company issued (a) 13,900,000 shares of Common Stock in connection with an underwritten public share offering at the price of $9.00 per share pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission, resulting in total gross proceeds of $125.1 million (excluding approximately $8.2 million of issuance costs) and (b) 30,000 shares of Common Stock in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $41,700. During the nine months ended September 30, 2022, the Company issued 13,933,168 shares of Common Stock, including the 13,930,000 shares of Common Stock discussed above, as well as 3,168 shares of Common Stock in connection with the exercise of stock options issued to non-employee consultants, resulting in total cash proceeds of $4,403.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, the total number of issued and outstanding shares of Common Stock was 105,765,954 (December 31, 2022 — 105,649,741). As of September 30, 2023, there were no issued and outstanding shares of Preferred Stock (December 31, 2022 — $nil).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Holders of Common Stock are entitled to receive dividends, if any, as may be declared by the Company’s board of directors (the “Board”). During the three and nine months ended September 30, 2023, no cash dividends were declared or paid by the Company (September 30, 2022 — $nil).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law ("DGCL"). During the nine months ended September 30, 2023, no shares of Preferred Stock were issued by the Company.</span></div> 430000000 0.0001 20000000 0.0001 0 86585 120353 29628 211569 13900000 9.00 125100000 8200000 30000 41700 13933168 13930000 3168 4403 105765954 105765954 105649741 105649741 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Stock-based compensationIn March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and non-qualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, the Board adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. The Company assumed the outstanding equity awards under the 2020 EIP, but no further grants may be made under the 2020 EIP. The 2021 EIP provides that the <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">number of shares reserved and available for issuance under the 2021 EIP will automatically increase each January 1, beginning on January 1, 2022, by 4% of the number of outstanding shares of Common Stock on the immediately preceding December 31, or such lesser amount as determined by the Board. As of January 1, 2023, the number of shares of Common Stock available under the 2021 EIP increased by 4,225,990 for a total of 9,049,548 shares of Common Stock authorized for issuance under the 2021 EIP as of September 30, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company recorded $666,368 and $1,797,759 to research and development expenses and $1,210,064 and $2,798,518 to general and administrative expenses for stock-based compensation for the three and nine months ended September 30, 2023, respectively (September 30, 2022 — $476,481 and $1,220,426 to research and development expenses and $602,575 and $1,326,643 to general and administrative expenses for the three and nine months ended, respectively). The Company did not recognize a tax benefit related to stock-based compensation expense during the three and nine months ended September 30, 2023 as well as during the three and nine months ended September 30, 2022, as the Company had net operating loss carryforwards and recorded a valuation allowance against the deferred tax asset.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table summarizes the activity relating to the Company’s stock options.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>Average Exercise<br/>Price Per Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,592,173</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,294,071</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.09</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(116,213)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(176,942)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,510)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">8,577,579</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">6.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and expected to vest as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,577,579</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options exercisable as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,985,114</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2023, 150,000 stock options were granted to an employee of the Company, with a weighted average grant date fair value of $4.57 per share. During the nine months ended September 30, 2023, 3,294,071 stock options were granted, including the 150,000 stock options discussed above as well as 3,144,071 stock options granted to employees and directors of the Company, with a weighted average grant date fair value of $3.85 per share. The vesting terms of the options granted to employees of the Company are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in <span style="-sec-ix-hidden:f-716"><span style="-sec-ix-hidden:f-717">three</span></span> equal annual installments thereafter. The vesting terms of the options granted to directors of the Company are such that they vest on the one-year anniversary of the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2022, there were no stock options granted. During the nine months ended September 30, 2022, 1,948,614 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.59 per share. Except as provided below with respect to options granted to directors, the vesting terms of these options are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest in <span style="-sec-ix-hidden:f-725">three</span> equal annual installments thereafter. On June 6, 2022, the terms of 128,070 stock options granted to directors of the Company during the quarter were amended to reduce the vesting period to one year. This amendment was accounted for as a modification and there was no material impact to stock-based compensation recorded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.71% - 4.47%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.24% - 3.13%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.50 - 4.25</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66% - 68%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72% - 75%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September 30, 2023, there were no stock option exercises. During the nine months ended September 30, 2023, non-employee consultants of the Company exercised 86,585 stock options with an intrinsic value of $700,217, and employees and directors of the Company exercised 29,628 stock options with an intrinsic value of $38,300, for total cash proceeds to the Company of $331,922. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended September 30, 2022, non-employee consultants of the Company exercised 30,000 and 33,168 stock options with intrinsic values of $238,300 and $257,601, respectively. The exercises resulted in cash proceeds to the Company of $41,700 and $46,103, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, the unrecognized stock-based compensation expense related to unvested stock options was $17,944,644 and the estimated weighted average remaining vesting period was 2.9 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, 146,044 performance share units ("PSUs") were granted to employees of the Company, with a grant date fair value of $6.61 per unit based on the closing share price of the Company's Common Stock on the date of grant. The vesting terms of these PSUs are such that 100% vest upon the regulatory approval of PNT2002 by the FDA. During the three and nine months ended September 30, 2023, the Company did not record any stock-based compensation expense related to these PSUs on the basis that they cannot be considered probable to vest as the regulatory approval requirement is outside the control of the Company and the clinical trial remains ongoing.</span></div> 0.04 4225990 9049548 666368 1797759 1210064 2798518 476481 1220426 602575 1326643 <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table summarizes the activity relating to the Company’s stock options.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>Average Exercise<br/>Price Per Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,592,173</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,294,071</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.09</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(116,213)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(176,942)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15,510)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">8,577,579</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">6.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and expected to vest as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,577,579</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options exercisable as of September 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,985,114</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7</span></td></tr></table></div> 5592173 5.85 3294071 7.09 116213 2.86 176942 7.23 15510 8.29 8577579 6.33 P4Y4M24D 8577579 6.33 P4Y4M24D 2985114 5.19 P3Y8M12D 150000 4.57 3294071 150000 3144071 3.85 0.25 P1Y 0.75 P1Y 0 1948614 4.59 0.25 P1Y 0.75 128070 P1Y The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.47%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.71% - 4.47%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.24% - 3.13%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.50 - 4.25</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66% - 68%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72% - 75%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—%</span></td></tr></table> 0.0447 0 0.000371 0.000447 0.000124 0.000313 P4Y3M P3Y6M P4Y3M P4Y3M 0.66 0 0.0066 0.0068 0.0072 0.0075 0 0 0 0 0 86585 700217 29628 38300 331922 30000 33168 238300 257601 41700 46103 17944644 P2Y10M24D 146044 6.61 1 Commitments and contingencies <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Indianapolis facility commitments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to certain agreements for the continuing expansion of the manufacturing capabilities of the Indianapolis facility (see Note 7). Effective in the second quarter of 2022, the Company entered into an agreement for the design and build of a commercial manufacturing line. As of September 30, 2023, the Company is committed to aggregate future payments of approximately $22.5 million in connection with these agreements. During the three and nine months ended September 30, 2023, approximately $5.2 million and $15.5 million, respectively, has been recorded within property, plant and equipment in connection with these agreements (three and nine months ended September 30, 2022 — approximately $3.7 million and $7.7 million, respectively).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial and commercial commitments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company, in the normal course of business, enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain products and product lines during the Company’s clinical phase. These agreements often have minimum purchase commitments and generally terminate upon the termination of the clinical trial. As at September 30, 2023, aggregate remaining minimum commitments amount to approximately $5.4 million with payments ranging from <span style="-sec-ix-hidden:f-773">three</span> to eight years or upon completion of the clinical trial, if earlier. The Company recorded research and development expenses in connection with these agreements of approximately $3.1 million and $14.4 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $3.8 million and $8.1 million, respectively).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has supply agreements with third parties to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of products in the amount of approximately $109.2 million ($148.3 million CAD) with payments ranging from <span style="-sec-ix-hidden:f-781">two</span> to nine years. The purchase commitments are contingent upon the completion of certain milestones by the third-party suppliers. During the three and nine months ended September 30, 2023 and September 30, 2022, the Company did not record any research and development expenses in connection with this agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the Company entered into an Irradiation Services Agreement (the "Irradiation Agreement") which expands the Company's reactor network. Pursuant to the Irradiation Agreement, the Company will receive irradiation services to irradiate ytterbium-176 (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yb”) and has minimum purchase commitments of approximately $32.4 million over </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the ten-year contract term. During the three and nine months ended September 30, 2023, the Company did not record any research and development expenses in connection with this agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 25, 2023, the Company entered into a Supply Agreement (the "Supply Agreement") for the supply of carrier-free lutetium-177 (n.c.a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lu). The Supply Agreement has a term of ten years and has minimum purchase commitments of approximately $107.4 million (€101.8 million) subject to certain conditions in the Supply Agreement, including the successful validation of the supplier-produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lu with the intended compounds. The Company recorded research and development expenses in connection with this agreement of approximately $0.2 million and $0.2 million during the three and nine months ended September 30, 2023, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. As of September 30, 2023, the remaining minimum purchase commitment under this agreement is approximately $23.7 million with payments that range from <span style="-sec-ix-hidden:f-797">one</span> to five years. The Company recorded research and development expenses in connection with this agreement of approximately $3.5 million and $14.6 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $6.5 million and $15.4 million, respectively).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">License agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company, in the normal course of business, enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details about the Company’s license agreements, see Note 15 to the 2022 Financial Statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 17, 2023, POINT Biopharma Inc. entered into first and second amendments (the "Amendments") to that certain Sublicense Agreement, dated November 14, 2019, between POINT Biopharma Inc. and Scintomics GmbH ("Scintomics"). Pursuant to the Amendments, the exclusive, sublicensable, license was expanded to include all geographies worldwide and the Company has increased flexibility in connection with sublicense arrangements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 11, 2023, POINT Biopharma Inc. entered into a collaboration and license agreement between POINT Biopharma Inc. and Athebio AG ("Athebio") (the "Athebio Agreement"). Pursuant to the Agreement, the Company is granted exclusive access to Athebio's intellectual property and capabilities in the designed ankyrin repeat proteins ("DARPins") development. The Company recorded research and development expenses in connection with this agreement of $1.0 million during the three and nine months ended September 30, 2023. In addition, in connection with the Athebio agreement, the Company is committed to enter into a stock purchase agreement by which the Company will invest a total of $5.0 million subject to certain conditions and milestones set forth in the Athebio Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded aggregate research and development expenses in connection with its license agreements of approximately $1.5 million and $5.0 million during the three and nine months ended September 30, 2023, respectively (three and nine months ended September 30, 2022 — $0.8 million and $5.3 million, respectively).</span></div> 22500000 5200000 15500000 3700000 7700000 5400000 P8Y 3100000 14400000 3800000 8100000 109200000 148300000 P9Y 0 0 0 0 32400000 P10Y 0 0 P10Y 107400000 101800000 200000 200000 23700000 P5Y 3500000 14600000 6500000 15400000 1000000 1000000 5000000 1500000 5000000 800000 5300000 Net loss per share<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic loss per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,774,353 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,013,069 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,715,863 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,973,890 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average common shares outstanding-basic and diluted </span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,765,954 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,401,484 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,717,330 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,891,031 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share-basic and diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.26 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.63 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.71 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company's PSU's are considered contingently issuable shares for the purpose of the computation of loss per share and have been excluded on the basis that </span></div>as of September 30, 2023, the performance condition for vesting had not been achieved. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to the holders of Common Stock is the same. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,774,353 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,013,069 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,715,863 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,973,890 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average common shares outstanding-basic and diluted </span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,765,954 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">92,401,484 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,717,330 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,891,031 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share-basic and diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.26 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.63 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.71 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -24774353 -24013069 -66715863 -64973890 105765954 105765954 92401484 92401484 105717330 105717330 90891031 90891031 -0.23 -0.23 -0.26 -0.26 -0.63 -0.63 -0.71 -0.71 Income Taxes<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company calculates its interim tax provision at the end of each interim period and estimates the annual effective tax rate, which is applied to its ordinary quarterly earnings. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has operations in both the United States and Canada, and as such it is subject to tax in both countries. The income tax expense for the three months ended September 30, 2023 and September 30, 2022 was $871,449 and $180,500, respectively and the income tax benefit and expense for the nine months ended September 30, 2023 and September 30, 2022 was $288,491 and $452,021, respectively. The income tax amounts for the three and nine months ended September 30, 2023, include tax benefits related to research and development tax credits partially offset by current federal, state, and Canadian income tax adjustments. The three months ended September 30, 2023 also includes prior year current income tax adjustments in the United States jurisdictions. The income tax expense for the three and nine months ended September 30, 2022, consists of current taxes in Canada.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company files income tax returns in the U.S. federal, certain states, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations would have a significant impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, the Company believes no significant changes in the unrecognized tax benefits will occur within the next 12 months.</span></div> 871449 180500 -288491 452021 Related party transactions<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized expenses in connection with related party transactions in the unaudited interim condensed consolidated statements of operations as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consulting fees on business activities to Board member </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">296,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">259,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reimbursement to Board member for occupancy costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,395 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">108,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">107,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">349,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">312,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine-month periods ended September 30, 2023 and 2022, the Company received consulting services for research and development from a Board member. As of September 30, 2023, $43,859 is recorded within accrued liabilities in relation to this consulting arrangement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC 842 to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.</span></div> <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized expenses in connection with related party transactions in the unaudited interim condensed consolidated statements of operations as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> September 30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consulting fees on business activities to Board member </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">296,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">259,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reimbursement to Board member for occupancy costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,395 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">108,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">107,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">349,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">312,203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 90161 90040 296072 259132 18219 17395 53532 53071 108380 107435 349604 312203 43859 6000 Subsequent eventsIonetix Amendment of Convertible Note Purchase Agreement<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 29, 2023, POINT Biopharma Inc. entered into the Amendment, whereby on October 2, 2023 the Company purchased an additional $5.0 million of unsecured promissory notes from Ionetix-α. In connection with the Convertible Note Agreement, this additional purchase was originally scheduled for six months from the initial purchase date of June 1, 2023. See Note 5.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Merger Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously announced, on October 2, 2023, Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”). Merger Sub commenced the cash tender offer (the “Offer”) to purchase all of the outstanding shares of Common Stock (the “Shares”), at a price of $12.50 per share, net to the stockholder in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Merger Agreement. The Offer commenced on October 13, 2023 and was initially scheduled to expire at one minute after 11:59 p.m., Eastern time, on November 9, 2023. On November 8, 2023, Parent extended the expiration of the Offer until 5:00 p.m., Eastern Time, on November 16, 2023, unless further extended or earlier terminated in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (a) there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received” by the “depository,” as such terms are defined by Section 251(h) of the DGCL) that, when added to the Shares then owned by Parent, Merger Sub or any subsidiary of Parent, would represent at least a majority of the Shares outstanding as of immediately following the consummation of the Offer, (b) the expiration or termination of the waiting period under the HSR Act, (c) the accuracy of the Company’s representations and warranties contained in the Merger Agreement (except, generally, for any inaccuracies that have not had a Company Material Adverse Effect (as defined in the Merger Agreement)), (d) the Company’s performance in all material respects of its obligations under the Merger Agreement, (e) consent by the U.S. Nuclear Regulatory Commission of the indirect transfer of control with respect to the Company and (f) the other conditions set forth in Exhibit A to the Merger Agreement. On October 23, 2023, Parent and the Company filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the U.S. Federal Trade Commission (the “FTC”) and the Antitrust Division of the U.S. Department of Justice (the “Antitrust Division”), initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on November 7, 2023 at 11:59 p.m., Eastern Time. Accordingly, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied. The Company could be required to pay the Parent a termination fee of approximately $54.4 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The consummation of the Offer and the Merger is not subject to a financing condition.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For more information on the Offer and the Merger, refer to the Company's Current Report on Form 8-K filed October 3, 2023.</span></div> 5000000 12.50 54400000 2800000 0 17100000 0 false false false false EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .\Y;5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #O.6U7W6@FE>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVG50^CFHGA2$%Q0O(5D=C?8-"$9:??M3>-N%]$'\)B9/]]\ M ]/K(+2/^!Q]P$@6T]7LAC$)'3;L0!0$0-('="K5.3'FYLY'IR@_XQZ"TA]J MC] VS2TX)&44*5B 55B)3/9&"QU1D8\GO-$K/GS&H<",!AS0X4@)>,V!R65B M.,Y##Q? B.,+GT7T*S$4OT36SK 3LDYV34U35,]=267=^#P]O3X4M:M[)A( MC1KSKV0%'0-NV'GR:W=WOWU@LFW:KN*\XMV6MX+?"'[]OKC^\+L(.V_LSOYC MX[.@[.'77<@O4$L#!!0 ( .\Y;5>97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M[SEM5RC<6D7=!0 G!\ !@ !X;"]W;W)K/ACHNOR88QB5["($JN6QLIXW>6E;@;%M+DDL+S" FVNFZ-\;N) MX^B [(L_?;9+CJZ11EER_E7?3+WKEJU+Q +F2BU!U;\MF[ @T$JJ'-_VHJWB M-W7@\?5!_3Z#5S!+FK )#S[[GMQA'^7_ZLJ^(HP#2KP@@^P#R)@!7_8*S#\AJSLI+EF'= M4DE'0\%W2.BOE9J^R.HFBU8T?J2;<2&%>NNK.#F:\"T3J(V2#14L&5I2:>HW MEKN/O\GC247\ 'WDD=PDZ"[RF/=]O*7*4A2(' IT0T#!!8LOD6-?(&(3QU"> M"1P^X]M+9/=-X=\5QRGJQ\GT'+!^_AXO$RE4E_O'5$.Y0L>LH,?ANR2F+KMN MJ8&6,+%EK='//^&>_9L)[P>)?0?;*6 [D/KHEKNI&J(2/;_&S$0*AV.[_+UZ>',F?.[I M48C4/&!L/%BI&'>5 P^,;\AY57!>U>R9@JHE)%L!JML1UEK1(#$V)!C6$+!? M /;!0MU%TI>OZ-X/&)JEX9()$QBL8=NX[0PT8WT\?YA_'3QS%Z__!X,WY T]GDTH0,BC5$QG:YL-IU MH*>1RX7JJ%3WV0NTD&IT(B[0A*>1%*_JOV>LB1/JMW4O*0.[]CSE'IR<;A #^H[ M]!B9VQ66[/2[-OK,$HFN^G*CNHM0SLZ(#NHT12]M$0:-R'_0)_I.=>MGOHN, MV+#<-/)\&M&8!WYR8<0]AR_"I3'"L+5YBUL,X[G@6S]RS4T-:TYG1M!SN"5< MVB4,FYRWH'.>2!J@O_RX>J:"%3L]TNL;2<]AG'#IG#!L>+(>.U9;WVHP6,#! M5T:L<_@D7!HE#+N;!^ZJ]IIO> 09B1,BW8[3'@RZ9KYSV"1<^B0,FYQG7RJ+ MQ%<(DU^6OZ(%!BJI6DAN?O5"'H.RX1+SX1ALZ.)V;-QOPH%- M"4L71&JYH$DJA-ZQY-N4K"75HI$:-2FKLN4C!+Q M.:4I9V MA\!.Y=!9-TQU5J@-&^:$X+BF>*7;(;720L=616T^LEP]>DRE\N:1-@E&XA]D M7_;UD*MU,S5]-K0=8;O7[0V(@X?6U@19.AU2*STT48N&4-Y5[079"_J=F=L1 MEK)M&_%H< M/8^S U>K_#P_M_Y(M2M(4,!6*M2^O%(SGLB/@O,;R>/L-'7)I>1A=KEAU&-" M?Z#>KSB7AQO] \6!_.A?4$L#!!0 ( .\Y;5=(12!9]P8 4= 8 M>&PO=V]R:W-H965T&ULK5EM;]LV$/XKA#<4+>#4XILD=HF! M-D6Q GLIFG7[S$AT+%02-8EVTOWZ'677LD6*<;8$2"+9=Z?G2-X]=Z?+>]U^ M[=9*&?10E75W-5L;T[Q9++ILK2K9O=:-JN&;E6XK:>"VO5MT3:MDWBM5Y8)$ M4;RH9%'/EI?]9Y_:Y:7>F+*HU:<6=9NJDNVW=ZK4]U?B;FWL!XOE M92/OU(TR7YI/+=PM#E;RHE)U5^@:M6IU-7N+WUQ3;A5ZB3\+==\=72/KRJW6 M7^W-Q_QJ%EE$JE29L28D_-NJ:U66UA+@^'MO='9XIE4\OOYN_4/O/#AS*SMU MKE^:SO?U9[AWJ F2Z[_B^ZW\M&,Y1M.J.KO3(@J(IZ M]U\^[!?B2 &S"06R5R#G*M"] NT=W2'KW7HOC5Q>MOH>M58:K-F+?FUZ;?"F MJ.TVWI@6OBU SRP_UD:U186N=9W#YJC<7G6Z+')IX.:=+&6=*71C']"A"_3E MYCUZ^>.KRX6!AUL3BVS_H'>[!Y&)!]VHYC6BT1R1B%"/^G58_;W*0!WWZN14 M?0$N'_PF![]);X].V+O>M*VJ#9)=!X[YW-GI,[^^C:XW72,S=36#\.E4NU6S MY8L?6U[-9(UCG*[(7Z>U-L90F^>[W>F8I[4S8% M;)<$8"0,PZ)OCSWR"*8Q(RE-\$'R!"X[P&5!N#=KW9H+.)45*NJMZDPUA75G MAQ]!H#CAG L:C\"ZDH2F24I9$OG!\@-8'@3[J56-+'*D'AH;/5V_SMJL50O! M^]@)XPXJ(2*<$#%"[\KQ&$=I*OS8XP/V.(C]8YWI2B$C'P!WJS(%Y^*V5#ZD ML8. X12S>(S4E9M8W^2 ,0EB_$,;69ZQE(E[%#@E+.9L?!1<24ZCE)"$3D!- M#U#38$;Y3=<7CP--GS.K/).Q$W?%P5T1W)E?='UW5I0*=\%%(BB.\6AG7$&0 MP8)-;0R.!HZ+@EA_TT8]4)3R"GZE%'A@1AREQASB TN4WEB1)Q!B)QBA=47"&VOPW M!7/@0LS/JJG*0MX696$*Y4<;I-2GYL#GLG;J\\"A.$RB;[-,;R#SH49^F\PM M+BVF:1K#X1AOCBL(NT@QGSKS XWB,(\"S'8#]?QC6^.R(V:<",J=T^Z1%)& MT& 36 <>Q4'>@E)_I> @Y9"QMZK>^)%X;$VP4*'(WCT"-HLR#E4V$X,"0) MMXNG87@XS4]:>[<;9)&@)!HWZ![!J4,SL!T)L]TX+O^;!YYN,F:$QWSLP=GM M)!F(D)S34#X6H+XFD6,2T3$->B0%IG$JCGCH%.E @R1,@]>ZJHI=6[6;WNC: MKKRJ,T"-7O8]#2;>25S8LK\F0MZQU?\W=.K]P*U$!&O)&Z.SKVM=YJKM7OR0 M$IS\U+=$$ZD_2-1/'M8]D[73:=W U33,U7;C=8WZ%8".4+9H*\N-0C]&KZ&9 MP AB$'5KV4+*AMYX#I_97R0W9JW;XA^5SQ&.^#R)^5QPUI\=>Q\S,4\81D77 MV4JP'U1M3&?@P@:T[&SXWJC&J.I6M3M_OL]K>^GWT$ ??;6?QL6.DL+I<@ZU! W7$F_SO+"I",+>CNHNBAIELBD@#7C! MNL4!XY1BD<3.!-0CRE(J,$\F:F ZU!,T7$^\A()]4VW*?@B?JU61%>85^JR, M!,$<*=G6L&G^":Y;,UQ 91$EE(]+-X\H%5&40BL^X<#1S#E<7ASCW\]#=07A MLK9O@+; '+KSHWKU23(>IWQB_DR'TH*>TVYW3\I U-."$X8% M5!C.0?>(IK'@-!$3I$&' H.&"PR'WOK(?:(KW!GM3TT3/*)3TX3%T3LJ^X+P M5]G>%74'A<0*=*/7"9AJ=^_<=C=&-_UKJUMMC*[ZR[62X((5@.]7&AAP?V/? MA!W>?"[_!5!+ P04 " #O.6U7HMJ:N+(" !Z!P & 'AL+W=O&Q@*@%1,YHH\S9NJ:&9F,E MMT39:&2S U<;AT8W3-A=G!N%;QGB3'8G#"A6D:D4!>X-%':D)6<%-3BYHIR* M',C<)M#D9$85"%."83GEI^0C>4]\HDM&J"M#]!)[-I55A6Z;33TC-55D0_D:R D3I)"<4Z5)#:J)..VK19-@Y!+8 M-K+)@D$0!,.QO]EU^6K8GOZXTQ\?I=_(_.&,T+4II6)_\"Q;_8VK7M$-:[*C M)HZ"YO=,]S&1>]*33GKR!NF-5L*T7K^N/OE'TS!(1FERGL3/U/=&IO'Y*#Y0 M^+13G[Y=/5XR%X+_DYGM+?2%ZI63&C"88G88&#[N&HZ M?3,QLG;-&3^EZHTW#=':WC=?R4>K/VX\EW$U/+$F:RZ)*54%*N;J?O&6W$:\- M:L2?J3Q4%]?$N/*DU!=S\SZYGU#S1C*32VTH8OC9R[G,,L,$[_%W2SHY]6D, M+Z^/[.]JY\&9I[B2I 2H,&-G-1JU];@UYI80+E49?P- 4[/?M5RM(D-H\?-?Q A.B*J!7Y?2O+V(QT15Z3SX\+SF9_? =\^A/F*9CDBW&)(M&(KM2WSFI[PRQ#ZG? M&'JUH5D(]C/N!V$80LSL+X7MXN@U8M%%,)\Q 7_7P&B(ZLH]]^2>.QA<;0(I MUD0^;TVZJ3!/W3'C;$RRQ9ADT4AD5P/AG0;"^Y&HV%R+P//"QGE@6=%'@*D?N@[U (NNL# I:$O!+,"L MT'<8X$QX>A_[) M?7_0_9]E 8&8U=['"2RP::5-8.[1F>=WW\*E;N"%EO]=G A$Z'';_2Z.N1YU M'&J[CP"9S_WPHNPT_]K;L:3 M>=:;SC$D[CV"#(0;!!ZSPBE"D,/N,WHN_^AP'M8;69*T6*I\*1GUWG@Z[#Y@^V=@7L?,I2%LNO9 U[77*3P33% M8Y(CSKDNMV1 X]NR),$*0@?*^27&N4MEPF?J;U,1D =1?K[,[@)2WJ+B#-:_W[QJC\FV&)4M&HOM>J#.E30;+J4?ZK$I+H?KUJUX/F\Z"B[#B;[AG5C&8?8> X=U8QB%^7T3]UQ@L^$*>]$&ZBC" MA"\3!H=UA$%A76%06)\P_%QY\\$JLHV70_TE&_2)][#_6,LK:2JB=KK2,-_- MWLSHU#2CXK3=6:60[[FAO5S-$6AHLJ 3V#5A#RGLT(2U1D08*0U"1D6?5.>" MF \7Q,<8&E$LK"CN$:L+[1,+)T7%0DAQL:87W_9S6:[K0Y4*/-\5NOF6>VH] M'=R\K8\KK/8'=CMG2/N"W4;-LN3A2>EM3#"0Z)Z:V@6U_?<=)2"'UX 3>AN&WN3N#G3+)U(<2#2 M6".;&339;]"8K[(V.EEJB;LEXG3Z5+-=7FK(R4S4.=:_'2G!RYR9Y:7&#PI# M*R+6N%6A' NCDSV0GX52Y(8\+>?D^V]_F+@:#V1HW:QS_M Z#UYP'I+WHM:% M(@MTG5OP\\OX\06\BXGHLQ$VF$#5_X$M^Q\O\M_+LZ$Q60W^]72DN\ZW_8:M^R1W9V\_]WI[8L M@ZF#Q KD'ISTNV]\ZOUH2_PUR>;7)%MRL1%%?HN@2>_H+/B0<+Z$M_2V2 M-DCS6NS3FR!*DBB,45O[T]Q:+3T_].CXW')NL:0T\>,1'7 N;);1. E'8Z^W M/ LY[D..+ZKR5UV )-F9'$T*WI :&J5J]FQ+1WQ--5Z3;'Y-LL65R,Y*0_O2 MT"^J<5=CM\++O_'E,%4AIA?8LY*S%8<;;&MN%.. +_E*$P793I:Z!*M\6U?Q MJ8!"ZE/?'XC78A=0&@;>0+H6.Y0C7H>!<"UVU!O1\<@NVZ3/37(Q-Q^%9MPB M6UOHB>4^QGX8CVDT"-YF&07)&*_9('R+)4WH:$P].DB S3*.1T$\&J; /6D[ M*I";IM]3&.2NUNTSTZ_V+>5]TTD-UA_\NYEO69]C"]IVC/_2M_WK>R8W9:T( MAS6Z\FX3+)AL>\)VHL6V:7I60F,+U0P+;*-!&@/<7PNACQ/CH&_,TW\ 4$L# M!!0 ( .\Y;5&PO=V]R:W-H965T&ULS5UK<]NX%?TK'+73)C.KF'B23&W/)!(Q3:?;9I*F_=#I!T:B;4XD MTDO2S MF[Z_?7UVUJUNRFW1O6INRUI^<]6TVZ*7;]OKL^ZV+8OUKM%V M79[O/GO?7IXW=_VFJLOW;=3=;;=%^^O;; 4GVXY<]Z.S@[_Z'YO&\^BU5W7 M-]M]8]F#;54__"V^[0?BJ &B(PWPO@$V&Y"1!F3?@!@-<#+2@.X;4*,!'3L& MMF_ C 9DS /?-^"[L7\8K-U(+XN^N#QOF_NH':PEVO!B1]>NM1S@JAYFUL>^ ME=]6LEU_^:DN[M957ZZC=W5?MM4V6C3U6LX<^8E\U36;:ET,7W_LY1\YI?HN M:J[DNV;UY:;9K,NV^W.4_W)7];]&\^C3QV7TXH\OS\]ZV;7!P=EJWXVW#]W M(]WX5],7&T>SA;_9HMENY?3<]<;1>NEO_68MCUQ.[V(3O2^J];RJHT5Q6[E[ MDONQ/I2]7,9RG/*BK:OZNHM>O%FM[K9WF]WH+1*Y&5;WUS+Z>]-U.NJ9G *'>8 /\P#OW- 1-V_+ZZH>.B[7Z::H5V7T M0@Y'=U.T9?3&3G>_*]FLYN_S3 M'Q"/_^*B_0&,[<"&D^/7RRQ&&"49/3_[>LPPI-<<$DP @6ELD@.;))#-*0P^ M8/*C0<>,843BE.NCOK M!WH,:FPC@BA-TR0U+'/;0%[;YHU_]SC2"% M7 .08$M(L!P23 "!:>RS _O,NT[>==W=;GG(2]K#N6YXM7JXJG3#'!@FPZJI MZWT@=%_U-_LOFMO=)^6WLEU5G6QY=,)TS0UO3T+G!K/.CSPQULH2TF$."2: MP#3*^8%R_@.4'P<2TREWT>F7*G)$[IHD9'D)ZS2'!!!"81B6*54(>AY YA< ]XO&@ M8Y+AA&2QN=3VIB="=P>@C-TS$B-SWN<.TWG".&?8#/.%PW0D>D='\@5ZXKS5 M[R!T^N_1)F2NH'YS4#0!A::3JK0(%"I&3"+2%@W&\M>]Z:E58 ..9; .T[$4 MUF$ZM@I4NH_(,V:QR"LN!*\(2+0E*%H.BB:@T/1)H)0,Y$V5)V0V/T6UC-?D MA^NJE=E-5-1K.4WDA!ETW6(C(^JN/YG'^GL1/#NHM1H0R0A!W$QG0?WFH&@" M"DUG7JD8R"]C^*)P9$L%ZV!/N0:;S"V0+""BF,:,9MRZ(D(YS4#0!A:93JG0)Y!"-6$BT)2A:#HHFH-#T M2:"$#.P7,IYS*\K?E> I8DL>F)K!Y1+49PZ*)J#0=.J/2B_\1*J^^.9DS"%H$(J)6?^P\'M=QDHG0*GSYFA M@6H6H&A+4+0<%$U H>F30.D:V*]K/-/^BK\7P;/#UBL0R>+AG[DH00LR0-$$ M%)I>3*T$&N(OR0!BWEES;==$(,13QI%Y45L0NW1CH-*LNAX!I(FI8>;^HP[E M" I-YTCI)^3WHY_XNQ*Z1(FMGQ#'^@1UFH.B"2@TG7LEH)#?5D AMIA!46(R MM"!V50DQ270A\2PQ5R:H+@*%IK-S="\*G"Y"7 )%DL7,N@,%5!>9ZC8'=2N@ MT'1BE"Y"?EP7(4Y!(48DYIE)!:@N HJ63S\, >58)T/I(N2)=1'B$ $PYP1; MIRE07004+0=%$Q.&1&=+Z2+D22LX_.C! <3T"@Y0QSDHFH!"TRE5P@@!K^ @ MMMHQ5L'A,'55<)#I%1P.T]$*#I>MKX*#*&6$/+*"X[ALUSV(=LT%DA=>FB74 MW**:;KKT=SMXHH/J&%!H.F5*QR _4)]QFB:[Z(+*"<1(DIDBH,-TH,F:Z[8T M06E*,F3=7),[3 <1(V7F A(.RSEE,O]%[IE.E0A G[-*@X)6:8"B+4'16(Q%">HT!T434&@Z]TIEH+^MRD!M;0!1 MEG*S_(V>EAG&H,SZ"_\1!_/S%#H#53H#A=,9J"OACS,9,9N##:HS3'6;@[H5 M4&@Z,4>/V/AQG8$Z$G3$F7_CPM^/8+I 9090-'%Z1'2NE,I 'Z,R')=4$R=3H"H#=:D,,K+&/$G, MRP^HR@"*)J#0=$J5RD!#58;3--K2 4U0DF1)8EVM7"H#LVZEHZ['5&2,\HQ8 M$8*C]@/3)$F)^0 $A^4<,_DO&5D&2F.@3ZTQT.D:PW33I;_;P=,<5&. 0M,I M4QH#?0J-@4[7&!RF+HV!3M<8'*8C&H/#TJLQ,*4QL.?4&!BHQ@"*M@1%RT'1 M!!2:/@F4QL#\&H,O7-XWU1Z5QV6,*7,[1,B,>\'LC'LL'0%UG(.B"2@TG=6CYU_ZU8"3]^JZF;03WK&, M9&]Z*B-Q(8YD) [3D8S$8>G-2)A*S!E_SC@--$\'15N"HN6@: (*39\$*I5G M_E3^61\>"_G$R 6S4_648/N\">DT!T434&@Z]TJ28'Y)XJGW@IA#A4AY;%[P M%WN[X].K=6H=@3*?2>H_XF!^GD)_8$I_8'[](60OB#END4A03*A9Z.CW&7QF MG>@V!W4KH-#TAR\KA8/[;Z7P);?<\2A)S"B*4V)2X?<22@4H6C[], 248YT, MI31PO]+PZ+T@;A<5S%-$*#;#0']'@OD"%2- T<2$(='94CH#?XS.<'P7IS-H M]Z.'AA!\NA0!ZC@'11-0:#JE2HK@H5+$:1H=4@1-*$,9,H,#AZE+BN N*0)1 M2@@Q8P2'Z1QGTL[2R%V6*.9IEI*1=:"4"$Z?,?GBH*H$*-H2%"T'11-0:/HD M4,(%]PL7SW0S+K!^9>+Q,;TM*X<.4U? [D(=C2.YEP< #P@ 8 >&PO=V]R:W-H965T&ULM5IM;]LX$OXK@F]QV 6:6B3UFDL,I.D5VP^[&S3HW6=&HF->)=%+ M4DFSOWZ'DB+9(D6G@*\(&ED>CIYYX3PS5*Z>A?RF=HSIX'M=->IZM=-Z?[E> MJV+':JK>BSUKX)NMD#75\%$^KM5>,EIVB^IJC<,P6=>4-ZO-57?O3FZN1*LK MWK [&:BVKJE\^< J\7R]0JO7&U_XXTZ;&^O-U9X^LGNFO^[O)'Q:CUI*7K-& M<=$$DFVO5S?H\I:D9D$G\1_.GM7!=6!,>1#BF_GPN;Q>A081JUBAC0H*OY[8 M+:LJHPEP_#DH78W/- L/KU^U?^J,!V,>J&*WHOHO+_7N>I6M@I)M:5OI+^+Y M5S88%!M]A:A4]W_P/,B&JZ!HE1;UL!@0U+SI?]/O@R,.%H >]P(\+,#S!='" M C(L()VA/;+.K(]4T\V5%,^!--*@S5QTONE6@S6\,6&\UQ*^Y;!.;[XVM"VY M9F7PN=%,\CJX%4T)88([<*5$Q4MJOK[7\ OBIU4@ML$M5;O@$^2 "BZ"K_![^)1N]4\&]X9'F\?@V&C-;@5VL^8*_" M>[9_'Y#P78!#3!QX;M^^''O@D-&YI--'%O1U7MIV7MI*40>P^235O'GLLY=K MSI3+:[W6R*W5;.Q+M:<%NU[!SE5,/K'5YI__0$GX+Y?)9U)VY(!H=$#DT[[Y M'>I0)92Z=%G9+TVZI:;:/&TNDB1%<99 Z)X.37!)1GE*LCP<)8_PQ2.^V!N@ MF_)_L,7ZK-8"RE(AFH)7+&@&X.:NN2Y,)%NS*7CC#*/3POB<<3R3LB,_):.? M$F\RV*;Q>&H\H 8 )QJSX [+NY9B[ F84DBO,$I^D, ML2V'XR@-D]P-.1\AY_[];GQKMDK% +8/:&X!0'F2IGB&TQ9;V/$HG @O]&*\ MJ874_*\AE[>0RZSF;:V"GVE12/9ZN^2J$"T4AE],PO/FB0V%XITI"$ZN"^TT MR*,X34@\L\HE&9$8DVS!N ,V1W[&V='FD:E9E5**08$SR5]Q^L"KY8HUJ#]3 MR3J7MF-GX,D9V!OI.\GVE)>O:=A[0.@=D\%K >A=X_0$MF*4ACE@F\?2EB,H M Q);".74.R O,V]NBC[_@CU]H0^5%B31PB*W-MN24O3\R*_-3:ETE3)>F0 MO=Q,/U#B.T>7T-3!#%0J&,;TCA^5?Z()*G46Y5"X=DDD896;!H(EYT M@GG?TJ0ZL=L4>X%PE$$)R:V=Z9"-"1AZV& <#VX3+>/PAV:EWN6G\6,OV_\H M8YU+V[$3)OK&7D;,TQ_,J MYI1-XBQ"4;;0C^")@O$)"CXPZ(>'!FQ3*Y1B'.4QFN\KIRBTLPE)%NH:GH@8 M^XGXT(9&:'90EIVH'9PF)^Z@.O'D?.?@910 ZC8B5 M,B[9-(E)FL4+E0Q/)(W],_F\$&QY0V$H/VW 6:?M.HVS.P*K3M@B""59G*!DH7O'4]^ MW]@W0'4V34\9/+R\?&7IZ ,Q?Z-N*8PV'0R'"8Q_/<V"-O&A,+0Z%,^/G>8P@S MP[?7!)O#,134-$+SJN201#A.,P(C[8(%!T?V_C/[^W:_KUZWKCD$JH1J9;?] MBU=F@D3K7Z!!G74>HY#SGN#_/X[PR=12$']+T<6T.T@!HT\>F1*[-S#$$B'K M%,PA&2$4X6@AA%,'0?P=Q'@*.;70IT[JR5F;AW-I.[9_:AZ(OWGX,AT;]!$; MO>"?&HA-]N[&U2&XP+-DZ@C(B8[@K9-"]Y9&EGUW2V>'9)TH?=N)U #H\+42 M2; Y-9F;:PN:/,7I?#Q:'[R'K9E\[%Y/JZ"#V+_$'.^.K\!ONA>_L_L?T.5M M_R)[4M._5_^-2N #!,?S"P^1M02P,$% @ [SEM5\(K2>FE P \@< !@ !X M;"]W;W)K^L6H"]&W:P?AGTX2V>+"$6R)&77^_4]4K+J9&G0?;'%EWON>>Z-D[VV]ZXD M\O"UDLI-D])[6=C;1M9="T=*"JZL*[6%.4N^GR3 Y;GP4V]*'C70V,;BE%?D[L[2\2CN4 M0E2DG- *+&VFR_#XK:8)H- B"3E/B @_^UH M05(&(*;QI<5,.I?!\/3[B/XF:FO\GM7K. M UZNI8N_L&_O#A+(:^=UU1HS@TJHYA^_MG'X&8.L-<@B[\919/D;>IQ-K-Z# M#;<9+7Q$J=&:R0D5DK+RED\%V_G9>_2U)= ;6->.SYR;I)YQPVF:MQCS!B/[ M <:O\$XK7SKX7154/+1/F4]'*CN2FF?/ J[(].%LT(-LD)T]@W?6B3R+>&<_ MP/M@MZC$OQCJH <+K9R6HL"F+%0!2TN.E&\V.!1OA$*5"Y2PXDWB&O0._KY9 M.V^YBOYY*D(-@='3!$)G73F#.4T3$WS9'26SER^&%X/K9^2-.GFCY]!_,H?_ M%P.6'V[??X*YT*9$KG_X0^HUA^16Y?T>>+TE7Y+ETX]EC0A9CMMFX(AO2VY9$ M4!V]2,%U4C@V1P^;T,^0ZE#L4.H(.Y+%X>4U]R:]W0* M%JA8- = 8R3364N*US0'N\%VD13N4,@'IX:TD=2+ +0^@*B,U;L@-JB3/,M< M(-Z @&$EL4Q;G\+"!BLA0_Q9OSWL \Q#'66C@W-8:H[X+WJO'J6N]Y\B:++_ M>/=N=1-/HO?/Y#Q_7V]>PW=HMT(Q3=JPZ:!_>9Z ;5Z89N&UB5-]K3V_$?$S2"0;+O#Y M1FM_7 0'W3,_^P902P,$% @ [SEM5_7-A5L&V/[T^%AJ+:JD6'A6F7Q9.U\(R,N_>8PM%[)FCB:1OK]:V7<[N7L>-;?>*\WVT@W#E^]:.5& M7:KXL;WPN#HL5&K=*!NTL\*K]%N_ MG!T10\JH*A(%B7_7ZEP90X3 QN=,NX_;E M[-E,U&HM.Q/?N]UO*LOS/=&KG G\5^S2VM.3F:BZ$%V3-X.#1MOT7W[)>AAM M>'9TSX9EWK!DOM-!S.7/,LI7+[S;"4^K08U^L*B\&\QI2T:YC!Y/-?;%5Y?) M&,*M1= ;J]>ZDC9"697K;-1V(UIG=*55>'$8<1[M.JPR[=>)]O(>VC^*=\[& M;1"_V%K5T_V'X+,PN^R9?;U\D."E:A?BY&@NED?+DP?HG13A3YC>R3WTS@8I M+[*4XM]GJQ ]G.4_=PF38\"Z*?0RDJ]G"%"@O+7:O;JVV^.?SAZ_@"W MIX7;TX>H/])47XNV>"V##K201;11W;32[FE]9V57ZZAJH6U47C>B MK[65MM+2B !:"@$?@]C*:R562EDZI96>R? !OL9JA2B) M6Q%QZ)NR?63-RRAM+7T-;AW^B2???O-LN3QZ_N;L\C7_/'[^W=WKSUW-PK-0 M_;:SR_.RZX-K=2663^&%;[-@[U7K/-,!%?!9F:Y6S%S6'ZN+KL^3?G@=75]V MJZ!K+3T4.Q> V)$VM$V0R]B%]6WG0T=&B8[W^L[ &O3$JTUG>&$YZ%)5G==1 MYQ6_?*FVTFZ8@48'1M0GL\M?SF??+5@/O@;[9C^GS7M1.V%=+))(8WJZ-YE: M.Q>Q%,=X];G39*?5?N(V'E1T2ZQNE%4>M/BY:I-K,-6/EAWEDNS/(IPU4&PE MBP%^/3N[Z"T AHU)3E7UZNS5S'KUT@99)74,?J2,!GS*?.K@@5BV@"69#YC6 MDF3@H)$6.8FA'$L*-M@""WIV MJO$&JRH5 H4J>0MQMI;:#V?UAEI)0W'2.TA D@IE2PL!')P]1["J%^0A,(F0 M 2DM5%ZOR)*4LN=C1YX 5%N5-P2)9Q*QN@R&LBV-7JP[^.4ER0PO"#Y&O9$ MU!N*@\@K0@:OF)(.D920T<$%55B!6XXC$'LTTR6]4)3: MQ,^P2K-27IP<TM&2C%)F3-N99RXXDX#%)6B):EK# M(,D90$FC_UO8D2&H'@/Q%!?1%$PP6JZT&3)"18D@@4H?I1EX$.@>ML">51?@ MP0'F.?_SK[<_'QS_*"ZP5S6ZF@,@*^\4>'*X3#0=12-@WA%$1."W$>J:3_@P MCCS$+Y -]P%V:"Z\9%@AFV1@NEF%]*? /Z /"JN(3)5 C;:NO6L0'XW#[\1# MW.)^2-"E<6Q5<+%(TA9))@S'U&]@;^B@#6GU75[N4D[IPR8KYA&0!FF\;/:VFZ5(]QJLSP0OB48F_04%8 >T05H5LP(!5(C4\W)954I-!Z;0A;B-[<#8WX^ M.H332@A=D_4H5ZZ+8MU%^-M8<)R/0DRMU^ (?BA9M9$T18)Y MPU:LP5@0.T5.VC/3YU*"^B9-/U)%=TD=3RKI\@ CV8"<"'',7@P=E3H OU=3 MNMGEOU$B54QZ ("5AN:KK77& M;?9WH?(<"!,YQJFI2IQSPJ3>9-T9PIW*(8Y2,A@C;083E%IU!V9AM)H#DI)- M:F,=[6JI%I/FH>5CJI08((6*A.Z,6.3P10@&:8V O)8YL=6J);,0Y$ A5^AY MH=;@K%4F-SQ<+>U)5S+R/"CW(9Q]/J.4A\L1C*$@-/!UQ\#/% MU<*@S3GSB6*L%)X;TI,E*;CI*YW\S>)E4F^-@7UEA'M$/7G3_1ZP0#U^\]ZHLJ2H]Q,GX3J[QUCUA0NN:ZKZ5670]Y./, _] M1>2*;3,>L4Q\$^8E]',CKG,UWOGUGQJA]MYFHJ6>:D&D(Z7E. M[ 50T)0HU*2@FA+FK8XF=2=3H3WE((!;\LULOD"U\13.I F.P5L*VS%H0DWW MH5I?4>0,\R?<->6W=\IOV ?Z@4:?5(Y_Z"UT'TT2?K*O<7P'"PA)T >AB7_[ M=B'> M3%\=FB[[@I7XHWB%G@4&ZRJ(\-HSL7UL;Q2 TOS4GG_'C6DH_9S7@Q&60+)M4M58LI\&R['[]PH.P,:XJKL3#L3J#[4CNRD&"?E$.3W8; M"$E52:]H",\5(F=,Y)1-1NT$L_^GLBLS1-^EG$X:Y*G5S?*@5SH7&U[EM+AR MWKL=11"WG..2.CFX5:-14U)9@LEAOF"4#!/6$U/4XPRC\Q!==85-HP6E."-= M >GZ]):'@;PD6QX@$A25/P:XS/1H\&>3LUHM,PZ=APRC&?/)>7P]%=YX><6ZB@1F_RUAA4:.2XNA=1^RXSDH#<6J2 M:LT)@U-2JJ!&AO#C0%Z(/Q1;:Y*J^G:KQ>I&(OSZ(IFZ8H()^K^ZED M9_5G2LE%^1.K]&@W=5I*S2IC&F$/-^@,)4CX60DL-CF,UQO-0R=PRT%A\ZB; M%1:&N<,8]_+["\%OML/MT[E"Z%F@(CV9H8!U$I1[-F+.-!VY]T-$AHVS%"R0F=$KO #*U MK)1$2O1HR@,PTT"3'3!?CX)8AS%<#'._,MA.^)FJP%5Y [,0V=>'XD.R_14W MN]PRD@5)\9UMI:YOBMV%O@F9C""I2:)74K&7)$.]GZ>:5^9EPTB&WE)0^S_D MD3D?>W_.F3C@/QY:2>H9Y:?$L\RM4'US<>^N00*CDKM5^?4P&2"/G^%A#C5 M+*[*P_* A&_HC5'?%"I[K;WC7C)#59]/^9P;N3 D0Q;7=$P3K2[[-GT@D%]8 MW.%MXQ?=Z0U7H5W*IB&J[ZIK1M4,0<*M-A AL,T-#LU?$')IX#MYM0RYNQQ% MX38^Y714/[ G39$-S4]"1];)8XV]PDFUXW?4Q-"0+7L?OY_FT(+FU^CD__N^ M.[G9?MV0O"_FQB,A?H$EA^EN/Q.P=Q)\7&4)-QFJ\K"XZZN5P]''1@UU6/1) M%*7A_0 CRGSP_Z"SJ@?,OVZG]02P,$% @ [SEM5QK Y:'O M#0 ?"P !D !X;"]W;W)K&UL[5I;<]LV%OXK MM6=H61)VDFV2>N*T^["S#Q )26A)@B5 .]I?O]\Y $C*HN1F MI[LSW>E+8I' P;E^YT(\OS/U+W:ME!.?B[RT+T9KYZJGIZ]6CMZ257ZD:Y'ZOK&K].6RJ9+E1IM2E%K98O1I?3 MIZ_.:#TO^$FK.]O[6Y D"V-^H1]OLQ>C"3&DS_':E_Q[)#EH6TZK7)_ZXSMWXQNAB)3"UED[N/YNZ-"O(\)GJIR2W_ M*^[\VK/SD4@;ZTP1-H.#0I?^?_DYZ*&WX6*R9\,L;)@QW_X@YO)*.OGR>6WN M1$VK08W^8%%Y-YC3)1GEQM5XJ['/O?RH;E79J.>G#L3HT6D:-K[R&V=[-GXC MWIO2K:WXMLQ4MKW_%$RTG,PB)Z]F!PG>J&HLYI-$S":S^0%Z\U:R.=.;'Y9, M+&M3B-?@M88'0+MN+5ZS7E4M_G&YL/S\GT,*\/3/ANE3M#RUE4S5BQ'"P:KZ M5HU>?OW5],GDV0'NSUKNSPY1/V27W[3Q;2D^F%M5+" E%#I+Q/4/;S]\$K(L M35.F*A,DN%,KG0KX4"X7!C\Y3LI,J,]IWEB$B\AUB@A40JYJI1",SGH5OI,P MOFJL>&/R3)*+T;$ 9/0H(3KS#,ZM1$V18ODU,_57*ZK:K&I9 M6*%+^MLZL"92"49K<73]X1,P9G;,K)6JJ8TJ,Y/6D%RXIC"UC6OFQXD_D5@2 MV.P 2\*INM;.U%IAX=]D)Z ME& JDGQC\,_W^"<1[V4J&U[T2>H[61Z+(P@N1H%;<1DU-N)%O7?SWKL$R&8K MQ=B4;_RA9(_XQ.]KM?TNF*,E #V/Q2>LV39B)36T$K6K/E=0A<8^:*-4GYU8 MJ5*%I;7,M,GUBD[.X#RYJ8@P'(#\?02?O8>[EA+&.VR=!H;FX^T8@1WO%.U$A:JMDNMLG$(PQKRP+Z9D.+1[/%D/ &V MYSF9HZD 6%!_)3=LAHZW'<=BE=UA7R2'!T)F7B.P1R0!/IM*.+-[%/[Y<7PS MQOY5DTN$R$;(BJ24.:L]$DN$(3W%@*H5/*+$,^CU5EG'IRP1*27[@5O#I]? M!2O6$EPME*+TN]:*)0;3!O+4?>NU"HHXQ6(ME%#P3+W(%;$?I:S-1N:.HAF2 MS29_(48DEI>H8:S,*"X6WGQ#KC3]$D_JP5"RZTK^P&V'>C3_ O?Y-'00 M[&0-J>P6B0 QNI:N;_!!"T\?LX4[=8'7Y/?0]$/!6H9ID+!R, M2@\!KTV!/+,AGR. AX^S%Q-* 3&K7!'S_96 Z0*5I#X!P"-A(2] 3%/H?U%, M4 TN .\*?*[AE&(N;I#ZLHU0T'4CF5BAG"3$I8PN.;N#T1.XFU M80R=GI^+=Z(YB8(0)'/ R&HC+L42S. P1<%Z0L6&>"-0#K/.'+*G#_XC2@>S MR;.;ZW>7-V^ Z*XF)(B)KP*LDC79R%2F0\$KQ2 32\UQ3>6?4 1?U4W*W%9 M52@\?'Z*I#]<7?)?TV>$JE']*42B($Z;ND8,Z&$CL9=^9XQ''W]$AFI:1S4A M%7UW19G(-HM"6VXY%HK4@Y0*F1>;-K&P9T/P)5NI33<1L.Y;FX"IYV8I5$AI MS:>[+FZB'"V[\$\05;3;,A&_@DCVLG32$62-V_MT8SQ&TF"/?5R#5K\N0CED MJ3;KCD<=I2HG+E$+062#4[&^X)H+:Y@N4);<218H*9EJ'6IN&)55D9I521X< ML.?RYC4H57#0)Y,GB1BLT.UVB6[%=CP!OJD3M?QPB9K'W)&5K%.5?2J.]+& M%$"&I:^K8.#'B8CD5@"4UQ+ MF 754IS5^F5'C]J&]V3P/;QV?3ZH,@NY98LM\%4H:9O:Z[Y7V8 S<-$_*&PF MQ]9DE%+<2IB)W)$>0SO>XXGP[3%YEDG)B(.$R9 L_[" [&Q'H-):NO4 R(N@ M(O^WQUL&C)D>52E*@CV4_V.T];9''7'//_K'=&6'=QA:&=L<[>CUK=H0!=./ M;C 0*G5Z$3,+5*RX6&\HA2 B\'P37"FX2,QV3#!@OU>W!TL?N F0IZ+ZP@/A MU64?B4C-#*&IKLA6./AG0]:%VRLNS7FXH1ECV2;>9[:J]VZ)S\U19ZW'9WM\ M8"!VA?1\PNV $;V2:+=&]5! [QXH=(GOM<. 2_0R(W9F]OM@6 M:Q*& OI1'4&)+Y,Y\CVL@6/)$U@F+-9!#_O6="W%PV=SD=]3I,^LC)/9ST R M1:U4_0O*$&FMLM8+3!!*,1"S)+5I*:TEJ!<5^F;(@GTKV'M@WW;KN&U4.#$! M BL1MAJ& ")J4LVZ;B,,M+,&3K[M/*Q1J,2:G)M2;Y1]#K9'3R*4::Q\SQCB M#44--0;AP98>.MGOL8GMVY)HQG,N3WA)T+:W;9WYJ+"A$86';5J)@BA=%::6 M8-WQ"X]5&TZ6V[+VC/\ 5LW_/[ *TL'_)"J*#I=\A P5&W\TP)H/ ];!=NI/ MO/H3K_Z8>+453 8T2^-"!:GVJ3XRJ3HZ<;BIV%^ L7AF=AN4/-FRZ.4IX+;R"?/ MQ+4A8:A/73:.BNL>E+6#@G8*<]!AV<1[5!>,SP4Y!XM_Z2..=.8G8W'ZP([: MCBEH=^S-R*S<%YA\[[ I2&*;E/":5?T;&\2%[YC0!O,2'O/Y' (B?F!WJ&'< MK]5=50ZUZ3%+^3F-0R0I+.SWP-!ZM%,<#SU@$V5[9_Z*M$=M843)..OS?2XW M'3^V$[*=EXEG[,2C=C>?DO66YP9$H%"M26^^#9KZQ(W,:=6O#=F+B%$;V5BY M4M[5N:T\FAT?:+BZ@:9%;RS"="'XC.>O);K%Z88SE9_#MNE*]\:N2, T!S6> M*_H(@^S-7Q8HT/VPC*SJ>H@!H^HBMHY=:,L!36U(,;&E[9+P,X$06?.P*[:- MILFS>[,#UN& _JS7FSCJ!IM WJ;P^;U%YQX:[]%JJYM.'5 "UR\,O>WCXR$O M;QTL.M:]+$- CM8.="@8NZ\E(7']7K "&3P@WT>%76R+(6][F5RE32R+Y'X) MVJ^ GNO6 X(+!BG"IZ&]G/L*2T=) Y3OUG$0IJDRMAQTP>."6O$,'EQE/'FB MBB-=2XA+9"(_-.L+@YLO@OCM AT*R>& ?M144(F3ZU^HF@B^WM9#;F5URZ6^S)T.B-"6*30R5K\;^S]0--V;.O'4NS"W\8/8 M0 J(\U*9IG0:SN!I*<[I%=0'IT^=YD)'9 ?[H6V-]&2*F,-1TD7 OOP8?/S MI]B'LE'')]R8K@S$2@JDETV9AA'Q8)]&KLX10K[%Z[4!'@W#:?\^M-96J MDK&3O@*PJW2?L:BD8"?!!A[#,C_[:'8:[S<3_YNQUI[)_D !V)4,#W'Z7VQJ M8S)X8 C0NJ/MW-%V8USK3IPYX?:J4&YM$$X^__O>/_C7@F;ZF4*KZVP'I4M? M@<2",<12&N;J_6)G\)Q>M0\J?#^#"DIG[K@_B1^Q?"(*T^FL:VJYB"*U/V3R9G3@3WTS94;/;\U8LX\.9]-DHN+J9A.DNGY13(].Q>?V 5 M_4DRGYPG\]D9?LSGR1F6GLW/Q:7;'=PR9>%1J#VGTQ_9H)MXHNFSU]NH6:>=RC!SOL+F3. M2$%]9M=,^"LA)$-MFI7/*QLE:U(BF?M^S%R,Q0?3A2B-NER8J1UVJ0?]MON, MM_M=VRRH/V[G=%W5,73;\+1W(Q1HO^)[KP0K*+7\Y=#V:7NU]M+?*.V6^WNY M[WFH946NEM@Z&9\_'OD;?/&',Q7?+UT8A]3"?Z[Y)A@MP/NE06$;?M ![87C ME_\&4$L#!!0 ( .\Y;5>WR;^[Y 8 , 2 9 >&PO=V]R:W-H965T MA'GIA^* M?J!6E,1Z=ZF0E!7WU^<,5Y+7EJRZ:('T@[1\S7!F>,[P<;4V]L$ME/+L][;I MW/5HX?WRK0,S.VE1Y5.Q^[I55R&H3:9BRB*!^W4G>CFZO0 M]MG>7)F5;W2G/EOF5FTK[=,'U9CU]2@>;1M^UO.%IX;QS=52SM6]\E^6GRUJ MXYV6J6Y5Y[3IF%6SZ]%M?/DAI?%AP*]:K=V@S,B3B3$/5/G+]'H4D4&J4;4G M#1*?1W6GFH84P8S?-CI'NRE)<%C>:O\N^ Y?)M*I.]/\34_]XGI4CMA4S>2J M\3^;]0]JXT]&^FK3N/#/UOW8I!JQ>N6\:3?"L*#57?^5OV_B,! HHS<$Q$9 M!+O[B8*5'Z67-U?6K)FET=!&A>!JD(9QNJ-%N?<6O1IR_N9.N@5G-?Z9^FVE M'V6C.N^8[*9,=X_*^9;J5V./N4AB7&_T?NCUBC?T5NR3Z?S"L6^[J9J^E!_# MQIVA8FOH!W%4X;U:7K DXDQ$(CFB+]DYG@1]R1''@YNA\.W ][_?3IRW@,L_ M#KG=:TT/:R4*7;JEK-7U"!QQRCZJTDQ[?_%8OTO]+)W M#JL-*.N\FC(S8WZAV,PTX+[NYI?LUE$CUM*K=J+L;D$W'1]5O6F/0[OH5^>$ MQ3%/TYP7HJ2*X*FH>"Z*OGM@S"7!3CV!(?8!&6VVZJ:.Y;S,!,_CG(DBX555 M\B)-V9UI6V5K+1NVE$N:DR=1R:.\9%]_58I8?,-^,1Z]]18I>YZ+F.=1P=-8 M,%'F,*KD21&S^X6Q_MPKV[X,W^L)8\AF><&3+(*#&8\SZ,@R#+1+8Z57;&+( M_BKA15GP(DE8FG$15SQ*!?MR<7_!OC>/RG:DGR&%=O43,M+$,Z?JE=5>*\>2 MC%!,'=]BM)(87 M&69)$-\$L2T3GA81^]%T\_W1[[0ZSGF$=G-F4EL&^U:*N"6/3SIY8OYI&49N@OO$Y%ML72NKJ+=G-EAWNS/W#N:R M+\_V?$]V#AM^[ W\CHS[-1AWM[*6L/"3Z<[K37F/+"<]7:H"-,E0J\H8_Z

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�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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 255 284 1 false 59 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://www.pointbiopharma.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Interim Condensed Consolidated Balance Sheets Sheet http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets Interim Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Interim Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical Interim Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Unaudited Interim Condensed Consolidated Statements of Operations Sheet http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations Unaudited Interim Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss Unaudited Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows Sheet http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows Unaudited Interim Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Nature of business Sheet http://www.pointbiopharma.com/role/Natureofbusiness Nature of business Notes 8 false false R9.htm 0000009 - Disclosure - Summary of significant accounting policies Sheet http://www.pointbiopharma.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Sheet http://www.pointbiopharma.com/role/Revenue Revenue Notes 10 false false R11.htm 0000011 - Disclosure - Cash, cash equivalents and investments Sheet http://www.pointbiopharma.com/role/Cashcashequivalentsandinvestments Cash, cash equivalents and investments Notes 11 false false R12.htm 0000012 - Disclosure - Fair value measurements Sheet http://www.pointbiopharma.com/role/Fairvaluemeasurements Fair value measurements Notes 12 false false R13.htm 0000013 - Disclosure - Prepaid expenses and other current assets Sheet http://www.pointbiopharma.com/role/Prepaidexpensesandothercurrentassets Prepaid expenses and other current assets Notes 13 false false R14.htm 0000014 - Disclosure - Property, plant and equipment, net Sheet http://www.pointbiopharma.com/role/Propertyplantandequipmentnet Property, plant and equipment, net Notes 14 false false R15.htm 0000015 - Disclosure - Accrued liabilities Sheet http://www.pointbiopharma.com/role/Accruedliabilities Accrued liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Leases Sheet http://www.pointbiopharma.com/role/Leases Leases Notes 16 false false R17.htm 0000017 - Disclosure - Stockholders' equity Sheet http://www.pointbiopharma.com/role/Stockholdersequity Stockholders' equity Notes 17 false false R18.htm 0000018 - Disclosure - Stock-based compensation Sheet http://www.pointbiopharma.com/role/Stockbasedcompensation Stock-based compensation Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and contingencies Sheet http://www.pointbiopharma.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Net loss per share Sheet http://www.pointbiopharma.com/role/Netlosspershare Net loss per share Notes 20 false false R21.htm 0000021 - Disclosure - Income Taxes Sheet http://www.pointbiopharma.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 0000022 - Disclosure - Related party transactions Sheet http://www.pointbiopharma.com/role/Relatedpartytransactions Related party transactions Notes 22 false false R23.htm 0000023 - Disclosure - Subsequent events Sheet http://www.pointbiopharma.com/role/Subsequentevents Subsequent events Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 26 false false R27.htm 9954472 - Disclosure - Revenue (Tables) Sheet http://www.pointbiopharma.com/role/RevenueTables Revenue (Tables) Tables http://www.pointbiopharma.com/role/Revenue 27 false false R28.htm 9954473 - Disclosure - Cash, cash equivalents and investments (Tables) Sheet http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsTables Cash, cash equivalents and investments (Tables) Tables http://www.pointbiopharma.com/role/Cashcashequivalentsandinvestments 28 false false R29.htm 9954474 - Disclosure - Fair value measurements (Tables) Sheet http://www.pointbiopharma.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://www.pointbiopharma.com/role/Fairvaluemeasurements 29 false false R30.htm 9954475 - Disclosure - Prepaid expenses and other current assets (Tables) Sheet http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsTables Prepaid expenses and other current assets (Tables) Tables http://www.pointbiopharma.com/role/Prepaidexpensesandothercurrentassets 30 false false R31.htm 9954476 - Disclosure - Property, plant and equipment, net (Tables) Sheet http://www.pointbiopharma.com/role/PropertyplantandequipmentnetTables Property, plant and equipment, net (Tables) Tables http://www.pointbiopharma.com/role/Propertyplantandequipmentnet 31 false false R32.htm 9954477 - Disclosure - Accrued liabilities (Tables) Sheet http://www.pointbiopharma.com/role/AccruedliabilitiesTables Accrued liabilities (Tables) Tables http://www.pointbiopharma.com/role/Accruedliabilities 32 false false R33.htm 9954478 - Disclosure - Leases (Tables) Sheet http://www.pointbiopharma.com/role/LeasesTables Leases (Tables) Tables http://www.pointbiopharma.com/role/Leases 33 false false R34.htm 9954479 - Disclosure - Stock-based compensation (Tables) Sheet http://www.pointbiopharma.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://www.pointbiopharma.com/role/Stockbasedcompensation 34 false false R35.htm 9954480 - Disclosure - Net loss per share (Tables) Sheet http://www.pointbiopharma.com/role/NetlosspershareTables Net loss per share (Tables) Tables http://www.pointbiopharma.com/role/Netlosspershare 35 false false R36.htm 9954481 - Disclosure - Related party transaction (Tables) Sheet http://www.pointbiopharma.com/role/RelatedpartytransactionTables Related party transaction (Tables) Tables http://www.pointbiopharma.com/role/Relatedpartytransactions 36 false false R37.htm 9954482 - Disclosure - Nature of business - Narrative (Details) Sheet http://www.pointbiopharma.com/role/NatureofbusinessNarrativeDetails Nature of business - Narrative (Details) Details 37 false false R38.htm 9954483 - Disclosure - Revenue - Narrative (Details) Sheet http://www.pointbiopharma.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 38 false false R39.htm 9954484 - Disclosure - Revenue - Contract Liabilities (Details) Sheet http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails Revenue - Contract Liabilities (Details) Details 39 false false R40.htm 9954485 - Disclosure - Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details) Sheet http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details) Details 40 false false R41.htm 9954486 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details) Sheet http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details) Details 41 false false R42.htm 9954487 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details) Sheet http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details) Details 42 false false R43.htm 9954488 - Disclosure - Cash, cash equivalents and investments - Narrative (Details) Sheet http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsNarrativeDetails Cash, cash equivalents and investments - Narrative (Details) Details 43 false false R44.htm 9954489 - Disclosure - Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details) Sheet http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details) Details 44 false false R45.htm 9954490 - Disclosure - Prepaid expenses and other current assets (Details) Sheet http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails Prepaid expenses and other current assets (Details) Details http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsTables 45 false false R46.htm 9954491 - Disclosure - Property, plant and equipment, net (Details) Sheet http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails Property, plant and equipment, net (Details) Details http://www.pointbiopharma.com/role/PropertyplantandequipmentnetTables 46 false false R47.htm 9954492 - Disclosure - Property, plant and equipment, net - Estimated Useful Life (Details) Sheet http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails Property, plant and equipment, net - Estimated Useful Life (Details) Details 47 false false R48.htm 9954493 - Disclosure - Accrued liabilities (Details) Sheet http://www.pointbiopharma.com/role/AccruedliabilitiesDetails Accrued liabilities (Details) Details http://www.pointbiopharma.com/role/AccruedliabilitiesTables 48 false false R49.htm 9954494 - Disclosure - Leases - Narrative (Details) Sheet http://www.pointbiopharma.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 49 false false R50.htm 9954495 - Disclosure - Leases - Schedule of Lease Expense (Details) Sheet http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails Leases - Schedule of Lease Expense (Details) Details 50 false false R51.htm 9954496 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 51 false false R52.htm 9954497 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rates (Details) Sheet http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails Leases - Weighted Average Remaining Lease Term and Discount Rates (Details) Details 52 false false R53.htm 9954498 - Disclosure - Leases - Operating Lease Maturity (Details) Sheet http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails Leases - Operating Lease Maturity (Details) Details 53 false false R54.htm 9954499 - Disclosure - Stockholders' equity (Details) Sheet http://www.pointbiopharma.com/role/StockholdersequityDetails Stockholders' equity (Details) Details http://www.pointbiopharma.com/role/Stockholdersequity 54 false false R55.htm 9954500 - Disclosure - Stock-based compensation - Narrative (Details) Sheet http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation - Narrative (Details) Details 55 false false R56.htm 9954501 - Disclosure - Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) Sheet http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) Details 56 false false R57.htm 9954502 - Disclosure - Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details) Sheet http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details) Details 57 false false R58.htm 9954503 - Disclosure - Commitments and contingencies - Property in development commitment (Details) Sheet http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails Commitments and contingencies - Property in development commitment (Details) Details 58 false false R59.htm 9954504 - Disclosure - Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) Sheet http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) Details 59 false false R60.htm 9954505 - Disclosure - Net loss per share - Summary of basic and diluted net loss per share (Details) Sheet http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails Net loss per share - Summary of basic and diluted net loss per share (Details) Details 60 false false R61.htm 9954506 - Disclosure - Income Taxes (Details) Sheet http://www.pointbiopharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.pointbiopharma.com/role/IncomeTaxes 61 false false R62.htm 9954507 - Disclosure - Related party transactions - Schedule of Related Party Transactions (Details) Sheet http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails Related party transactions - Schedule of Related Party Transactions (Details) Details 62 false false R63.htm 9954508 - Disclosure - Related party transactions -Narrative (Details) Sheet http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails Related party transactions -Narrative (Details) Details 63 false false R64.htm 9954509 - Disclosure - Subsequent events (Details) Sheet http://www.pointbiopharma.com/role/SubsequenteventsDetails Subsequent events (Details) Details http://www.pointbiopharma.com/role/Subsequentevents 64 false false All Reports Book All Reports pnt-20230930.htm pnt-20230930.xsd pnt-20230930_cal.xml pnt-20230930_def.xml pnt-20230930_lab.xml pnt-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pnt-20230930.htm": { "nsprefix": "pnt", "nsuri": "http://www.pointbiopharma.com/20230930", "dts": { "inline": { "local": [ "pnt-20230930.htm" ] }, "schema": { "local": [ "pnt-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "pnt-20230930_cal.xml" ] }, "definitionLink": { "local": [ "pnt-20230930_def.xml" ] }, "labelLink": { "local": [ "pnt-20230930_lab.xml" ] }, "presentationLink": { "local": [ "pnt-20230930_pre.xml" ] } }, "keyStandard": 255, "keyCustom": 29, "axisStandard": 21, "axisCustom": 0, "memberStandard": 30, "memberCustom": 26, "hidden": { "total": 11, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 6 }, "contextCount": 255, "entityCount": 1, "segmentCount": 59, "elementCount": 545, "unitCount": 11, "baseTaxonomies": { "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/us-gaap/2023": 758, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.pointbiopharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Interim Condensed Consolidated Balance Sheets", "shortName": "Interim Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxesReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R3": { "role": "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Interim Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Interim Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations", "longName": "0000004 - Statement - Unaudited Interim Condensed Consolidated Statements of Operations", "shortName": "Unaudited Interim Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "longName": "0000005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R6": { "role": "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity", "longName": "0000006 - Statement - Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-39", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R7": { "role": "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Interim Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.pointbiopharma.com/role/Natureofbusiness", "longName": "0000008 - Disclosure - Nature of business", "shortName": "Nature of business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pointbiopharma.com/role/Summaryofsignificantaccountingpolicies", "longName": "0000009 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.pointbiopharma.com/role/Revenue", "longName": "0000010 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pointbiopharma.com/role/Cashcashequivalentsandinvestments", "longName": "0000011 - Disclosure - Cash, cash equivalents and investments", "shortName": "Cash, cash equivalents and investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pointbiopharma.com/role/Fairvaluemeasurements", "longName": "0000012 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pointbiopharma.com/role/Prepaidexpensesandothercurrentassets", "longName": "0000013 - Disclosure - Prepaid expenses and other current assets", "shortName": "Prepaid expenses and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "pnt:PrepaidExpenseAndOtherAssetsCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pnt:PrepaidExpenseAndOtherAssetsCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pointbiopharma.com/role/Propertyplantandequipmentnet", "longName": "0000014 - Disclosure - Property, plant and equipment, net", "shortName": "Property, plant and equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pointbiopharma.com/role/Accruedliabilities", "longName": "0000015 - Disclosure - Accrued liabilities", "shortName": "Accrued liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "pnt:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pnt:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pointbiopharma.com/role/Leases", "longName": "0000016 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pointbiopharma.com/role/Stockholdersequity", "longName": "0000017 - Disclosure - Stockholders' equity", "shortName": "Stockholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pointbiopharma.com/role/Stockbasedcompensation", "longName": "0000018 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pointbiopharma.com/role/Commitmentsandcontingencies", "longName": "0000019 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pointbiopharma.com/role/Netlosspershare", "longName": "0000020 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pointbiopharma.com/role/IncomeTaxes", "longName": "0000021 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.pointbiopharma.com/role/Relatedpartytransactions", "longName": "0000022 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pointbiopharma.com/role/Subsequentevents", "longName": "0000023 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies", "longName": "9954471 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.pointbiopharma.com/role/RevenueTables", "longName": "9954472 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsTables", "longName": "9954473 - Disclosure - Cash, cash equivalents and investments (Tables)", "shortName": "Cash, cash equivalents and investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.pointbiopharma.com/role/FairvaluemeasurementsTables", "longName": "9954474 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsTables", "longName": "9954475 - Disclosure - Prepaid expenses and other current assets (Tables)", "shortName": "Prepaid expenses and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetTables", "longName": "9954476 - Disclosure - Property, plant and equipment, net (Tables)", "shortName": "Property, plant and equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pointbiopharma.com/role/AccruedliabilitiesTables", "longName": "9954477 - Disclosure - Accrued liabilities (Tables)", "shortName": "Accrued liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pointbiopharma.com/role/LeasesTables", "longName": "9954478 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.pointbiopharma.com/role/StockbasedcompensationTables", "longName": "9954479 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.pointbiopharma.com/role/NetlosspershareTables", "longName": "9954480 - Disclosure - Net loss per share (Tables)", "shortName": "Net loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.pointbiopharma.com/role/RelatedpartytransactionTables", "longName": "9954481 - Disclosure - Related party transaction (Tables)", "shortName": "Related party transaction (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.pointbiopharma.com/role/NatureofbusinessNarrativeDetails", "longName": "9954482 - Disclosure - Nature of business - Narrative (Details)", "shortName": "Nature of business - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "pnt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pnt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pointbiopharma.com/role/RevenueNarrativeDetails", "longName": "9954483 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-76", "name": "pnt:ContractWithCustomerLiabilityRevenueRecognizedForFuturePerformance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "pnt:ContractWithCustomerLiabilityRevenueRecognizedForFuturePerformance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails", "longName": "9954484 - Disclosure - Revenue - Contract Liabilities (Details)", "shortName": "Revenue - Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R40": { "role": "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "longName": "9954485 - Disclosure - Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details)", "shortName": "Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "longName": "9954486 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details)", "shortName": "Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R42": { "role": "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails", "longName": "9954487 - Disclosure - Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details)", "shortName": "Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsNarrativeDetails", "longName": "9954488 - Disclosure - Cash, cash equivalents and investments - Narrative (Details)", "shortName": "Cash, cash equivalents and investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails", "longName": "9954489 - Disclosure - Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details)", "shortName": "Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R45": { "role": "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails", "longName": "9954490 - Disclosure - Prepaid expenses and other current assets (Details)", "shortName": "Prepaid expenses and other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "pnt:PrepaidClinicalTrialExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "pnt:PrepaidClinicalTrialExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "longName": "9954491 - Disclosure - Property, plant and equipment, net (Details)", "shortName": "Property, plant and equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails", "longName": "9954492 - Disclosure - Property, plant and equipment, net - Estimated Useful Life (Details)", "shortName": "Property, plant and equipment, net - Estimated Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-151", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails", "longName": "9954493 - Disclosure - Accrued liabilities (Details)", "shortName": "Accrued liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "pnt:AccruedPersonnelCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "pnt:AccruedPersonnelCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "longName": "9954494 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-159", "name": "pnt:OperatingLeasePresentValueOfMinimumLeasePaymentsMaximumPercentageOfFairValue", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "pnt:OperatingLeasePresentValueOfMinimumLeasePaymentsMaximumPercentageOfFairValue", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails", "longName": "9954495 - Disclosure - Leases - Schedule of Lease Expense (Details)", "shortName": "Leases - Schedule of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails", "longName": "9954496 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails", "longName": "9954497 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rates (Details)", "shortName": "Leases - Weighted Average Remaining Lease Term and Discount Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails", "longName": "9954498 - Disclosure - Leases - Operating Lease Maturity (Details)", "shortName": "Leases - Operating Lease Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.pointbiopharma.com/role/StockholdersequityDetails", "longName": "9954499 - Disclosure - Stockholders' equity (Details)", "shortName": "Stockholders' equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R55": { "role": "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "longName": "9954500 - Disclosure - Stock-based compensation - Narrative (Details)", "shortName": "Stock-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails", "longName": "9954501 - Disclosure - Stock-based compensation - Summarizes activity relating to options to purchase stock (Details)", "shortName": "Stock-based compensation - Summarizes activity relating to options to purchase stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-178", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails", "longName": "9954502 - Disclosure - Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)", "shortName": "Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails", "longName": "9954503 - Disclosure - Commitments and contingencies - Property in development commitment (Details)", "shortName": "Commitments and contingencies - Property in development commitment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-207", "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-208", "name": "pnt:AggregatedRemainingLongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R59": { "role": "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "longName": "9954504 - Disclosure - Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details)", "shortName": "Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-239", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-239", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "longName": "9954505 - Disclosure - Net loss per share - Summary of basic and diluted net loss per share (Details)", "shortName": "Net loss per share - Summary of basic and diluted net loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.pointbiopharma.com/role/IncomeTaxesDetails", "longName": "9954506 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails", "longName": "9954507 - Disclosure - Related party transactions - Schedule of Related Party Transactions (Details)", "shortName": "Related party transactions - Schedule of Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "longName": "9954508 - Disclosure - Related party transactions -Narrative (Details)", "shortName": "Related party transactions -Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-252", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } }, "R64": { "role": "http://www.pointbiopharma.com/role/SubsequenteventsDetails", "longName": "9954509 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-141", "name": "us-gaap:PaymentsToAcquireNotesReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-255", "name": "pnt:MergerAgreementTerminationFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pnt-20230930.htm", "unique": true } } }, "tag": { "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r37", "r38", "r334", "r582", "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r70", "r225", "r226", "r561", "r731" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r23", "r119", "r121", "r126", "r450", "r469" ] }, "pnt_OperatingLeasePresentValueOfMinimumLeasePaymentsMaximumPercentageOfFairValue": { "xbrltype": "pureItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "OperatingLeasePresentValueOfMinimumLeasePaymentsMaximumPercentageOfFairValue", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value", "label": "Operating Lease, Present Value of Minimum Lease Payments, Maximum Percentage of Fair Value", "documentation": "Operating Lease, Present Value of Minimum Lease Payments, Maximum Percentage of Fair Value" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "pnt_LicenseAgreementsPNT2003AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LicenseAgreementsPNT2003AgreementMember", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements, PNT2003 Agreement", "label": "License Agreements, PNT2003 Agreement [Member]", "documentation": "License Agreements, PNT2003 Agreement" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r69", "r109", "r463" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r73" ] }, "pnt_AccruedPersonnelCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AccruedPersonnelCostsCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued personnel costs", "label": "Accrued Personnel Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for personnel costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r334", "r582", "r583" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted- Average Remaining Contractual Term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "pnt_DepositOnProductionEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "DepositOnProductionEquipment", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposit on production equipment", "label": "Deposit on Production Equipment", "documentation": "Deposit on Production Equipment" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r354", "r360" ] }, "pnt_OperatingLeaseNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "OperatingLeaseNoncashExpense", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Noncash Expense", "documentation": "Operating Lease, Noncash Expense" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "pnt_ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ConsultingFeesOnBusinessActivitiesToRelatedPartiesMember", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting fees on business activities to Board member", "label": "Consulting Fees On Business Activities To Related Parties [Member]", "documentation": "Represents the information pertaining to consulting fees on business activities to Board member." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r306" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government agency debt securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r569", "r579", "r781" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r280", "r395", "r396", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r494", "r495", "r496", "r497", "r498", "r519", "r521", "r552", "r771" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r306" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss:", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r104", "r117", "r120", "r128", "r133", "r142", "r150", "r151", "r165", "r170", "r174", "r176", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r336", "r339", "r340", "r353", "r361", "r452", "r465", "r487", "r522", "r543", "r544", "r572", "r587", "r588", "r601", "r699", "r732" ] }, "pnt_InvestmentReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "InvestmentReceivableCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable on matured short-term investment", "label": "Investment Receivable, Current", "documentation": "Investment Receivable, Current" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Netlosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r152", "r160", "r161", "r162" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r129" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r129" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r139", "r140", "r141", "r164", "r435", "r479", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r501", "r504", "r505", "r506", "r507", "r508", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r521", "r523", "r524", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r545", "r595" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r39", "r40", "r41", "r102", "r103", "r123", "r139", "r140", "r141", "r143", "r149", "r212", "r213", "r258", "r317", "r318", "r319", "r327", "r328", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r366", "r368", "r372", "r391", "r474", "r475", "r486", "r503", "r520", "r546", "r547", "r559", "r601", "r701", "r725", "r765", "r785" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r64", "r65", "r66" ] }, "pnt_LabratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LabratorySpaceMember", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Labratory Space", "label": "Labratory Space [Member]", "documentation": "Labratory Space" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r684", "r700" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r387", "r589" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r52", "r501" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r335" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r52", "r501", "r520", "r785", "r786" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r377", "r383", "r589" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r28" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r280", "r395", "r396", "r494", "r495", "r496", "r497", "r498", "r519", "r521", "r552" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment committed", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r300" ] }, "pnt_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options", "label": "Lessee, Operating Lease, Number of Renewal Options", "documentation": "Lessee, Operating Lease, Number of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r653" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r651" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r101", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r272" ] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in accrued interest and dividends within investments", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": [ "r4" ] }, "us-gaap_TransferOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfInvestments", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable for investment maturities", "label": "Transfer from Investments", "documentation": "Value of investments transferred from the entity's investments in noncash transactions." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r604" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r375" ] }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetRentableArea", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net rentable area", "label": "Net Rentable Area", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized loss on available-for-sale debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r114", "r115", "r116" ] }, "pnt_ShareBasedCompensationToBoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ShareBasedCompensationToBoardMemberMember", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board member", "label": "Share Based Compensation To Board Member [Member]", "documentation": "Share Based Compensation To Board Member" } } }, "auth_ref": [] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r608", "r619", "r629", "r654" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director", "label": "Director [Member]" } } }, "auth_ref": [ "r706", "r783" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r26" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes receivable", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r46", "r694" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/IncomeTaxesDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax (provision) benefit", "terseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r85", "r99", "r150", "r151", "r168", "r323", "r330", "r471" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r13", "r118", "r121", "r125", "r366", "r367", "r372", "r449", "r467", "r697", "r698" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized for issuance under plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r586" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r652" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r304" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r296" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r604" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r295" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party expenses", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r45", "r395" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted in period, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r303" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r610", "r621", "r631", "r656" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency gain (loss)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r542" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Cashcashequivalentsandinvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and investments", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r107", "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r289", "r290" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r289", "r290" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r106", "r133", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r338", "r341", "r342", "r361", "r590", "r732", "r772", "r773" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r651" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r166", "r167", "r169", "r172", "r173", "r177", "r178", "r179", "r269", "r270", "r435" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r389" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future payments relating to the construction and retrofit of the building", "label": "Other Commitment, to be Paid, Year One", "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r376", "r389" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r309" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r604" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r44", "r45", "r525", "r526", "r529" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r615", "r626", "r636", "r661" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r650" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Relatedpartytransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r392", "r393", "r394", "r396", "r399", "r483", "r484", "r485", "r527", "r528", "r529", "r549", "r551" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r310" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease current liability", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r376" ] }, "pnt_SquareFootOfBuilding": { "xbrltype": "areaItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "SquareFootOfBuilding", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Square-foot of building", "label": "Square Foot of Building", "documentation": "Represents the square-foot of building." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r389" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r608", "r619", "r629", "r654" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r641" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Note receivable", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r653" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r77", "r110", "r133", "r165", "r171", "r175", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r341", "r361", "r456", "r514", "r590", "r602", "r732", "r733", "r772" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails", "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r525", "r526", "r529" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r641" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r609", "r620", "r630", "r655" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r653" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per basic and diluted common share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options granted (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r293" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r376" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r60", "r524" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r51", "r501", "r520", "r785", "r786" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r51", "r501" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r223", "r224", "r529" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r241", "r274", "r275", "r276", "r277", "r278", "r279", "r356", "r408", "r576", "r577", "r579", "r580", "r581" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r51", "r244" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r664" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r137", "r138", "r240", "r246", "r398", "r566", "r568" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r224", "r529" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r646" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r61" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r763" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails", "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r373", "r401" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued costs", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r646" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r59" ] }, "pnt_SupplyAgreementsInConnectionWithClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "SupplyAgreementsInConnectionWithClinicalTrialsMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply agreements in connection with clinical trials", "label": "Supply Agreements In Connection With Clinical Trials [Member]", "documentation": "Represents the supply agreements in connection with clinical trials." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r646" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r112", "r590" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r51", "r244" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r646" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r242", "r256", "r349", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r468", "r574", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r721", "r722", "r723", "r724" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r646" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r646" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r382", "r589" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r585" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r646" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "(Accumulated deficit) Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r54", "r73", "r461", "r476", "r478", "r481", "r502", "r590" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r133", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r341", "r361", "r732", "r733", "r772" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r315" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r384", "r589" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares available (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities, Current [Abstract]", "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r381" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r647" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual increase in shares authorized, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r649" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r648" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, share price (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r64" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r64", "r130" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r641" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r135", "r136", "r395", "r396", "r397", "r398", "r494", "r495", "r496", "r497", "r498", "r519", "r521", "r552" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r186" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r664" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r242", "r256", "r349", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r468", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r721", "r722", "r723", "r724" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r381" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r665" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r185" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r615", "r626", "r636", "r653", "r661" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r133", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r338", "r341", "r342", "r361", "r499", "r571", "r602", "r732", "r772", "r773" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of Common Stock, net of direct and incremental costs paid", "verboseLabel": "Proceeds from issuance of shares of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r665" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r306" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r615", "r626", "r636", "r661" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192" ] }, "pnt_FacilityLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "FacilityLeaseMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility lease", "label": "Facility Lease [Member]", "documentation": "Facility Lease" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r21", "r22", "r56", "r111", "r460", "r477", "r478" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r317", "r318", "r319", "r488", "r702", "r703", "r704", "r764", "r785" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r592", "r593", "r596", "r597", "r598", "r599", "r782", "r785" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "pnt_AccruedCostsForPurchasesOfPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AccruedCostsForPurchasesOfPropertyPlantAndEquipmentCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued costs for purchases of property, plant and equipment", "label": "Accrued Costs For Purchases Of Property, Plant, And Equipment, Current", "documentation": "Accrued Costs For Purchases Of Property, Plant, And Equipment, Current" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r139", "r140", "r141", "r143", "r149", "r151", "r212", "r213", "r317", "r318", "r319", "r327", "r328", "r343", "r345", "r346", "r348", "r351", "r473", "r475", "r488", "r785" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r88", "r89", "r92", "r93" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r137", "r138", "r240", "r246", "r398", "r567", "r568" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due between one and five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r716" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r579", "r714", "r719", "r720" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxes", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes receivable and payable", "label": "Increase (Decrease) in Income Taxes", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets." } } }, "auth_ref": [ "r700" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r102", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r149", "r151", "r164", "r212", "r213", "r258", "r317", "r318", "r319", "r327", "r328", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r366", "r368", "r369", "r370", "r371", "r372", "r391", "r473", "r474", "r475", "r488", "r545" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r715" ] }, "pnt_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance", "documentation": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r7", "r22", "r344", "r347", "r391", "r473", "r474", "r697", "r698", "r699", "r702", "r703", "r704" ] }, "us-gaap_RevenueRecognitionMilestoneMethodLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMilestoneMethodLineItems", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Milestone Method [Line Items]", "label": "Revenue Recognition, Milestone Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r189", "r453" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due between one and five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r190", "r454" ] }, "us-gaap_RevenueRecognitionMilestoneMethodTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMilestoneMethodTable", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Milestone Method [Table]", "label": "Revenue Recognition, Milestone Method [Table]", "documentation": "Schedule detailing the characteristics of milestone payments recognized under the milestone method by arrangement. For each arrangement that includes a milestone payment, this includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors the entity considered in determining whether each milestone or milestones are substantive; and (5) the amount of contingent consideration recognized during the period for each milestone." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost and fees on issuance of common shares", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r25" ] }, "pnt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "pnt_StockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "StockPurchaseAgreementMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Purchase Agreement", "label": "Stock Purchase Agreement [Member]", "documentation": "Stock Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "pnt_CashCashEquivalentsAndInvestments", "weight": 1.0, "order": 1.0 }, "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r108" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r374" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per common share (in dollars per share)", "negatedLabel": "Net loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r127", "r144", "r145", "r146", "r147", "r148", "r153", "r155", "r157", "r158", "r159", "r163", "r352", "r353", "r451", "r470", "r570" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r615", "r626", "r636", "r661" ] }, "pnt_PropertyInDevelopmentCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "PropertyInDevelopmentCommitmentMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, in development commitment", "label": "Property In Development Commitment [Member]", "documentation": "Represents the commitment related to property, in development." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r434", "r700" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "pnt_PrepaidClinicalTrialExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "PrepaidClinicalTrialExpensesCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid clinical trial expenses", "label": "Prepaid Clinical Trial Expenses, Current", "documentation": "Represents the prepaid clinical trial expenses that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain on available-for-sale debt investments", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r721" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r108", "r180", "r219" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair Value", "verboseLabel": "Available-for-sale debt securities:", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r183", "r219", "r448", "r707" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessor, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r94", "r95", "r96", "r390" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r281", "r433", "r472", "r491", "r492", "r553", "r554", "r555", "r556", "r557", "r562", "r563", "r573", "r578", "r584", "r591", "r734", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "pnt_PrepaidExpenseAndOtherAssetsCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Prepaidexpensesandothercurrentassets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense And Other Assets, Current [Text Block]", "documentation": "The entire disclosure of prepaid expenses and other current assets." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r273", "r281", "r308", "r309", "r310", "r409", "r433", "r472", "r491", "r492", "r553", "r554", "r555", "r556", "r557", "r562", "r563", "r573", "r578", "r584", "r591", "r594", "r730", "r734", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents [Table]", "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Stockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r72", "r132", "r243", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r350", "r548", "r550", "r560" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r281", "r433", "r472", "r491", "r492", "r553", "r554", "r555", "r556", "r557", "r562", "r563", "r573", "r578", "r584", "r591", "r734", "r774", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r300" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r107" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/LeasesNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r273", "r281", "r308", "r309", "r310", "r409", "r433", "r472", "r491", "r492", "r553", "r554", "r555", "r556", "r557", "r562", "r563", "r573", "r578", "r584", "r591", "r594", "r730", "r734", "r775", "r776", "r777", "r778", "r779" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r53", "r590", "r784" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred and non-current income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r52" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term income taxes payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r50", "r78" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r702", "r703", "r764", "r782", "r785" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r122", "r123", "r366", "r368", "r369", "r370", "r371", "r372" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, in development", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested and expected to vest (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r305" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationAssumptionsusedinBlackScholesMertonoptionpricingmodelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r307" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r590" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r616", "r627", "r637", "r662" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r388", "r589" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Propertyplantandequipmentnet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r68", "r91", "r97", "r98" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r69" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.pointbiopharma.com/role/Natureofbusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r87", "r100" ] }, "us-gaap_LandAndBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandAndBuildingMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and building", "label": "Land and Building [Member]", "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r615", "r626", "r636", "r661" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r388", "r589" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r614", "r625", "r635", "r660" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r180", "r219" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r389" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r69" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Stockbasedcompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r282", "r285", "r313", "r314", "r316", "r585" ] }, "pnt_CanadianHarmonizedSalesTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CanadianHarmonizedSalesTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian harmonized sales tax receivable", "label": "Canadian Harmonized Sales Tax Receivable, Current", "documentation": "Represents the Canadian harmonized sales tax receivable that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "pnt_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": [] }, "pnt_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "pnt_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails", "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "totalLabel": "Total", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r769" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r71", "r596", "r597", "r598", "r599" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r769" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r19", "r47", "r457", "r500" ] }, "pnt_AthebioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AthebioMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Athebio", "label": "Athebio [Member]", "documentation": "Athebio" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r766" ] }, "us-gaap_CommercialPaperAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper, at Carrying Value", "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "pnt_CollaborativeArrangementUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CollaborativeArrangementUpfrontPayment", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Collaborative Arrangement, Upfront Payment", "documentation": "Collaborative Arrangement, Upfront Payment" } } }, "auth_ref": [] }, "pnt_EliLillyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "EliLillyMember", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eli Lilly", "label": "Eli Lilly [Member]", "documentation": "Eli Lilly" } } }, "auth_ref": [] }, "pnt_StockIssuedDuringPeriodSharesNewIssuesAndShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "StockIssuedDuringPeriodSharesNewIssuesAndShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with an underwritten public share offering and exercise of stock options (in shares)", "label": "Stock Issued During Period, Shares, New Issues and Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Stock Issued During Period, Shares, New Issues and Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r644" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r643" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, par value $0.0001 per share, 430,000,000 authorized, 105,765,954 and 105,649,741 issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r52", "r459", "r590" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued corporate legal fees and other professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r645" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r335" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r373", "r401" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r673" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r642" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r373", "r401" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r642" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r674" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r63" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Investments", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r395", "r396", "r771" ] }, "pnt_ReimbursementToBoardMemberForOccupancyCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ReimbursementToBoardMemberForOccupancyCostsMember", "presentation": [ "http://www.pointbiopharma.com/role/RelatedpartytransactionsScheduleofRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement to Board member for occupancy costs", "label": "Reimbursement To Board Member For Occupancy Costs [Member]", "documentation": "Represents the information pertaining to reimbursement to Board member for occupancy costs." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r49", "r321", "r780" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r673" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r643" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails", "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r373", "r401" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r355", "r356", "r359" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r675" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r674" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails", "http://www.pointbiopharma.com/role/SubsequenteventsDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of note receivable", "terseLabel": "Purchase of note receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r24" ] }, "pnt_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LicenseAgreementMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement", "label": "License Agreement [Member]", "documentation": "License Agreement" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation on property, plant and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r35" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r615", "r626", "r636", "r661" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r645" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r603" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r644" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "pnt_CashCashEquivalentsAndInvestments", "weight": 1.0, "order": 2.0 }, "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r107", "r564" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r618", "r626", "r636", "r653", "r661", "r665", "r673" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r241", "r274", "r275", "r276", "r277", "r278", "r279", "r406", "r407", "r408", "r576", "r577", "r579", "r580", "r581" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r676" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetEstimatedUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r644" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r737" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense and Supplemental Cash Flow", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r768" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r607", "r677" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investments, net of sales and maturities", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r62" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r86", "r458", "r489", "r509", "r590", "r602", "r692" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted weighted average common shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r154", "r159" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r618", "r626", "r636", "r653", "r661", "r665", "r673" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r644" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r664" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-For-Sale Investments", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r605" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r607", "r677" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic weighted average common shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r153", "r159" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r645" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, redemption price, percentage of principal and interest outstanding", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r607", "r677" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r84" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails", "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r373", "r401" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "http://www.pointbiopharma.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "negatedLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r58", "r66", "r83", "r104", "r117", "r120", "r124", "r133", "r142", "r144", "r145", "r146", "r147", "r150", "r151", "r156", "r165", "r170", "r174", "r176", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r353", "r361", "r466", "r522", "r543", "r544", "r572", "r600", "r732" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r42" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r645" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareSummaryofbasicanddilutednetlosspershareDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per common share (in dollars per share)", "negatedLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r127", "r144", "r145", "r146", "r147", "r148", "r155", "r157", "r158", "r159", "r163", "r352", "r353", "r451", "r470", "r570" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r606" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r645" ] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r374" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r565", "r575", "r726" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r355", "r356", "r359" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r312", "r320" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r639" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r640" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r165", "r170", "r174", "r176", "r572" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "verboseLabel": "Subsequent events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r400", "r402" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r645" ] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of premiums (accretion of discounts) on investments, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r66" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r55", "r79", "r462", "r590", "r701", "r725", "r765" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of Common Stock, net of direct and incremental costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r51", "r52", "r73", "r488", "r545", "r558", "r601" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES & STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of Common Stock in connection with stock option exercises", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r36" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating cash flow use from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r380", "r385" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Assumptions Used to Determine the Grant Date Fair Value of Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r75" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of Common Stock in connection with stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r20", "r73" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on finance lease", "terseLabel": "Payments on finance lease", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r378", "r385" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of Common Stock, net of direct and incremental costs (in shares)", "verboseLabel": "Number of shares issued during period (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r51", "r52", "r73", "r480", "r545", "r558" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r386", "r589" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility lease", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r680" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total property, plant and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r680", "r693", "r728" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r386", "r589" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Accumulated depreciation", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r681", "r683", "r729" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Total", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r683", "r727" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r682" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r134", "r322", "r324", "r325", "r326", "r329", "r331", "r332", "r333", "r482" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails", "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares of common stock in connection with stock option exercises (in shares)", "verboseLabel": "Stock options exercised (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r51", "r52", "r73", "r294" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r682" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Risks and uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r48", "r90" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails", "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r20", "r102", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r149", "r151", "r164", "r212", "r213", "r258", "r317", "r318", "r319", "r327", "r328", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r366", "r368", "r369", "r370", "r371", "r372", "r391", "r473", "r474", "r475", "r488", "r545" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "pnt_PublicShareOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "PublicShareOfferingMember", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Share Offering", "label": "Public Share Offering [Member]", "documentation": "Public Share Offering" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r671" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r613", "r624", "r634", "r659" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r668" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r666" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r673" ] }, "pnt_CollaborativeArrangementNumberOfPeopleRequiredInCommittee": { "xbrltype": "integerItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CollaborativeArrangementNumberOfPeopleRequiredInCommittee", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of people required in committee", "label": "Collaborative Arrangement, Number of People Required In Committee", "documentation": "Collaborative Arrangement, Number of People Required In Committee" } } }, "auth_ref": [] }, "pnt_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "EmployeeMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee", "label": "Employee [Member]", "documentation": "These member stand for employee." } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r667" ] }, "pnt_AccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AccruedLiabilitiesTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Accruedliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities [Text Block]", "documentation": "The Entire Disclosure On Current Accrued Expenses." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term for total aggregate remaining minimum commitment", "label": "Long-Term Purchase Commitment, Period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "pnt_MergerAgreementTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "MergerAgreementTerminationFee", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "label": "Merger Agreement, Termination Fee", "documentation": "Merger Agreement, Termination Fee" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "pnt_CashCashEquivalentsAndInvestments", "weight": 1.0, "order": 3.0 }, "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r80", "r81", "r695" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r672" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r706", "r770" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r122", "r123", "r366", "r368", "r369", "r370", "r371", "r372" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "pnt_LeasesWeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LeasesWeightedAverageDiscountRateAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rates:", "label": "Leases, Weighted Average Discount Rate [Abstract]", "documentation": "Leases, Weighted Average Discount Rate" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r669" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r769" ] }, "pnt_SupplyAgreementsInConnectionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "SupplyAgreementsInConnectionMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply agreements in connection", "label": "Supply Agreements In Connection [Member]", "documentation": "Represents the supply agreements in connection." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investment activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "pnt_CashCashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CashCashEquivalentsAndInvestments", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents and investments", "label": "Cash, Cash Equivalents, And Investments", "documentation": "Cash, Cash Equivalents, And Investments" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r670" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "pnt_CollaborativeArrangementAnnualNetSalesMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CollaborativeArrangementAnnualNetSalesMilestonePayment", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual net sales milestone payment", "label": "Collaborative Arrangement, Annual Net Sales Milestone Payment", "documentation": "Collaborative Arrangement, Annual Net Sales Milestone Payment" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r604" ] }, "pnt_SupplyAgreementToPurchaseNcaLuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "SupplyAgreementToPurchaseNcaLuMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Agreement To Purchase n.c.a. Lu", "label": "Supply Agreement To Purchase n.c.a. Lu [Member]", "documentation": "Supply Agreement To Purchase n.c.a. Lu" } } }, "auth_ref": [] }, "pnt_UHNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "UHNMember", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UHN", "label": "UHN [Member]", "documentation": "UHN" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r664" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r671" ] }, "pnt_ShareBasedCompensationToNonEmployeeConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ShareBasedCompensationToNonEmployeeConsultantMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee consultant", "label": "Share Based Compensation To Non Employee Consultant [Member]", "documentation": "These member stand for share based compensation to non-employee consultant." } } }, "auth_ref": [] }, "pnt_AggregatedRemainingLongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AggregatedRemainingLongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails", "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesPropertyindevelopmentcommitmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total aggregate remaining minimum commitment", "label": "Aggregated Remaining Long Term Purchase Commitment Amount", "documentation": "The aggregate remaining minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flow use from finance lease", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r379", "r385" ] }, "pnt_GoodManufacturingPracticesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "GoodManufacturingPracticesMember", "presentation": [ "http://www.pointbiopharma.com/role/PropertyplantandequipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Good Manufacturing Practices", "label": "Good Manufacturing Practices [Member]", "documentation": "Good Manufacturing Practices" } } }, "auth_ref": [] }, "pnt_SupplyAgreementToPurchaseCertainProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "SupplyAgreementToPurchaseCertainProductsMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply agreement to purchase certain products", "label": "Supply Agreement To Purchase Certain Products [Member]", "documentation": "Represents the supply agreement to purchase certain products." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Summaryofsignificantaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r67", "r131" ] }, "pnt_ContractWithCustomerLiabilityRevenueRecognizedForFuturePerformance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ContractWithCustomerLiabilityRevenueRecognizedForFuturePerformance", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized for future performance", "label": "Contract with Customer, Liability, Revenue Recognized For Future Performance", "documentation": "Contract with Customer, Liability, Revenue Recognized For Future Performance" } } }, "auth_ref": [] }, "pnt_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Going concern", "label": "Going Concern [Policy Text Block]", "documentation": "Disclosure of accounting policy related to going concern." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r604" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/PrepaidexpensesandothercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r696" ] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Category of Item Purchased [Axis]", "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r241", "r274", "r275", "r276", "r277", "r278", "r279", "r356", "r406", "r407", "r408", "r576", "r577", "r579", "r580", "r581" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r12", "r42", "r43", "r76" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r105", "r113", "r133", "r211", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r341", "r361", "r590", "r732", "r733", "r772" ] }, "pnt_LicenseAgreementsPNT2002AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LicenseAgreementsPNT2002AgreementMember", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements, PNT2002 Agreement", "label": "License Agreements, PNT2002 Agreement [Member]", "documentation": "License Agreements, PNT2002 Agreement" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r671" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r611", "r622", "r632", "r657" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r389" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r604" ] }, "pnt_CollaborativeArrangementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CollaborativeArrangementMilestonePayment", "crdr": "debit", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Collaborative Arrangement, Milestone Payment", "documentation": "Collaborative Arrangement, Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 }, "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "verboseLabel": "Deferred revenue, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r259", "r260", "r271" ] }, "pnt_AccruedResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AccruedResearchAndDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/AccruedliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development costs", "label": "Accrued Research and Development Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "pnt_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://www.pointbiopharma.com/role/NatureofbusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of wholly-owned subsidiaries", "label": "Number Of Wholly-Owned Subsidiaries", "documentation": "Represents the number of wholly-owned subsidiaries." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liability", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r377", "r383", "r589" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r767" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r767" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets", "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r259", "r260", "r271" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/RevenueContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r259", "r260", "r271" ] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r604" ] }, "pnt_IndianapolisLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "IndianapolisLeaseMember", "presentation": [ "http://www.pointbiopharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indianapolis Lease", "label": "Indianapolis Lease [Member]", "documentation": "Indianapolis Lease" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r294" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r387", "r589" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market mutual fund", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r736" ] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Line Items]", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r611", "r622", "r632", "r657" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r296" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r672" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r360" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum purchase commitments", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.pointbiopharma.com/role/LeasesOperatingLeaseMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Per Share ($)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofcashcashequivalentsandinvestmentsDetails", "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationSummarizesactivityrelatingtooptionstopurchasestockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r295" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.pointbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r679" ] }, "pnt_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting ratably over the remaining three years", "label": "Share-based Payment Arrangement, Tranche Four [Member]", "documentation": "Share-based Payment Arrangement, Tranche Four" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r139", "r140", "r141", "r164", "r435", "r479", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r501", "r504", "r505", "r506", "r507", "r508", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r521", "r523", "r524", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r545", "r595" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/Fairvaluemeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r354" ] }, "pnt_AgreementInConnectionWithSplashClinicalPhaseStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "AgreementInConnectionWithSplashClinicalPhaseStudyMember", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement in connection with the SPLASH clinical phase study", "label": "Agreement In Connection With Splash Clinical Phase Study [Member]", "documentation": "Represents the agreement in connection with the SPLASH clinical phase study." } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r616", "r627", "r637", "r662" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/NetlosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Basic and Diluted Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r705" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r672" ] }, "pnt_NumberOfVotesPerCommonShare": { "xbrltype": "integerItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "NumberOfVotesPerCommonShare", "presentation": [ "http://www.pointbiopharma.com/role/StockholdersequityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes per share", "label": "Number of Votes Per Common Share", "documentation": "Represents the number of votes per share." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://www.pointbiopharma.com/role/CommitmentsandcontingenciesClinicaltrialandcommercialcommitmentsLicenseagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease current liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r376" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsDetails", "http://www.pointbiopharma.com/role/CashcashequivalentsandinvestmentsScheduleofavailableforsaleinvestmentsbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r182", "r219", "r455" ] }, "pnt_CollaborativeArrangementRoyaltyRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "CollaborativeArrangementRoyaltyRate", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate", "label": "Collaborative Arrangement, Royalty Rate", "documentation": "Collaborative Arrangement, Royalty Rate" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r672" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/UnauditedInterimCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r57", "r82", "r165", "r170", "r174", "r176", "r452", "r464", "r572" ] }, "pnt_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.pointbiopharma.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years):", "label": "Weighted Average Remaining Lease Term [Abstract]", "documentation": "Weighted Average Remaining Lease Term" } } }, "auth_ref": [] }, "pnt_LantheusHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "LantheusHoldingsIncMember", "presentation": [ "http://www.pointbiopharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lantheus Holdings, Inc.", "label": "Lantheus Holdings, Inc. [Member]", "documentation": "Lantheus Holdings, Inc." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r241", "r274", "r279", "r356", "r406", "r579", "r580", "r581" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.pointbiopharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r735" ] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting on 1st year anniversary", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r672" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]", "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r617", "r628", "r638", "r663" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r241", "r274", "r279", "r356", "r407", "r576", "r577", "r579", "r580", "r581" ] }, "pnt_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pointbiopharma.com/20230930", "localname": "EmployeesAndDirectorsMember", "presentation": [ "http://www.pointbiopharma.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and Directors", "label": "Employees and Directors [Member]", "documentation": "Employees and Directors" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.pointbiopharma.com/role/FairvaluemeasurementsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r107" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pointbiopharma.com/role/InterimCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r376" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 82 0001811764-23-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001811764-23-000046-xbrl.zip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end